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Genetic and Pharmacological Approaches to Preventing Neurodegeneration
Abstract
The Insulin/Insulin-like Growth Factor 1 Signaling (IIS) pathway was first identified as a major modifier of
aging in C.elegans. It has since become clear that the ability of this pathway to modify aging is
phylogenetically conserved. Aging is a major risk factor for a variety of neurodegenerative diseases
including the motor neuron disease, Amyotrophic Lateral Sclerosis (ALS). This raises the possibility that
the IIS pathway might have therapeutic potential to modify the disease progression of ALS. In a C.
elegans model of ALS we found that decreased IIS had a beneficial effect on ALS pathology in this model.
This beneficial effect was dependent on activation of the transcription factor daf-16. To further validate
IIS as a potential therapeutic target for treatment of ALS, manipulations of IIS in mammalian cells were
investigated for neuroprotective activity. Genetic manipulations that increase the activity of the
mammalian ortholog of daf-16, FOXO3, were found to be neuroprotective in a series of in vitro models of
ALS toxicity.
The small molecule Psammaplysene A (PA) is known to increase the nuclear abundance of FOXO3. PA
was also found to be protective in mammalian in vitro models of ALS toxicity as well as a fly and worm
model of neurodegeneration. Due to the wide variety of neurodegenerative diseases that share aging as a
risk factor, a small molecule modifier of FOXO/daf-16 such as PA could hold great therapeutic potential.
Most clinically viable drugs have certain physico-chemical properties that fall within a well-defined set of
values, which unfortunately PA does not share. Due to its poor "drug-likness", an investigation into the
mechanism of action of PA was undertaken in order to potentially identify more "drug-like" compounds
with similar activities.
This investigation revealed the heterogeneous nuclear ribonucleoprotein K (HNRNPK) is a direct physical
target of PA. PA modifies the ability of HNRNPK to stabilize rRNA but does not affect many of HNRNPK's
other functions. How changes in rRNA stability modify IIS or whether these changes definitively underlie
PA's neuroprotective mechanism remains to be determined.
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ABSTRACT:
GENETIC AND PHARMACOLOGICAL APPROACHES TO PREVENTING
NEURODEGENERATION

Marco Boccitto
Robert G. Kalb

The Insulin/Insulin-like Growth Factor 1 Signaling (IIS) pathway was first identified as a
major modifier of aging in C.elegans. It has since become clear that the ability of this pathway to
modify aging is phylogenetically conserved. Aging is a major risk factor for a variety of
neurodegenerative diseases including the motor neuron disease, Amyotrophic Lateral Sclerosis
(ALS). This raises the possibility that the IIS pathway might have therapeutic potential to modify
the disease progression of ALS. In a C. elegans model of ALS we found that decreased IIS had
a beneficial effect on ALS pathology in this model. This beneficial effect was dependent on
activation of the transcription factor daf-16. To further validate IIS as a potential therapeutic
target for treatment of ALS, manipulations of IIS in mammalian cells were investigated for
neuroprotective activity. Genetic manipulations that increase the activity of the mammalian
ortholog of daf-16, FOXO3, were found to be neuroprotective in a series of in vitro models of ALS
toxicity.
The small molecule Psammaplysene A (PA) is known to increase the nuclear abundance
of FOXO3. PA was also found to be protective in mammalian in vitro models of ALS toxicity as
well as a fly and worm model of neurodegeneration. Due to the wide variety of
neurodegenerative diseases that share aging as a risk factor, a small molecule modifier of
FOXO/daf-16 such as PA could hold great therapeutic potential. Most clinically viable drugs have
certain physico-chemical properties that fall within a well-defined set of values, which
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unfortunately PA does not share. Due to its poor “drug-likness”, an investigation into the
mechanism of action of PA was undertaken in order to potentially identify more “drug-like”
compounds with similar activities.
This investigation revealed the heterogeneous nuclear ribonucleoprotein K (HNRNPK) is
a direct physical target of PA. PA modifies the ability of HNRNPK to stabilize rRNA but does not
affect many of HNRNPK’s other functions. How changes in rRNA stability modify IIS or whether
these changes definitively underlie PA’s neuroprotective mechanism remains to be determined.
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CHAPTER 1
Background
Introduction
Aging is the greatest risk factor for the development of a variety of neurodegenerative
diseases including Amyotrophic Lateral Sclerosis (ALS). Although numerous mutations have
been identified which invariably lead to neurodegenerative disease, the onset of disease
pathology typically does not occur until mid to late life. This suggests that there is an innate
capacity for cells/organisms to cope with the stresses of mutant proteins associated with
disease, but that these systems lose their ability to cope with toxic proteins as they age.
Therefore, manipulations that prevent the changes associated with cellular/organismal aging
represent potential therapeutic interventions for neurodegenerative diseases.

Insulin Signaling Pathways:
One of the most well characterized modifiers of longevity and aging is the
Insulin/Insulin-like Growth Factor Signaling (IIS) pathway. IIS was first implicated as a modifier
of longevity when it was found that C. elegans with a hypomorphic allele of the insulin receptor,
daf-2, had increased activation of the downstream transcription factor, daf-16, and lived roughly
twice as long as wild type worms1. Since this original characterization, a more complete
understanding of the role of the IIS pathway in aging has emerged. Upon ligand binding, a series
of downstream phosphorylation events occur which conclude in phosphorylation of daf-16.
Phosphorylated daf-16 is retained in the cytoplasm and is unable to execute its pro-survival
1

transcriptional output. The downstream kinase age-1, which is activated by daf-2, acts to
promote phosphorylation of daf-16 and exclude it from the nucleus. Mutants which are null for
age-1 are extremely long lived and have a lifespan approximately ten times greater than wild
type worms2. Nuclear localization of daf-16, although necessary, is not sufficient to promote
longevity3, suggesting that other signaling events need to be integrated in order for daf-16 to
execute its beneficial transcriptional profile. The transcription factor hsf-1 is thought to be an
important cofactor for expression of a subset of daf-16 longevity promoting genes, with
overexpression of hsf-1 leading to a daf-16 dependent increase in longevity4. There is also a
level of cross talk between stress induced signaling pathways and IIS. The c-Jun N-terminal
Kinase (JNK) which is a stress responsive kinase, directly interacts with daf-16 and leads to its
nuclear accumulation5. TGFβ signaling is also known to influence IIS and modify longevity in
adult worms. There are two canonical TGFβ signaling pathways in the worm. One functions to
regulate reproductive lifespan independently of longevity while the other functions in a daf-16
dependent fashion to significantly enhance longevity6,7. The family of Forkhead box O (FOXO)
transcription factors represent the mammalian orthologs of daf-16. The FOXO family regulates
cellular processes including metabolism, stress response, DNA damage repair and cell death and
has also been implicated in lifespan extension in mammals. Many of the post-translational
modifications that modify the function of daf-16 have also been found to regulate the function
of the FOXO transcription factors. For a complete discussion of post-translational modifications
that regulate FOXO function, see appendix 1.
Interestingly, mutations resulting in increased longevity in C. elegans often increase
stress resistance as well. For example, alterations in the IIS pathway that lead to increased
lifespan, such as mutations in daf-2 or age-1, also increase organismal resistance to a wide
2

variety of stresses such as heat shock, oxidative stress, heavy metal stress, UV damage and
infection8-11. Changes in IIS have also been found to increase resistance to proteotoxic insults
such as expression of: polyglutamine expanded proteins, and mutant TDP-434,12-14. Decreased
IIS signaling has also been shown to be protective against amyloid beta toxicity. A cooperative
effect between daf-16 and hsf-1 has been described for protection against amyloid beta toxicity,
with both playing a role in reducing amyloid beta toxicity in a model of Alzheimer ’s disease
when IIS is reduced15. The transcriptional profile of daf-16 and hsf-1 helps to explain the robust
increase in stress resistance that accompanies their activation when IIS is decreased. They
initiate transcription of a number of chaperones, including members of the small heat shock
protein family, reactive oxygen scavenging enzymes, and anti-microbial genes16. A role for
reduced IIS in protecting against mutant SOD1 toxicity in the worm had not previously been
described, so we investigated the potential for mutations in daf-2 that promote daf-16 nuclear
localization to protect against SOD1 toxicity13. The ability of reduced IIS to broadly increase
stress resistance and protect against such varied insults makes this pathway of particularly
broad therapeutic interest. Our work, along with other findings in the worm, suggests that
genetic or pharmacological manipulations that enhance the transcriptional activity of daf16/FOXO could beneficially modify disease progression in numerous neurodegenerative
diseases.
Lifespan extending alterations in IIS signaling are mediated cell nonautonomously.
Mosaic analysis of worms with a hypomorphic allele of daf-2 revealed that reductions in IIS are
not required throughout the whole organism to promote longevity17. Rather, reduced IIS in
specific cells leads to a signaling cascade which coordinates aging throughout the worm. A
specific subset of neurons, as well as the intestine, were strongly longevity promoting when IIS
3

was reduced in these cells. Drosophila FOXO has also been shown to regulate the expression of
insulin responsive genes in a non-cellautonomous fashion18,19. While descriptions of cell
nonautonomous effects of reduced IIS on longevity exist, similar studies have not been
undertaken to describe cell autonomous/nonautonomous changes in stress resistance under
conditions of reduced IIS. In order to explore whether reduced IIS signaling functions in a cell
autonomous or cell nonautonomous fashion, we employed a worms strain with a genetic
background that increases the effectiveness of feeding RNAi in the nervous system. Our work
suggested that reduced IIS in the periphery had little or no effect on SOD1 toxicity the nervous
system. A thorough description of cell autonomous/nonautonomous changes in stress
resistance after reduced IIS may be of clinical importance. When designing therapeutics based
on decreased IIS activity it will be important to know which cell types should be targeted in
order to elicit the maximal increase in stress resistance.
Although the worm has become a favorite tool for the study of longevity and aging, due
to its relatively short lifespan and ease of genetic manipulation, the IIS pathway is an
evolutionarily conserved regulator of longevity. As in C. elegans, mutations which lead to
decreased IIS signaling, either through reduced activity of the drosophila insulin-like receptor
InR or reduction of its ligand chico, result in lifespan extension20. dFOXO, the drosophila
ortholog of daf-16 has also been shown to extend lifespan when over expressed in the adult
pericerebral fat body19.
Regulation of longevity by the IIS pathway is conserved in mammals as well. A number
of transgenic mice have been generated that have reduced IIS, including: fat specific insulin
receptor knockout, insulin receptor substrate -/-, IGF-1R +/- and klotho over expression (klotho
4

is a circulating factor which represses signaling from insulin and IGF receptors), all of these mice
have been found to have increased lifespan21-24. Another interesting line of support for IIS
regulating aging in mice comes from four different naturally occurring long-lived mouse strains.
The Ames dwarf, Snell dwarf, Laron dwarf and Little dwarf mice all have significantly increased
lifespans and all have very low levels of circulating IGF-125. Correlations between reduced IIS
and longevity have even been observed in human cohorts. An association between longevity
and decreased IGF-1R activity was reported in a cohort of Ashkenazi Jewish centenarians26.
Similarly, mutations in the FOXO1 and FOXO3 transcription factors have been reported to
correlate with longevity in other long lived human cohorts27-30. Taken together these data
suggest that the IIS pathway is an evolutionarily conserved regulator of longevity and aging. The
conserved nature of the IIS pathway suggests that findings from C. elegans regarding effects of
IIS on SOD1 toxicity may be of therapeutic interest in humans as well.
Figure 1.
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Figure 1. The DAF-16/FOXO transcription factors act as an integrator of signals mediated by IIS,
stress responsive pathways, germline signaling and changes in metabolism in order to
coordinate control of longevity and aging.

Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a progressive degenerative disorder of upper and
lower motor neurons that results in progressive paralysis and finally death from respiratory
failure. The incidence of ALS is approximately 2 per 100,000 individuals with more men affected
than women. Average age of onset is between 55-60 years and after the onset of symptoms
average survival is only 3 years. While the earliest and most overt symptoms of ALS affect
motor neurons, it is becoming apparent that ALS is not a pure motor neuron disease. Recent
6

findings have demonstrated involvement of sensory neurons as well as spino-cerebellar
pathways in ALS pathology, particularly in certain subsets of patients with frontotemporal
dementia31,32. Approximately 10% of ALS cases are familial (fALS) and mutations in 15 genes, as
well as a hexa-nucleotide repeat expansion of an intron in C9orf72, have been associated with
fALS33. Despite the identification of numerous fALS associated genes, no clear pathogenic
mechanism has yet been identified.
Potential Mechanisms of Toxicity in ALS
Damage from Reactive Oxygen Species
One potential cause of toxicity in ALS is ROS. ROS became a prime candidate for toxicity
in ALS when the first genetic linkages to fALS were identified as mutations in SOD1, a Cu/ZN
superoxide dismutase34. SOD1 acts to convert harmful ROS into H2O2, thus protecting the cell
against ROS damage. Elevated levels of oxidative damage to lipids, proteins, DNA and RNA have
all been reported either in post mortem tissue from ALS patients or in mouse models of ALS.
Although ALS associated mutations in SOD1 have been found in all five SOD1 exons35 these
mutations do not seem to cause toxicity through a loss of function mechanism. In mutant SOD1
mouse models of ALS, an fALS associated SOD1 mini-gene is inserted into the mouse genome.
This results in mutant human SOD1 being expressed under the control of its endogenous
promoter. These mice develop a sporadic, fatal, motor neuropathy despite having fully
functional mouse SOD135. This argues strongly for a gain of function toxicity of mutant SOD1.
Mice null for SOD1 develop normally and show no sporadic motor abnormalities, again arguing
against a loss of function model. ROS scavenging enzymes are known targets of daf-16/FOXO,
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and reduced ROS damage may represent one way that genetic and pharmacological
manipulations which increase daf-16/FOXO activity protects against mutant SOD1 toxicity.
Proteotoxic Aggregates
Like all other neurodegenerative diseases, insoluble protein aggregation is a hallmark of
ALS. In a study of 102 autopsies of sporadic ALS cases with various ages of onset and clinical
presentation between 1962 and 2000, all 102 cases presented with ubiquitin positive skein-like
and/or spherical inclusions36. TDP-43, SOD1 and FUS have all been identified as prominent
protein constituent of inclusions in sporadic and familial ALS37-39. Two genes linked to fALS,
Ubiquilin2 and valosin containing protein, are involved in facilitating the degradation of
improperly folded proteins, further supporting a link between protein aggregation and toxicity
in ALS. The exact mechanism of protein aggregate toxicity remains a mystery. Much debate
exists about the exact nature of the toxic species in ALS and other neurodegenerative diseases.
While protein aggregates are a hallmark of neurodegenerative disease, their abundance often
doesn’t correlate well with toxicity. This has led to the suggestion that large aggregated
inclusions may not be the toxic species. When disease associated proteins adopt non-native
conformations, they can form aggregates ranging in size from soluble oligomers all the way up
to macro-aggregates, which can be viewed by optical microscopy. It has been suggested that
the large protein aggregates, which are easily observable in many neurodegenerative diseases,
may represent a protective mechanism (i.e. sequestration), where smaller toxic oligomers are
sequestered into large aggregates by the cell in order to diminish their toxicity. The mechanism
of toxicity of aggregated proteins and the exact nature of the toxic species continues to be a
contentious topic in the field of neurodegenerative disease40. We explored the capacity of
8

reduced IIS to modulate SOD1 toxicity and found that decreased IIS leads to an increase in the
ratio of soluble to insoluble SOD1. We also found that total SOD1 burden was not correlated
with impaired movement but rather that the soluble to insoluble ratio of SOD1 was a better
predictor of changes in motor function. Reduced IIS elicits a significant increase in protein
solubility at the whole proteome level41. This fact coupled with the ubiquity of protein
aggregates in neurodegenerative disease suggests that activation of daf-16/FOXO may be
broadly therapeutic against many proteotxic insults associated with neurodegeneration.
Abnormal RNA Processing
A number of genes associated with fALS are known to play a role in RNA processing.
These include TDP-43, FUS and Senataxin42. TDP-43 is an RNA binding protein involved in
translational control, RNA splicing and miRNA processing. TDP-43 is a prominent component of
ALS inclusions37. While TDP-43 is usually present in both the cytoplasm and nucleus, once TDP43 inclusions appear in the cytoplasm there appears to be a loss of nuclear TDP-43 with TDP-43
becoming predominantly cytoplasmic and entering stress granules43. This potentially represents
a scenario where the aggregation of mutant TDP-43 results in a loss of function of wild type
TDP-43 through nuclear exclusion. TDP-43 has been found to interact with roughly 30% of the
mouse transcriptome. Immunoprecipitation of TDP-43 followed by deep sequencing of
associated RNAs has revealed that TDP-43 preferentially binds GU rich sequences44. This binding
can occur in exons, introns and 3’UTRs but a strong bias exists for binding to introns. More
specifically, intronic bindings sites that are relatively far (>500bp) from the nearest exon-intron
boundary make up 82% of TDP-43 binding sites identified in adult mouse brain. After TDP-43
knockdown, mRNAs with the greatest reduction in abundance have a mean intron size 6x
9

greater than unaffected messages. This has led to the hypothesis that TDP-43 acts to stabilize
messages with exceptionally long introns45. Interestingly this class of messages is particularly
abundant in the brain and could potentially explain the susceptibility of neurons to mutations in
a ubiquitously expressed gene such as TDP-43. Loss of TDP-43 also significantly effects
alternative splicing, with knockdown resulting in changes in 203 alternative splicing events in the
mouse brain45. While TDP-43 toxicity may be entirely dependent on changes in its own activity,
TDP-43 is also known to regulate the stability and splicing of other genes associated with ALS
and neurodegeneration including FUS, SMN2, progranulin, parkin and huntingtin45,46.
Fused in Sarcoma (FUS), another fALS associated gene involved in RNA processing,
regulates mRNA transport, translation, and miRNA processing. Similarly to TDP-43, ALS
associated mutations in FUS result in cytoplasmic localization of FUS in stress granules and the
formation of FUS containing aggregates. This seems to be a result of a defect in nuclear
transport caused by mutations in the C-terminal region47,48.
Hexanucleotide expansions of the first intron of C9orf72 were recently discovered to
represent the most common genetic cause of ALS49. Patients with this expansion present with
ubiquitin and p62 positive inclusions that are TDP-43 negative. One possibility is that like
mutations of TDP-43 and FUS C9orf72 expansion causes foci of aggregated RNA binding proteins
resulting in disrupted RNA processing50.
The potential involvement of abnormal RNA processing in ALS made the identification of
HNRNPK as the target of Psammaplysene A (PA) all the more interesting. While our original
interest in PA stemmed from the fact that it was able to activate FOXO transcription, we do not
know definitively that this is its therapeutic mechanism. The fact that PA binds HNRNPK
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suggested the possibility that PA is acting to correct toxicity associated with abnormal RNA
processing in neurons. Alternatively it presented the possibility that there is a signaling pathway
that links RNA processing with FOXO activity. Both are novel concepts that we wish to explore.

Heterogeneous Nuclear Ribonucleoprotein K
In our work identifying the target of PA we identify the Heterogeneous Nuclear
Ribonucleoprotein K (HNRNPK) as a PA target. HNRNPK is a member of the family of
heterogeneous nuclear ribonucleoproteins (hnRNP), historically characterized for their ability to
bind and form a complex with heterogeneous RNA polymerase II transcripts in the nucleus.
Further studies have revealed that HNRNPK is not only present in the nucleus but also functions
in the cytoplasm and mitochondria. HNRNPK has a modular structure with three K homology
(KH) RNA/DNA binding domains, a classical nuclear localization sequence (NLS), a K nuclear
shuttling (KNS) domain which facilitates bi-directional shuttling across the nuclear membrane,
and a highly unstructured protein-protein interaction domain (KI) (figure 2). It is believed that
the highly unstructured nature of the KI domain allows this domain to take on various structures
based on protein-protein interactions and accounts for the fact that HNRNPK has over 100
binding partners51. HNRNPK is phosphorylated at numerous sites by a variety of kinases and has
two distinct isoforms. HNRNPK binds tenaciously to poly-C stretches and has been shown to
interact with both coding and non-coding RNAs. The ability of HNRNPK to interact with such a
wide variety of proteins as well as RNA and DNA make it an excellent protein for integrating
cellular signals and facilitating cross talk between environmental signals and RNA
processing/transcription. HNRNPK’s role as an integrator of signaling pathways, including stress
responses, made it an intriguing target of PA. Unfortunately, the broad range of HNRNPK
11

activities made identification of a specific PA dependent change in HNRNPK function quite
challenging.
Figure 2.

Activities of HNRNPK:

Transcriptional Control: HNRNPK is capable of binding DNA as well as RNA and acts as a
transcriptional regulator of various genes52. While HNRNPK is thought to constitutively
associate with a number of promoters, including c-myc, its recruitment to many sites is thought
to be dependent on extracellular stimuli. For example serum shock selectively recruits HNRNPK
to the immediate early genes egr-1 and c-myc53. HNRNPK plays a crucial role in execution of the
p53 transcriptional profile after cellular stress. HNRNPK has been found to act as a
transcriptional co-activator of p53 target genes. HNRNPK and p53 are both recruited to p53
target gene promoters in a p53 dependent manner and loss of HNRNPK is found to inhibit p53
target transcription54. Interestingly, a number of genes are known to be downregulated upon
cellular stress and induction of p53, but the mechanism by which p53 inhibited these genes was
largely unknown. Recent findings indicate that p53 regulates the expression of a number of long
intergenic non-coding RNAs (linc). Linc-p21 acts as a transcriptional repressor of genes which
had previously been identified as being downregulated upon activation of p53. Interestingly,
this transcriptional repression by linc-p21 is dependent upon linc-p21 interaction with
HNRNPK55. HNRNPK acts as a regulator of transcription and is involved in transcriptional
responses to a variety of external stimuli.
12

RNA Shuttling: HNRNPK is an unusual member of the hnRNP family because unlike many other
hnRNPs it is capable of shuttling in and out of the nucleus. Evidence suggests that an important
function of this shuttling ability is to move mRNAs out of the nucleus and load them onto
polysomes. Knockdown of HNRNPK in Xenopus embryos leads to terminally differentiated
neurons with a severely disorganized axonal cytoskeleton. Immunoprecipitation of HNRNPK
followed by microarray analysis of its associated mRNAs revealed that messages encoding many
of the dysregulated cytoskeletal components are associated with HNRNPK. Analysis of nuclear
versus cytoplasmic abundance of mRNAs revealed a specific reduction in export and polysome
loading of some HNRNPK target mRNAs, suggesting a role of HNRNPK in mRNA nuclear export56.
Translational Repression: One of the best characterized examples of HNRNPK translational
control occurs in developing erythrocytes. These cells undergo a complex maturation that
involves loss of both the nucleus and mitochondria. This requires them to synthesize all of the
necessary mRNAs needed for their development before loss of nuclear structure. These
messages then need to be controlled at the level of translational activation for the remainder of
the developmental process. Loss of mitochondria is one of the last steps in erythrocyte
development and occurs immediately before these cells take on a purely oxygen carrying
function. 15-lipoxygenase (LOX) plays a key role in the maturational degradation of
mitochondria57. Temporal control of LOX translation is achieved through binding of HNRNPK to
LOX mRNA. HNRNPK binds to the differentiation control element (DICE) sequence in the 3’ UTR
of LOX mRNA and prevents assembly of the 80s ribosome by inhibiting joining of the 60s subunit
to the 40s subunit. In a developmentally regulated fashion, phosphorylation of HNRNPK by c-src
inhibits its binding to DICE and allows for translation of LOX58.
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RNA Stability: HNRNPK has recently been demonstrated to regulate the stability of rRNAs.
Homeostasis of translational machinery is crucial for normal cellular function. Regulation of
rRNA abundance is one mechanism by which cells are able to alter translational capacity.
Degradation of rRNAs is an important cellular response to stress and dysregulation of rRNA
degradation has been implicated in certain types of cancer59. Under conditions of cellular stress
the eukaryotic initiation factor 3 subunit f (eIF3f) interacts with HNRNPK causing HNRNPK to
dissociate from rRNAs and allowing for their degradation. Loss of eIF3f or overexpression of
HNRNPK leads to abnormal stabilization of rRNAs and may contribute to malignant
transformation60. In addition to non-coding rRNAs HNRNPK has also been found to bind and
stabilize mRNAs such as collagen 1A1, 1A2 and 3A161.
Alternative Splicing: Many of the hnRNPs, including HNRNPK, have been found to influence
alternative splicing. Analysis of the effects of 14 different hnRNPs on 56 alternative splicing
events in genes associated with apoptosis identified HNRNPK and HNRNPC as having the
broadest effects62. Further investigation of the effects of HNRNPK on alternative splicing of
apoptotic genes revealed that HNRNPK promotes the generation of the anti-apoptotic Bcl-x(L)
isoform over the pro-apoptotic Bcl-x(S) isoform63.
Summary: HNRNPK is a DNA/RNA binding protein that is capable of integrating cellular signals,
particularly those involved in stress response, and effecting downstream nucleic acid based
processes. Our identification of HNRNPK as the target of PA is particularly interesting because
of the important role HNRNPK plays in response to stress stimuli. We monitored many of the
above functions for changes after PA treatment in order identify which aspects of HNRNPK
biology were being affected by PA. No previous link between HNRNPK function and FOXO
14

activity has been described. Previous work in the worm has shown that knockdown of
ribosomal proteins can be lifespan extending in a daf-16 dependent manner. although the
ability of HNRNPK to modulate translation initiation through regulation of rRNA stability
suggests a potential link to aging and FOXO. No small molecules have previously been described
to interact with HNRNPK.
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Abstract: The DAF-2 Insulin/IGF-1 signaling (IIS) pathway is a strong modifier of
Caenorhabditis elegans longevity and healthspan. As aging is the greatest risk factor for
developing neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), we were
interested in determining if DAF-2 signaling modifies disease pathology in mutant superoxide
dismutase 1 (SOD1) expressing C. elegans. Worms with pan-neuronal G85R SOD1 expression
demonstrate significantly impaired locomotion as compared to WT SOD1 expressing controls
and they develop insoluble SOD1 aggregates. Reductions in DAF-2 signaling, either through a
hypomorphic allele or neuronally targeted RNAi, decreases the abundance of aggregated SOD1
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and results in improved locomotion in a DAF-16 dependant manner. These results suggest that
manipulation of the DAF-2 Insulin/IGF-1 signaling pathway may have therapeutic potential for
the treatment of ALS.

Introduction: ALS is an adult onset neurodegenerative disease characterized by progressive
weakness, due to dysfunction and eventual death of motor neurons. The majority of cases of
ALS are sporadic but single gene mutations have been described that lead to inherited versions
of the disease. These genes include SOD1, TAR DNA binding protein (TDP43), fused in sarcoma,
progranulin, ubiquilin 2 and a hexanucleotide repeat expansion of a noncoding region in
C9ORF7234,64-69. Expression of some of these mutant proteins in model organisms has been used
to successfully model ALS pathology.
Point mutations in SOD1 (e.g., G85R) are an example of a genetic cause of familial ALS
that has been successfully modeled in transgenic mice and nematodes70. The G85R point
mutation causes a toxic gain-of-function, which in mice leads to ubiquitinated SOD1 aggregates
and motor neuron death 71. C. elegans expressing human G85R SOD1 in the nervous system
accumulate SOD1 aggregates and demonstrate reduced mobility compared to WT SOD1
expressing worms 72. The availability of numerous loss-of-function mutants affecting highly
conserved signaling pathways make C. elegans an ideal system in which to explore the
relationship between such pathways and SOD1 aggregation and toxicity in an in vivo setting.
Aging is the greatest risk factor for the development of ALS. The Insulin/IGF-1 signaling
(IIS) pathway is a robust modifier of longevity and aging in C. elegans1. Loss of function of the
Insulin/Insulin-like growth factor receptor, DAF-2, promotes longevity via signaling cascades
mediated by inhibition of the phosphoinositide 3-kinase (age-1) and activation of the forkhead
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transcription factor DAF-16 via its nuclear localization 4. While nuclear localization of DAF-16 is
required for it to execute its transcriptional activities, it is not sufficient to enhance longevity
and stress resistance 3. Other pathways are known to interact with the IIS pathway and
modulate stress resistance and/or aging by regulating transcriptional activity of DAF-16,
without modifying its nuclear abundance 73,74. In addition to promoting longevity, loss of
function alleles of daf-2 or age-1 protects the worm against exogenous stressors including heat
shock, oxidative stress, heavy metal stress, UV damage and infection 8-11. The beneficial effects
of reduced IIS rely, in part, on the ability of decreased IIS to activate the transcription factor
DAF-16, leading to increased expression of numerous stress resistance genes, such as small heat
shock proteins and reactive oxygen species scavenging enzymes 11,16. Additionally, reduced IIS
also results in changes in protein glycosylation, metabolism, mitochondrial abundance and lipid
biosynthesis, all of which are thought to contribute to the stress resistant phenotype of reduced
IIS75-78 . Reduced DAF-2 signaling has been shown to have beneficial effects on other age related
neurodegenerative diseases such as polyglutamine expansion proteinopathy and Alzheimer’s
disease4,15. The ability to easily control the IIS pathway both genetically and via RNA interference
(RNAi) makes the worm an excellent system for studying the interactions between aging and the
toxicity of mutant SOD1. In the present study we asked if manipulation of IIS pathway can
improve the reduced mobility and insoluble protein aggregation seen in G85R SOD1 expressing
worms.

Results:
Decreased crawling speed of G85R worms is ameliorated by decreased IIS signaling
We began by monitoring the average crawling speed of G85R, G85R;daf-2(e1370),
G85R;daf-16(mgDf50), daf-2(e1370) and daf-16(mgDf50) worms on a bacterial lawn (OP50) at
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96, 120, 144 and 168 hours after depositing eggs onto plates with bacteria (figure 1 A). Group
differences were observed at 96, 120 and 144hrs post egg drop (96, 120 and 144hrs:
F(4,25)=22.96, F(4,25)=11.08, F(4,28)=12.57 respectively by single factor ANOVA p<0.01 at all
timepoints). At 96, 120 and 144hrs after growth initiation, the G85R;daf-2(e1370) worms
crawled approximately twice as fast as G85R worms (p<0.05 at 96, 120 and 144 hrs by Tukey’s
post-hoc) while at the 168hr time point no significant difference was observed. Although not
statistically significant, G85R;daf-16(mgDf50) worms tended to perform worse than G85R
worms at all time points. These results suggest that reduced IIS ameliorates the toxic effects of
mutant SOD1, and while this benefit is maintained for 144hrs of life, it can not be sustained
after this point. The fact that G85R worms that are also null for DAF-16 tend to perform worse
than G85R worms suggests that part of the worm’s endogenous response to proteotoxic insults,
such as mutant SOD1, may include activation of DAF-16.
In order to control for any potential variation in locomotion and/or behavioral
differences in worms with the daf-2(e1370) or daf-16(mgDf50) mutations, we examined the
average crawling speed of worms carrying these mutations on a non-SOD1 background. There
were no statistically significant differences between these two groups in locomotory activity at
any time point observed (by Tukey’s post-hoc), suggesting that these mutations are modulating
the toxicity of G85R as opposed to altering other aspects of behavior or locomotion in general.
Decreased swim speed of G85R worms is ameliorated by decreased IIS signaling
While the crawling assay allowed us to identify an improvement in the locomotory
activity of G85R worms when they were on the daf-2(e1370) background, the inability to control
for behavior during a given observation window made speed measurements variable. In order
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to reduce variability we examined swimming worms, a context which elicits continual
movement.
We compared the following worm strains in the swimming assay: WT SOD1, G85R,
G85R;daf-2(e1370), G85R;daf-16(mgDf50), and G85R;daf-2(e1370);daf-16(mgDf50) (figure 1 B).
Between group differences were detected at all timepoints by single factor ANOVA (72, 96, 120,
144, and 168hrs: F(4,25)=15.53, F(4,26)=14.22, F(4,25)=8.67, F(4,25)=10.82, F(4,25)=9.56 p<0.01 at all
timepoints). WT SOD1 worms were significantly faster than G85R worms at all timepoints
(p<0.01 by Tukey’s post-hoc). G85R;daf-2(e1370) worms were also significantly faster than
G85R worms at all timepoints (p<0.05 by Tukey’s post-hoc) and had mobility equivalent to WT
SOD1 worms at all time points (no significant difference by Tukey’s post-hoc). Ablation of daf-16
in the G85R;daf-2(e1370) worms eliminated the observed rescue effect of daf-2(e1370) as no
statistically significant difference was observed between G85R and G85R;daf-2(e1370);daf16(mgDf50) worms (by Tukey’s post-hoc). These observations provide further data in support of
the hypothesis that the daf-2(e1370) background is strongly protective against the toxicity of
G85R SOD1 as assessed by locomotory function and that this protection is daf-16 dependent.
There was a trend for G85R;daf-16(mgDf50) worms to perform worse than either G85R
or (G85R;daf-2(e1370);daf-16(mgDf50) worms although it was only significant at 96hrs (p<0.05
by Tukey’s post-hoc). The observation that G85R;daf-16(mgDf50) worms tended to perform
worse than G85R;daf-2(e1370);daf-16(mgDf50) worms suggests that part of the beneficial effect
of daf-2(e1370) may be daf-16 independent. As in the crawling assay, the fact that G85R;daf16(mgDf50) worms tended to perform worse than G85R worms also suggests a potential role of
daf-16 in the worm’s endogenous response to proteotoxic insults. Like the crawling assay, the
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swimming assay further supports the hypothesis that reduced IIS activity reduces G85R SOD
toxicity.
In order to determine the specificity of daf-2(e1370) on SOD1 toxicity we tested the
effects of daf-2(e1370) on worms expressing TDP-43 in the nervous system (Psnb-1::hTDP-43)
(Figure 1 C). Like the mutant SOD1 expressing worms, transgenic expression of TDP-43 in the C.
elegans nervous system causes locomotory defects and protein aggregation14. In a comparison
of swim speed of TDP-43 worms versus TDP-43;daf-2(e1370) worms, we found daf-2(e1370)
improved TDP-43 induced swimming deficit (p<0.01 by t-test) .
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Figure 1.
A) Videos of worms crawling on OP50 at the indicated
times were taken and used to calculate worm speed
using the parallel worm tracker software. B) Average
swim speed normalized to size was calculated at the
indicated times using the parallel worm tracker. C) Swim
speed normalized to size was calculated for TDP43 and
TDP43;daf-2(e1370) worms 72hrs post egg drop.

Improvement of the G85R phenotype is dependent on decreased IIS in the nervous system.
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daf-2(RNAi) has previously been described to mimic the longevity/healthspan promoting
effects of the daf-2(e1370) hypomorphic allele and RNAi to daf-16 has been shown to abrogate
the benefits of loss of function of daf-2 79. We next compared locomotion of G85R worms fed
daf-2, daf-16 or empty vector (EV) RNAi. Unexpectedly, feeding neither daf-2 nor daf-16 RNAi
to G85R worms had a significant effect on locomotion (Figure 2 D,E). One possible explanation
for these differences is the variable effectiveness of RNAi in the worm nervous system.
The resistance of worm neurons to RNAi can be mitigated by transgenic over expression
of SID-1 in the nervous system80. SID-1 allows for passive cellular uptake of double stranded
RNA, therefore increasing a cells response to RNAi. SID-1 is not normally expressed in neurons,
therefore one way to selectively increase the nervous systems response to RNAi is through
transgenic expression of SID-1 in the nervous system of worms that are null for sid-1 in
peripheral tissues. In order to maximize the efficacy of RNAi in the nervous system of G85R
worms we generated Psnb-1::G85R::YFP; sid-1(pk3321)[Punc119::sid-1];Pmyo-6::mcherry
worms, hereafter referred to as G85R;sid-1. G85R and G85R;sid-1 worms were fed G85R-YFP or
empty vectro (EV) RNAi. G85R;sid-1 worms fed G85R-YFP RNAi showed decrease YFP intensity
in the nervous system and a significant (p<0.05 by t-test) increase in locomotory activity
compared to G85R;sid-1 worms fed EV RNAi (Figure 2 A-B). Feeding G85R worms G85R-YFP
RNAi had no effect on fluorescence intensity or locomotory activity (Figure 2 A and data not
shown). These observations lead to two important conclusions 1) they confirm the increased
efficacy of neuronal RNAi in the sid-1 nervous system expressing sid-1(pk3321)[Punc119::sid1];Pmyo-6::mcherry background and 2) demonstrate that the locomotory phenotype in these
worms is likely to be due to mutant G85R SOD1 expression and not integration of the transgene
into a critical locus.
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To better understand the role of IIS in the nervous system on G85R toxicity we
compared the following groups: RNAi to daf-2, daf-16 and EV fed to G85R and G85R;sid-1
worms. While G85R worms fed daf-2 RNAi showed no significant improvement in mobility
compared to G85R worms fed EV, G85R;sid-1 worms fed daf-2 RNAi had significantly improved
mobility compared to all other groups (ANOVA F(3,16)=13.66 p<0.01 and p<0.01 by Tukey’s posthoc) (Figure 2 E). This disparity between the effects on G85R versus G85R;sid1 worms suggests
the need for decreased IIS activity in the nervous system in this model to rescue locomotory
activity.
We also compared locomotion of G85R;daf-2(e1370) worms fed daf-16 RNAi or EV.
Feeding G85R;daf-2(e1370) worms daf-16 RNAi abrogated a significant (p<.05 by t-test) amount
of the daf-2(e1370) induced rescue of locomotory function as compared to feeding EV RNAi
(figure 2 C). It is interesting that the daf-16 (RNAi) appears to diminish daf-2(e1370) rescue on a
non- Punc119::sid1;sid1(pk3321) background suggesting it is working outside of the nervous
system. This raises the possibility that although reduced IIS is required in the nervous system to
rescue locomotory activity in this model, there are daf-16 dependent effects in non-nervous
system tissues.
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Figure 2.
A) YFP signal was imaged in G85R or G85R;unc119p::sid1;sid1(pk3321) worms fed empty vector
(EV) or G85R:YFP RNAi in order to demonstrate the efficacy of RNAi in neurons on the
unc119p::sid1;sid1(pk3321) background B-E) Average speed normalized to size of swimming
worms fed bacteria expressing the indicated RNAi
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IIS activity modulates the solubility of SOD1
Aging in the worm is known to be a major modifier of generalized protein solubility and
aggregation, and decreased daf-2 signaling has been found to decrease the amount of
aggregation that occurs41. Since aggregated SOD1 generally correlates with toxicity in ALS we
wanted to determine if the daf-2(e1370) background was decreasing aggregation in G85R
worms. Zhang et. al. demonstrated that the daf-2(e1370) background significantly reduces the
steady state abundance of insoluble TDP-43 in the worms we assessed in our swimming assay 14.
To determine if IIS was modifying the solubility of SOD1 in this model, soluble versus insoluble
fractions were prepared from G85R, G85R;daf-2(e1370) and G85R;daf-2(e1370);daf-16(mgDf50)
and immunoblotted for SOD1 and actin (figure 3A). We found a significant amount of insoluble
SOD1 in the G85R worms which was greatly diminished in the daf-2(e1370) background.
Deletion of daf16 in the G85R;daf-2(e1370);daf-16(mgDf50) worms suppressed this effect.
While the absolute values of soluble SOD1 were not constant between the three groups the
ratio of insoluble to soluble SOD1 was significantly greater in the G85R;daf-2(e1370);daf16(mgDf50) and G85R worms as compared to G85R;daf-2(e1370) (figure 3B) (p<.05 by single
factor ANOVA, F(2,6)=7.719 and p<0.05 for both comparisons by Tukey’s post-hoc). This
suggested that daf-2(e1370) improves the solubility of SOD1, leading to an increased steadystate abundance of the soluble species. These data were collected from a mixed population of
animals so we were interested in further characterizing SOD1 abundance at various ages.
Total SOD1 burden does not correlate with locomotor activity
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While no differences in YFP intensity were evident by eye when observing the different
worm strains, we wished to explore the total burden of SOD1 at various times more closely. In
order to do this we used the COPAS worm sorter to measure YFP intensity and time-of-flight
(TOF, i.e., length) in individual animals from a mixed population of approximately ten thousand
worms from the following groups: G85R, G85R;daf-2(e1370) and G85R;daf-2(e1370);daf16(mgDf50) (figure 3C). Using TOF as a proxy for age, we were unable to identify a direct
correlation between total SOD1 burden and locomotory activity. The data were binned into TOF
measurements of 100 units and significant differences between groups were observed in all bins
by ANOVA (0-100 TOF F(2,11369)=881.69, 101-200 TOF F(2,7209)=250.90, 201-300 TOF F(2,4880)=48.1,
301-400 TOF F(2,3075)=243.23, 401-500 TOF F(2,1435)=411.05, 501-600 TOF F(2,708)=277.65). In young
worms( 0-200 TOF) SOD1 intensity was equivalent between G85R and G85R;daf-2(e1370) worms
(no significant differences between groups by Scheffe’s post-hoc), yet significant locomotory
differences were observed between these groups at all ages assessed using the swimming assay.
Conversely, young G85R;daf-2(e1370);daf-16(mgDf50) worms have significantly less YFP
intensity than G85R and G85R;daf-2(e1370) worms (p<0.05 by Scheffe’s post-hoc), yet they
perform worse than G85R;daf-2(e1370) worms and equivalent to G85R worms in our
locomotory assays. Looking at older worms (300-600 TOF), G85R worms have a total SOD1
burden that significantly exceeds that of G85R;daf-2(e1370);daf-16(mgDf50) worms (p<0.05 by
Scheffe’s post-hoc in 301-400, 401-500 and 501-600 bins) yet they show similar locomotory
activity in the swim test. This is unlikely to simply be a floor-type effect as G85R;daf-16(mgDf50)
worms perform worse in the swimming assay than both G85R and G85R;daf-2(e1370);daf16(mgDf50) worms, suggesting that there is room for decline in the locomotory phenotype.
Taken together these results suggest that overall SOD1 burden is not responsible for the
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locomotory differences observed between these groups, but rather suggest that the locomotory
differences result from changes in how SOD1 toxicity is handled in these various backgrounds.

Figure 3.
A) Representative western blot from three experiments looking at soluble vs insoluble SOD1 B)
Quantification of SOD1 insoluble : soluble ratio C) COPAS data showing average YFP intensity for
bins of various worm TOF

IIS effects on longevity in the SOD1 background
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The toxicity of mutant SOD1 expression in the C. elegans nervous system was previously
reported to have a negative effect on lifespan72. In order to determine whether decreased daf-2
signaling in this background has a beneficial effect on lifespan, similar to its effect on
locomotion, longevity was monitored in WT SOD1, G85R;daf-2(e1370) and G85R;daf2(e1370);daf-16(mgDf50) worms (figure 4). WT SOD1 and G85R;daf-2(e1370);daf-16(mgDf50)
worms had similar lifespans, while the G85R;daf-2(e1370) worms had a modest but statistically
significant increase in lifespan (p<0.05 by Mann-Whitney analysis). Interestingly, there is no
correlation between health and lifespan as assayed by locomotory activity.

Figure 4.
Longevity analysis, percent alive per day

Discussion:
Aging is a common risk factor for many neurodegenerative diseases81. The IIS pathway
is a well characterized genetic modifier of aging in C. elegans 1 and we demonstrate here that
alterations in this pathway can robustly modify the toxicity of mutant SOD1 as assessed by
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mobility, protein aggregation and longevity. We find that reduced daf-2 activity has a beneficial
effect on the toxicity of G85R SOD1 and that this beneficial effect is daf-16 dependent. While
aging in the worm has previously been shown to be coordinated at the organismal level, we
found a requirement for IIS to be reduced in the nervous system in order to modify SOD1
toxicity. Although the genetic modifiers of aging are less well characterized in humans, these
data suggest that IIS and pathways which beneficially modify lifespan/healthspan in humans
may be potential targets for therapeutic intervention in ALS.
Although their exact role in disease pathology is not entirely understood, aggregated
proteins are associated with numerous neurodegenerative diseases, including ALS82,83. As aging
occurs, the total burden of aggregated proteins increases, suggesting a diminished capacity for
proper folding and/or degradation of aggregation prone proteins with age 84. In this study we
demonstrate that a LOF mutation of daf-2 diminishes the amount of insoluble SOD1; an effect
that might be due to an increased capacity for clearance/folding in these worms. Similar
observations have been made regarding the ability of modifications of IIS to modulate the
solubility and toxicity of other disease related proteins 4,12,14. This is likely due to the ability of
decreased IIS to induce expression of chaperones such as the HSP family of proteins 16. An RNAi
screen performed on these worms identified chaperones as the most highly represented
functional class of proteins found to negatively modify SOD1 aggregation in this model 72.
Increased capacity for folding/clearance in worms with reduced IIS is likely to contribute to
decreasing the toxcicity of mutant SOD1 in this model. We can not rule out the contribution of
other changes in metabolism, lipid biogenesis, and free radical scavenger expression which have
also been linked to increased lifespan and stress resistance due to decreased IIS 11,77,78.
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Our data from the COPAS support both the concept that: 1) the daf-2(e1370)
background can help reduce buildup of insoluble protein and 2) the ratio of soluble to insoluble
G85R SOD1, rather than its total abundance, is associated with toxicity in this model. Using TOF
as an approximation for age, it appears that G85R worms accumulate less G85R SOD1 on the
daf-2(e1370) as opposed to wild type background over time. This suggests an increased
capacity for clearance of SOD1 over time in the daf-2(e1370) background. The abundance of
SOD1 in G85R;daf-2(e1370);daf-16(mgDf50) worms is less than both G85R and G85R;daf2(e1370) in young animals yet their mobility is reduced compared to G85R;daf-2(e1370) and
equivalent to G85R at all time points assessed. Although the relative abundance of SOD1 varies
between these strains over time, their relative locomotory activity remains constant, suggesting
that it is not total SOD1 abundance that dictates toxicity.
Previous work with a worm model of Aβ toxicity has demonstrated that the daf2(e1370) allele is protective against Aβ1-42 aggregates in two distinct ways. First daf-2(e1370) led
to activation of hsf-1 which resulted in breakdown of Aβ1-42 fibrils. Second daf-2(e1370) led to
activation of daf-16 which increased the abundance of Aβ1-42 in high molecular weight
aggregates. It is possible that both activities diminish Aβ1-42 toxicity by removing Aβ1-42from the
putatively toxic fibril pool15. If these observations can be generalized, they could account for the
lack of correlation between total SOD1 abundance and locomotory deficits in these worms.
G85R;daf-2(e1370);daf-16(mgDf50) worms may not show the robust increase in SOD1 over time
seen in the G85R worms because they are not accumulating the large aggregates of protein.
These worms still suffer from SOD1 toxicity due to high levels of insoluble SOD1, but may never
reach the same YFP intensity as G85R worms due to a lack of high molecular weight aggregation
facilitated by daf-16. Activation of hsf-1 in the G85R;daf-2(e1370);daf-16(mgDf50) worms may
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also explain their increased mobility compared to G85R;daf-16(mgDf50) worms in the motility
assay.
Using worms with neuronal expression of SID1, we demonstrate that the beneficial
effect of reduced daf-2 is likely to be mediated by decreased IIS signaling in the nervous system.
This contrasts with its effects on longevity, where daf-2 RNAi (on a background lacking pk3321
to enhance neuronal RNAi) mimics the lifespan extending effects of the daf-2(e1370) allele. In
this setting, daf-2 RNAi does not influence gene expression in the nervous system 17. G85R;daf2(e1370) worms fed daf-16 RNAi should have normal levels of DAF-16 in their nervous system
and it would be activated due to the daf-2(e1370) background. If the beneficial effect of
decreased daf-2 activity was completely mediated by the nervous system, then these worms
should have comparable locomotory function to G85R;daf-2(e1370) worms fed empty vector.
We find these worms to have an intermediate phenotype with a significant reduction in
locomotory activity as compared to worms on empty vector RNAi plates. This suggests that part
of the beneficial effect of daf-2(e1370) might be mediated through non-neuronal tissue(s).
Alternatively, daf-16(RNAi) may partially, although not completely, reduce daf-16 expression in
both neuronal and non-neuronal cells. Taken together, these findings suggest that although
decreased IIS is required in the in the nervous system in order to have a beneficial effect on
SOD1 toxicity, some of the downstream actions of reduced neuronal IIS may be functioning in
the periphery.
Our results demonstrate the strong capacity of the IIS pathway to modulate G85R
proteotoxicity. One possible mechanism of action for this beneficial effect is through the ability
of this pathway to increase the cellular capacity to prevent toxic insoluble protein accumulation.
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Interestingly this beneficial activity of IIS may not be completely cell autonomous but may be in
part a manifestation of alterations in cellular aging coordinated at the organismal level. This
pathway may represent a possible therapeutic target for proteotoxic diseases cause by insoluble
proteins.

Materials and Methods:
Worm Strains and Handling: C. elegans were cultured under standard conditions at
20⁰C and fed the E. coli strain OP5085. The following worm strains were used: daf-16(mgDf50)
and daf-2(e1370) were obtained from the CGC. Psnb-1::hTDP-43;Pmtl-2::GFP and daf-2(e1370);
Psnb-1::hTDP-43;Pmtl-2::GFP were a generous gift of Chris Link. Psnb-1::G85R SOD1::YFP and
Psnb-1::WT SOD1::YFP were a generous gift from Arthur Horwich and Jiou Wang.
Punc119::sid1;sid1(pk3321) was a generous gift from Martin Chalfie. Double and triple worms
were generated by standard genetic crosses and verified by PCR or fluorescence expression.
Locomotory Assay: Video recordings of worms were made using the image acquisition
tool in Matlab 2009b. These videos were then analyzed using the parallel worm tracker
software (downloaded from the Goodman lab http://wormsense.stanford.edu/tracker/). For
monitoring locomotion on OP50 a 1 minute video was recorded from each plate at the center of
the lawn of OP50. At 50 worms were analyzed for each genotype at each timepoint. The
number of worms was greater than 30 for each genotype at each timepoint. For the swimming
assay worms were suspended in a pool of M9 and their swimming was recorded for 30 seconds.
At least 30 worms were analyzed per group per timepoint. Statistics were performed using the
average of each video as an n of 1 for speed or size/speed.
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Feeding RNAi: HT115 bacteria containing the indicated genes in the L4440 vector were
grown overnight at 37⁰C in 50ug/ml ampicillin. They were then seeded on to NGM plates
supplemented with 12.5ug/ml tetracycline and 4mM IPTG and allowed to grow overnight at
room temperature. Gravid adults were allowed to drop eggs on the RNAi plates for 2 hrs and
were then removed. Plates were then kept at 20⁰C until they were assayed.
Imaging: Worms were immobilized in 25mM levamisole on agar pad slides and then
coverslipped. Images were acquired at a constant intensity on a confocal microscope using a
40uM Zstack.
Soluble vs Insoluble Protein Assay: Approximately 100ul of packed worms were lysed
via sonication in 300ul RIPA buffer (150mM NaCl, 50mM Tris pH 8.0, 1mM EGTA, 5mM EDTA, 1%
NP40, 0.5% Sodium Deoxycholate, 0.1% SDS) with complete protease inhibitor cocktail. A soft
spin of 800g for 5 min was performed to remove unlysed worms and large debris from the
lysate. The supernatant was then spun at 99,000 x g for 30min @ 4⁰C. The supernatant was
kept as the soluble fraction. The pellet was sonicated again in RIPA as a wash step to ensure
removal of all soluble protein. It was centrifuged again at 99,000 x g for 30min @ 4⁰C. The
pellet was then solublized in 50ul urea buffer (40mM Tris, 7M urea, 2M thiourea, 1% CHAPS).
Equal volumes of sample were run on SDS-page gels under reducing conditions and probed with
anti SOD1 antibody (Cell Signaling #2770) and anti actin (Sigma). Westerns were visualized using
the Odyssey system and quantified using ImageJ.
COPAS: COPAS was used to sort and collect fluorescence intensity from 10,000 worms
from each group as described in 86.
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Longevity Assay: An egg drop was performed on NGM plates with OP50. The lifespan
assay was carried out at 20⁰C and worms were transferred to fresh NGM OP50 plates as
necessary in order to avoid starving the animals. Each day worms were counted. FUDR was not
included in this assay so during the active reproductive period of the worms they were
transferred to a new plate each day.
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Chapter 3
The Small Molecule Psammaplysene A is Neuroprotective in
Multiple Models of Motor Neuron Disease
Adapted from:
FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor
neuron diseases. J Neurosci. 2009 Jun 24;29(25):8236-47. For complete article see Appendix 2

Abstract:
Aging is a risk factor for the development of adult-onset neuro-degenerative diseases. While
some of the molecular pathways regulating longevity and stress resistance in lower organisms
are defined (i.e., those activating the transcriptional regulators DAF-16 and HSF-1 in C. elegans),
their relevance to mammals and disease susceptibility are unknown. Although the mammalian
ortholog of daf-16 has been implicated in regulating longevity in mammals varying effects have
been reported regarding its ability to increase stress resistance and cell survival. Using a
compound (Psammaplysene A, PA) that increases nuclear localization of FOXO3 we demonstrate
that PA protects against insults associated with motor neuron disease.

Introduction:
Although motor neuron diseases due to single gene mutations are unusual (~10% of
cases), the affected genes have been successfully used to model these diseases in experimental
systems 87. Rare, genetic forms of motor neuron disease that arise from mutations in
superoxide dismutase (SOD) or p150glued have a disease phenotype that strongly resembles
sporadic ALS with lower motor neuron predominance 88. Another predominantly lower motor
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neuron disease, called spinobulbar muscular atrophy (SBMA or Kennedy’s Disease) is due to a
polyglutamine expansion in the androgen receptor 89. Despite identification of the “disease
protein”, the underlying pathogenic mechanism(s) remain incompletely understood.
In most cases of sporadic ALS, motor neuron death is triggered by the interaction of a
genetic pre-disposition and environmental factors 90. Genome-wide association studies have
failed to reveal consistent susceptibility loci 91,92. Correlative evidence suggests that aging is a
risk factor for the development of ALS as well as other adult-onset neurodegenerative disorders
93

. Studies from a variety of experimental systems have provided insight into the genetic factors

controlling aging, in particular, the insulin/insulin-like growth factor signaling pathway 94,95. In
Caenorhabditis elegans, hypomorphic alleles of the daf-2 gene (mammalian homolog,
insulin/insulin-like growth factor receptor) and the downstream signaling molecule age-1
(mammalian homolog, phosphotidylinositol-3’-kinase, PI3’K) promote longevity and lifespan
extension. These effects require the activity of the DAF-16 transcription factor (mammalian
homolog, FOXO3a)96.
DAF-16/FOXO3a shuttles between the cytoplasm (where it is inactive) and the nucleus
in a process that is controlled by its phosphorylation state 97. Phosphorylation of DAF16/FOXO3a by the PI3’K substrate kinases Akt and SGK 98 leads to the 14-3-3 protein-dependent
export of nuclear DAF-16/FOXO3a and re-entry into the nucleus requires dephosphorylation and
release of 14-3-3 98,99. Within the nucleus, DAF-16/FOXO3a leads to the expression of a number
of genes that have context-dependent effects on cellular physiology. Expression of a
constitutively nuclear FOXO3a can promote the death of purified motor neurons and cerebellar
granule cells and this has been linked to the expression of FasL 97,100. In contrast, active FOXO3a
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protects a variety of quiescent cells against death evoked by oxidative stress or glucose
deprivation and this has been linked to the expression of manganese superoxide dismutase
(MnSOD) and catalase 101,102. Thymocyte survival and differentiation is FOXO3a-dependent 103.
Differences in beneficial versus harmful effects of FOXO3a probably relate to cell-circumstancespecific level of activation and post-translational modifications 104. (For a review of posttranslational modifications effecting the activity of FOXO transcription factors see Appendix 1)
Some of the stresses that contribute to motor neuron death in ALS include
excitotoxicity, reactive oxygen species, accumulation of insoluble aggregates of neurofilaments,
and defects in axonal transport 87,105-107. Since DAF-16/FOXO3a-dependent gene transcription, in
some contexts, combats cellular stresses, we inquired whether manipulating FOXO3a nuclear
abundance using the small molecule PA protected neurons from insults relevant to motor
neuron diseases. We show that PA is neuroprotective across phyla and that its neuroprotective
qualities are likely due to enhancement of DAF-16/FOXO3a activity.

Results:
A chemical-genetic screen reported the identification of a series of compounds that can
inhibit FOXO1a nuclear export. Compounds fell into two classes: 1) inhibitors of general nuclear
export machinery and 2) inhibitors specific to the FOXO1a pathway 108. We inquired whether
compounds in the second class would also block the nuclear export of FOXO3a since they would
be predicted (based on the results above) to display neuro-protective activity. We focused on
Psammaplysene A (PA), which was isolated from a marine sponge, because it was the most
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potent of the class 2 inhibitors (Figure 1A) 109. In addition PA was reported to have no effect on
AKT phosphorylation suggesting it acted either downstream of AKT or in a synergistic pathway.
We began by looking at the effect of a synthetic sample of PA (for synthesis see 110) on
the distribution of FOXO3a endogenously expressed by neurons. We biochemically isolated
nuclei from spinal cord cultures treated with PA or vehicle (Figure 1B). Based on the distribution
of the nuclear envelope protein lamin, it is clear that our subcellular fractionation procedure
greatly enriched nuclei. There was an ~ 2.5 fold increase in the nuclear FOXO3a/nuclear lamin
ratio in the PA treated cultures in comparison to vehicle-treated cultures. Total FOXO3a and
lamin levels were unaffected by drug treatment. These observations indicate that PA promotes
the sequestration of FOXO3a into nuclei.
We next tested the ability of PA to promote FOXO-dependent transcription. HEK 293
cells were transfected with a plasmid containing a minimal promoter containing 3x Fork Head
Response Elements (3x FHRE) driving luciferase expression and then treated with various
concentrations of PA or vehicle for 72 hours. As a control for a non-specific action of PA on
transcription, a parallel set of cells were transfected with the parent plasmid (pGL3) that lacked
the 3x FHRE. In all experiments, an internal control plasmid expressing Renilla luciferase was
cotransfected and all results are expressed as the ratio Luciferase/Renilla fluorescence. PA
treatment led to a dose-dependent increase in luciferase signal in 3x FHRE, but not pGL3, expressing cells (Figure 1C). As an added control for specificity we looked at the ability of PA to
enhance transcription from a 3x retinoic acid response element (RARE) luciferase construct and
found that PA had no effect on this promoter. These results indicate that PA can promote FOXO
transcriptional activity.
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To determine if PA had neuroprotective activity, spinal cord cultures were treated with
the drug (10 nM) for two days and then subjected to an excitotoxic challenge (Figure 1D). The
percent of KA-induced cell death was ~50 % in vehicle-treated cultures (65 ± 2 versus 35 ± 3
vehicle versus KA, p < 0.01, Student’s t-test) and ~3 % in PA treated cultures (67 ± 3 versus 65 ± 2
vehicle versus KA, p < 0.6, Student’s t-test) indicating that PA protected motor neurons from
excitotoxic challenge. Next we looked at mutant AR proteotoxicity (Figure 1D). Significant
differences between groups (F(2,6) = 18.84, by ANOVA) were found in the three-way comparison
of 1) No DHT, 2) DHT + vehicle, and 3) DHT + PA). The post hoc analysis demonstrated a DHTdependent ~25 % loss of motor neurons in vehicle-treated cultures (p < 0.01) and
neuroprotection in the PA treated cultures (P > 0.05 in the comparison of no DHT versus DHT +
PA).
We followed up these observations by asking if PA blocked the proteotoxicity of SOD or
p150glued. Spinal cord cultures were infected with HSV engineered to express the WT or mutant
forms of SOD or the WT or mutant forms of p150glued and received PA (or vehicle) every other
day for 4 days. The drug treatment had no effect on transgene expression (not shown). After 4
days, the cultures were fixed and motor neuron number was determined. ANOVA revealed
statistically significant differences between groups in LacZ versus WT SOD versus mutant SOD (±
PA) comparisons (F(5,12) = 18.41, p < 0.001) as well as LacZ versus WT p150glued versus mutant
150glued (± PA) comparisons (F(5,12) = 19.26, p < 0.001) (Figure 1E). The post hoc analysis revealed
that statistically significant protection against the toxicity of mutant SOD or p150glued was
conferred by PA treatment on motor neuron survival. PA had no adverse effect on survival of
motor neurons expressing LacZ or wild type versions of SOD or p150glued. Thus PA is non-toxic
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on its own, but can protect against four different insults in vitro that are directly relevant to
motor neuron diseases.

In light of the neuroprotective effect of PA in vitro, we examined the effects of the drug
in two in vivo model systems of neuronal degeneration. Expression of polyglutamine-expanded
AR in the Drosophila eye leads to DHT-dependent degeneration 111,112. We found that flies
reared on food supplemented with 0.5 mM PA had a reduced degenerative phenotype when
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compared with vehicle treated flies (Figure 2a, b). These in vivo results complement the
observations made in spinal cord cultures from mice expressing polyglutamine-expanded AR
wherein we found treatment with PA blunts DHT-dependent mutant AR toxicity.
We next asked if the neuroprotective action of PA depended on FOXO. To this end, we
examined the efficacy of PA in flies that both expressed the polyglutamine expanded AR and
were haploinsufficient for Drosophila Foxo (dFOXO) (Figure 2c, d). In a dFOXO-deficient
background (foxoBG01018 allele)113, PA lost its ability to protect against DHT-dependent
degeneration. To corroborate these observations, we studied two additional dFOXO loss-offunction alleles (foxo21 and foxo25) and one predicted loss-of function allele (foxoC01841) 114,115. As
above, on all of these dFOXO-deficient backgrounds, PA lost its ability to protect against DHTdependent degeneration. Using a quantitative rating score, we found that PA led to a
statistically significant mitigation of polyglutamine-expanded AR degeneration but this was lost
in the dFOXO haploinsufficient flies (Figure 2 bar graph). Variation in the baseline (no PA
provided) level of neurodegeneration phenotype among the studied fly lines is likely due to
differences in the background genotype. These observations indicate that PA confers protection
against mutant AR proteotoxicity in a FOXO-dependent manner.
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We developed a C. elegans model system of neurodegeneration by combining a null
mutation in the glutamate transporter GLT-3 (∆glt-3) with a transgenic strain (nuIs5 - 116) in
which the glr-1 promoter drives expression of an activated form of Gs (abbreviated Gs*) and
GFP in glutamatergic neurons 117. The ∆glt-3; nuIs5 double mutants exhibit necrotic neuron
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death at all stages of postembryonic development, with the strongest effect seen in
developmental stage L3. PA had a dose-dependent neuroprotective effect at the L3 stage, with
complete rescue from death using 10 nM PA (Figure 3A). This concentration of PA had no
adverse effect on WT nematodes. We asked if the effect of PA is mediated by changing the
timing of neurodegeneration or by reducing it throughout development (Figure 3B). To examine
this, we studied the effect of PA on the ∆glt-3; nuIs5 double mutants as a function of larval stage
and we found neuronal death was reduced in all developmental stages, with the strongest effect
observed in the developmental stages most prone to excitotoxicity. Neuron death was reduced
in a statistically significant manner in larval stages L2 (3.4 ± 0.2 versus 2.5 ± 0.2 dying
neurons/animals, n = 44 versus n = 49, vehicle versus PA, p = 0.006) and L3 (4.2 ± 0.2 versus 2.2
± 0.1 dying neurons/animals, n = 63 versus n = 65, vehicle versus PA, p < 0.001) (Figure 3B).
Finally, while we showed that PA leads to accumulation of FOXO3a in mammalian
neuronal nuclei, we wished to determine if the same was true in C. elegans. To this end, we
studied nematodes in which a DAF-16::GFP fusion protein was expressed in body wall muscles.
Addition of PA, but not vehicle, to the growth substrate led to nuclear localization of the fusion
protein and quantification of the nucleus/cytoplasm ratio of DAF-16::GFP revealed a statistically
significant effect of PA (1.46 ± 0.05 versus 3.44 ± 0.55, n = 36 versus n=27, vehicle versus PA, p <
0.0001) (Figure 3C). This result indicates that PA has an evolutionarily conserved capacity to
promote nuclear localization of the DAF16/FOXO3a transcription factor and this is associated
with resistance to necrotic neuron death.
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Many post-translational modifications of FOXO3 have previously been described that
modify FOXO3’s activity and subcellular localization (see appendix 1). In order to better
understand how PA was influencing FOXO3 localization, we explored whether treatment with PA
led to any significant changes in the activity level of some of the kinases known to phosphorylate
FOXO3. In addition we monitored the abundance of 14-3-3, the protein responsible to shuttling
FOXO3 into the nucleus. As seen in figure 4, no changes in phosphorylation of FOXO3 at Thr32
or Ser253 were identified. These residues play a key role in regulating FOXO3’s nuclear
localization. Similarly no changes were seen in AKT or MAPK activity. Also no change in the
abundance of 14-3-3 was observed. These finding suggest that PA is acting in a previously
undefined manner to regulate the nuclear localization of FOXO3a.
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Figure 4.

Discussion:
Biochemical pathways that regulate longevity in yeast, C. elegans, Drosophila
melanogaster and mice also play a fundamental role in resistance to stresses such as UV
radiation, oxidative conditions, heat shock and misfolded and aggregation-prone proteins 118.
Two transcription factors, Heat-shock factor 1 and DAF-16/FOXO3a, are essential mediators of
this longevity/stress resistance program in nematodes 4,119. Here we show that treatment with
PA enhances nuclear localization of FOXO3 and protects mammalian motor neurons in vitro
from insults directly relevant to motor neuron diseases as well as abrogating neurodegeneration
in two in vivo invertebrate model systems. The broad neuroprotective action of PA suggests it
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acts on a phylogenetically conserved, core stress resistance pathway, most likely the daf16/FOXO transcriptional pathway.
Our results suggest that the neuroprotective actions of PA are mediated, at least in part,
by FOXO3a/daf-16. First, in both rat neuron cultures and C. elegans, application of PA promotes
nuclear accumulation of FOXO3a or DAF-16. Second, PA evokes a dose-dependent increase in
FOXO-dependent transcription. Third, PA-mediated protection against mutant AR-evoked
degeneration is dFOXO-dependent. Even without knowledge of the direct molecular target of
PA, this evidence favors the view that PA acts, at least in part, in a FOXO3a transcriptiondependent manner.
The onset of many neurodegenerative diseases in adulthood raises the possibility that
the causes of aging are specific contributors to disease pathogenesis. To the extent that this is
true, applying our understanding of the molecular biology of longevity may lead to new types of
therapy for neurodegenerative diseases. The present work on FOXO3a is an example of how
manipulation of a phylogenetically conserved, longevity-promoting signaling pathway can
effectively block neurodegeneration. This is particularly interesting in light of a recent
population-based study of human longevity showing a strong association of FOXO3a and healthy
aging 27. Agents such as PA which enhance the activity of daf-16/FOXO transcription factors may
therefore act to repress disease progression in a wide variety of neurodegenerative diseases.

Materials and Methods:
Tissue Culture: Embryonic Sprague-dawley rat spinal cord neurons were grown on confluent
monolayers of cortical astrocytes, as previously described 120. The substratum was acid washed
glass coverslips when imaging was performed and Primaria tissue culture plasticware (Falcon,
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Becton-Dickinson) when biochemistry was performed. Culture media consisted of astrocyteconditioned media supplemented with 10 ng/ml CNTF, BDNF, NT 4, CT 1 and GDNF and 50% of
media was replaced with fresh media every 3 days.
Male SBMA mice transgenic for the prion protein promoter-driven androgen receptor
cDNA containing an expanded (112) CAG repeat tract were mated with non-transgenic C57Bl/6
female mice 121. Dissociated, mixed spinal cord cultures obtained from 13.5-day embryos were
grown for 3 weeks in conditioned medium (conditioned on normal mouse astrocytes) containing
charcoal-stripped serum to remove hormones. At 3 weeks, motor neurons were well
differentiated and distinguishable from other neurons, including sensory neurons, by size and
morphology. At this time, cultures were treated with indicated conditions for 7 days; cells were
then fixed with 4% paraformaldehyde and immunostained using antibodies to neurofilament
heavy chain (NF-H) (SMI32; Sternberger Monoclonal Inc.). Motor neurons were visualized using
a Leica DMR fluorescence microscope, photographed, and analyzed using IP Labs software.
Statistical analyses of results were carried out using Student's t-test (viral infections) or ANOVA
(compound treatments; SigmaStat).
Recombinant HSV: cDNAs were cloned into the PrpUC amplicon plasmid to generate
recombinant HSV as previously described 122. The titer of virus used in these studies was
routinely 3-5 x 107 plaque-forming units/ml. The sources of constructs were: Michael
Greenberg, Harvard University (HA-tagged wild type and triple mutant human FOXO3a), David
Borchelt, University of Florida (WT and G85R mutant SOD), Erika Holzbaur, University of
Pennsylvania (WT and mutant p150glued) and Anne Brunet (3xFHRE-luciferase).
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Excitotoxicity Assay: After 14 days in vitro (DIV), culture media was removed (and saved) and
cells were exposed to 100 µM kainic acid (KA) for 1 hour. Subsequently they were washed three
times in Locke’s buffer not containing KA, the original media was replaced and incubated for
another 24 hours at 37 oC. in 5% CO2 before fixation in 4% paraformaldehyde. Motor neurons
were identified in mixed culture by immunostaining for nonphosphorylated neurofilaments and
counting only labeled cells with cell body diameter of 25 µm or greater. We have previously
validated this method as a means of specifically recognizing motor neurons (Figure 1 in 123). In
experiments involving recombinant HSV, 1 µL of viral stock was added to 1mL of culture media
24 hours or more prior to the next manipulation. Tubes containing viruses were color coded so
that the operator was blinded to the specific virus used.

Quantification of motor neurons: The # of immunostained cells were counted in 3 randomly
selected fields/coverslip and the mean value obtained. In each experiment 3+ independent
coverslips were used per condition and the results presented were obtained for 4+ independent
cultures and experiments.

Immunocytochemistry: Tissue culture cells were fixed in freshly prepared 4% paraformaldehyde
in 0.1 M pH 7.4 phosphate buffer for 30 minutes prior to extensive washing in phosphate
buffered saline. Overnight incubation with primary antibody was performed at room
temperature and after washing, coverslips were incubated with Alexafluor conjugated
secondary antibody (2 – 4 hrs.). When double labeling experiments were performed, speciesspecific secondary antibodies with distinct emission spectra were employed. Coverslips were
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washed prior to mounting in PermaFluor (Thermo Electron Corporation) and viewing on an
Olympus FV300 Fluoview laser confocal microscope.

Western Blots and quantification: Cultures were lysed in NP-40 lysis buffer (1% NP-40, 40 mM
Tris pH = 7.4, 0.15 M NaCl, 10% glycerol, 0,1% SDS, 0.1% deoxycholate + protease inhibitors and
phosphatase inhibitors), sonicated, particulate matter removed by centrifugation and subjected
to PAGE-SDS prior to transfer to nitrocellose. Equal amounts of protein (determined using BCA
reagents from Pierce) were loaded in each lane. After blocking in 5% milk in phosphate buffer
saline, membranes were incubated in primary antibody overnight, washed, incubated with
secondary antibody, washed and visualized to GE Healthcare (Buckinghamshire, U.K.)
chemiluminescent substrate according to the manufacturers directions. Densitometric analysis
of films was obtained using TINA (Isotopenmegeräte, GmbH) from 4+ independent
experiments, the results averaged and mean values ± S.E. formed the basis of the statistical
comparisons. Quantitative data on band intensity was expressed as the fold change in
comparison with values of HSV-LacZ infected cultures. The displayed western blot data are
representative of the results obtained from at least 4 independent cultures. In some
experiments the LI-COR Odysseus system was used for visualizing and quantifying western blot
bands. Secondary antibodies were from LI-COR Biosciences (IR 800 or 680 goat anti-mouse IgG
or anti-rabbit IgG).The source of primary antibodies was: (Calbiochem, Oncogene Research
Products, rabbit anti- MnSOD (Stressgen Bioreagents, Victoria, British Columbia, Canada), rabbit
anti- FKHRL1/FOXO3a and anti-phospho FKHRL1/FOXO3a (T32) (Upstate, Lake Placid, NY), antiphosphoFOXO3a (S253) (Abcam) and rabbit anti-HA (Santa Cruz Biotechnology, Santa Cruz, CA).
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Species-specific HRP-conjugated secondary antibodies were from Amersham (GE Healthcare,
Buckinghamshire, U.K.) and Alexa 488-conjugated anti rabbit secondary antibody from
Molecular Probes, Invitrogen (Eugene, OR).

Subcellular fractionation
Nuclear protein lysate was prepared using Sigma N-Xtract Tm kit. Briefly, cells collected from
one 60 mm dish were suspended in 150 ul hypotonic lysis buffer (10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, and 10 mM KCl). After incubating on ice for 10 minutes, 10% IGEPA CA-630 was added to
final concentration of 0.6%. Vortexed vigorously for 10 seconds and centrifuged immediately at
10,000-11,000g for 30 seconds. The supernatant is cyoplasmic fraction and the pellet is nuclear
fraction.

Luciferase reporter assay
Human embryonic kidney 293 cells were grown to approximately 80% confluence and then
transfected either 3x Fork Head Response Element Luciferase (FHRE), the parent vector lacking
the FHREs (pGL3), or pGL3 vector containing 3x Retinoic Acid Response Element (RAREluciferase from Addgene). In all cases, the Renilla luciferase reporter construct, driven by the
thymidine kinase promoter (pRL-TK), was co-transfected as an internal control for transfection
efficiency and cell death. After 24 hrs the cells were trypsinized and replated into media
containing the appropriate concentration of PA or vehicle. After 48 hrs the cells were
trypsinized again and replated into a 96 well plate in fresh media containing PA or vehicle (12
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replicates per condition). Twenty four hours later the plates were analyzed using the Dual-Glo
Luciferase Assay System (Promega) on the Xenogen In Vitro Imaging System. The ratio of
Luciferase signal to Renilla signal for each well was calculated and the various treatment groups
were compared to vehicle.
Study of Drosophila
Drosophila stocks were crossed on standard cornmeal agar media at 29°C. Food was
supplemented with DHT (Steraloids) and Psammaplysene A once it had cooled to <50 °C, to final
concentrations of 1 mM and 0.5 mM, respectively. Eye phenotypes of female flies of each
condition were examined and blindly scored according to the criteria described with one scoring
modification to increase sensitivity to differences in affected eye areas 111.
Flies haploinsufficient for dFOXO were generated by mating GMR-GAL4, AR52Q flies to
the following fly stock lines: foxoBG01018 (Bloomington stock 12530); foxo21, foxo25 114 and
foxoc01841 (Exelixis, Harvard).

Study of C. elegans
The following C. elegans strains were obtained from the C. elegans Genetic Center
(biosci.umn.edu/CGC) or constructed by us: ∆glt-3: ZB1096 glt-3(bz34) IV; nuIs5: KP742[glr1::gfp; glr-1::Gs(Q227L) V; lin-15(+)]; ∆glt-3; nuIs5: ZB1102 glt-3(bz34) IV; nuIs5 V. Pmyo-3:daf16::gfp Strain ZB2283 was produced by Jian Xue and Carolina Ibanez-Ventoso by making
transgenic animals carrying an extra-chromosomal array containing Pmyo-3:daf-16:gfp.
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For PA treatment, we soaked the diluted drug into standard NGM culture plates. We
transferred freshly growing nematode cultures to these plates and allowed them to grow for 2
days before assessing the effect. To determine the ratio of nuclear vs. cytoplasmic DAF-16 levels
we used a strain transgenic for Pmyo-3:daf-16::gfp, where the DAF-16::GFP reporter is expressed
in body wall muscle cells. We compared the intensity of GFP labeling in the nucleus and adjacent
cytoplasm using NIH-Image. We monitored the effect of PA or age-1 on nematode excitotoxicity
by measuring the extent of neurodegeneration in ∆glt-3; nuIs5 animals ± PA or ± age-1
mutation. We observed free-moving animals with an inverted scope under Nomarski DIC optics
with no anesthetics. Swollen cells in the nerve-ring region were counted as head necrotic figures
indicative of neurodegeneration.

Statistics. Pairwise comparisons employed two-tailed Students’s t-test and when three or more
groups were compared we used Analysis of Variance (ANOVA) and post hoc analysis with
significance set at p< 0.05.
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The Neuroprotective Drug Psammaplysene A Binds the RNA
Binding Protein HNRNPK
Marco Boccitto, Nayoung Lee, Satoshi Sakamoto, Hiroshi Handa, John Clardy, Benoit Chabot,
Steve Seeholzer, Robert Kalb

Abstract: We previously characterized the compound Psammaplysene A as having strong
neuroprotective properties in a number of in vitro and in vivo models of neurodegeneration.
Based on the physico-chemical properties of Psammaplysene A it is not considered to be druglike. Therefore we attempted to identify the target of Psammaplysene A in order to determine
its mechanism of action. Two separate methods were used in parallel to purify the protein
target of Psammaplysene A from cell lysates. Mass spectrometry was employed to identify the
Psammaplysene A target as the RNA binding protein HNRNPK. We investigated the effects of
Psammaplysene A on a number of HNRNPK regulated processes. The most consistent
observation is that treatment of cells with Psammaplysene A results in decreased abundance of
rRNAs. Coupled with prior work indicating HNRNPK can stabilize rRNAs, we suggest that the
ability of Psammaplysene A to decrease rRNA abundance may represent its mechanism of
neuroprotection.
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Introduction:

Psammaplysene A (PA) is a marine sponge derivative which was originally described in a
chemical screen to identify agents that promote FOXO1 nuclear localization in PTEN deficient
cancer cells109,110. We became interested in the potential neuroprotective qualities of PA based
on the role of the FOXO transcription factors as phylogenetically conserved regulators of
longevity81. Increased activity of the C. elegans ortholog of FOXO, daf-16, is associated with
lifespan extension ranging from 2-10 fold in worms, and polymorphisms in FOXO1 and FOXO3
have been linked to longevity in human cohorts1,2,27,30. Many long lived C. elegans mutants also
exhibit increased stress resistance, including protection against reactive oxygen species, heat
stress, and proteotoxicity11,13,14. Age is also a major risk factor for numerous neurodegenerative
diseases. Based on these observations we investigated the potential of PA to act as a
neuroprotective agent via activation of FOXO3. Indeed, we found that PA protects against
neuronal death in numerous in vitro and in vivo models of neurodegeneration124.
Unfortunately the physico-chemical properties of PA make it an unlikely candidate for
further development as a therapeutic. Testing in vitro and in small model organisms such as the
worm and fly allows for the use of DMSO for drug solubalization and delivery. This allows for
the characterization of compounds which would otherwise be inactive if delivered orally. Chris
Lipnski and colleagues defined a set of four characteristics that suggest whether a molecule is
“drug-like” based on its molecular weight (max 500 Da) , Log P (max 5), number of hydrogen
bond donors (max 5) and number of hydrogen bond acceptors (max 10)125. Each time a
compound violates one of these criteria it is given a flag and the total number of flags are tallied
giving a compound a score between 0 and 4. Compounds with a score greater than 1 are
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considered to be of marginal value for further development126. PA receives a score of 2 for
having a molecular weight of 769 Da and a Log P value of 6.57 suggesting it would be or
marginal clinical relevance. Owing to PA’s powerful neuroprotective qualities that we wanted to
characterize its mechanism of action, with the hope that more drug-like compounds could be
found that share the same activity as PA.
Using two parallel purification methods, we generated a list of PA target candidates that
consisted almost exclusively of RNA binding proteins. From this list we identified the target of
PA as heterogeneous nuclear ribonucleoprotein K (HNRNPK) and confirmed saturable binding
using surface plasmon resonance. HNRNPK is a member of the heterogeneous nuclear
ribonucleoprotein (hnRNP) family. This family of proteins was historically identified for its ability
to bind heterogeneous nuclear RNA produced by RNA polymerase II as part of the hnRNP
complex127. Although originally described as part of the hnRNP complex, it is now appreciated
that HNRNPK is present in the cytoplasm and mitochondria, as well as the nucleus. HNRNPK
participates in a wide variety of cellular functions including transcriptional control, translational
control, RNA transport, splicing, chromatin remodeling and RNA stability128. HNRNPK contains
three RNA binding motifs and exhibits robust binding to poly-C regions129. In addition to its
ability to interact with RNA, HNRNPK interacts with a very large number of proteins and can
receive numerous posttranslational modifications. More than 100 HNRNPK binding partners
have been characterized residing in the cytoplasm, nucleus and mitochondria51. Many of these
interactions are thought to be mediated through the K protein interactive (KI) domain, which is
a highly unstructured region within the protein thought to allow for a great diversity of binding
partners. HNRNPK is also the target of numerous posttranslational modifications including
phosphorylation and methylation which act to integrate numerous signaling pathways130-132.
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Taken together these characteristics make HNRNPK an excellent platform for integrating protein
based signaling cascades with the regulation of DNA/RNA based processes, making it an
intriguing target for a neuroprotective compound.

Results:

HNRNPK is a target of Psammaplysene A based on two parallel target purification strategies:
In order to characterize the mechanism of action of PA, we attempted to purify its
target from cell lysates. Two separate but complementary approaches were used to purify the
target of PA. The first approach involved a modified version of PA that allowed tagging with a
biotin moiety or fluorescent probe. The second approach involved covalently linking PA to
magnetic nanobeads using a flexible linker sequence.
Four different PA derivatives were generated (supplemental figure 1). We wanted to
verify that the modifications made to PA did not alter its activity so we compared the activity of
the four PA derivatives to PA in a forkhead response element (FHRE) luciferase assay(figure 1 A).
We had previously characterized PA as significantly increasing FHRE luciferase activity with a
72hr treatment124. We found that PA as well as all four PA derivatives elicited an increase in
FHRE activity upon 72hr treatment compared to vehicle. Single factor ANOVA showed a
significant effect of treatment on FHRE luciferase activity. Post hoc analysis showed vehicle
treated cells to have significantly less FHRE activity compared to all other groups (Vehcile vs :
PA, 1A, 1B, 2A, 2B F(5,22)=2.76, F(5,22)=5.8, F(5,22)=3.81, F(5,22)=2.64, F(5,22)=3.17 respectively. p<0.05
when comparing vehicle versus all drug treated groups by Sheffe’s post hoc). Our original
characterization of PA suggested that its neuroprotective properties were tied to its ability to
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influence FOXO activity. Since the derivative compounds retained the ability to alter FOXO
activity we presumed that they were still capable of binding the target of PA. The
photoactivatable crosslinker and azide groups on compound 2B provided a versatile platform to
work with therefore we conducted all derivative based purification assays with compound 2B.
We determined that 2B was binding to a discrete target and that it could be displaced
from that target using an excess of PA. We incubated HEK293 cell lysate and C. elegans lysate
with 2B, 2B + 100x PA, or no drug. After a one hour incubation we UV illuminated the lysates to
crosslink 2B to its target and then used click chemistry to label 2B containing complexes with
carboxytetramethylrhodamine (TAMRA). After labeling the proteins were dissolved in loading
buffer and resolved by SDS-PAGE . TAMRA labeled proteins were then visualized using in gel
fluorescence scanning (figure 1 B). Three specific bands were identified in HEK293 lysates and
two specific bands were identified in C. elegans lysates. Next, in order to identify the proteins in
the HEK293 lysate, we incubated 2B with lysate, UV crosslinked and then used click chemistry to
attach a biotin to crosslinked target-2B complexes. We then purified target-2B-biotin complexes
using magnetic avidin beads. The purified proteins were digested off of the avidin beads and
analyzed by LC MS/MS. We identified 37 candidate targets via this approach (figure 1 D and
supplemental table 1).
As a second parallel approach we covalently coupled a PA derivative to feriteglycidyl
methacrylate (FG) nano-beads. These beads are particularly well suited for this type of analysis
because their small size and uniform structure creates a large surface area for small molecule
presentation while minimizing non-specific interactions133. FG beads were coupled to PA at two
different concentrations of PA, 1X and 5X. We incubated HEK293 lysates with uncoupled FG
57

beads, 1X PA coupled FG beads and 5X PA coupled FG beads. Beads were washed, and then
boiled in loading buffer to elute the associated proteins. Eluted proteins were run on a SDSPAGE gel and visualized via coomassie brilliant blue staining (figure 1 C). We attempted to
identify bona fide PA interacting proteins by looking for bands whose abundance increased in a
dose-dependent manner. We were able to clearly identify two bands whose intensity was
strongly dose dependent (black *’s figure 1 C). These bands were also of roughly equivalent
molecular weight to two of the bands identified by the 2B approach. These bands were excised
and submitted to LC MS/MS. One additional band was excised (red * figure 1 C) based on its
molecular weight, as it roughly matched the molecular weight of the largest binding partner
identified by the 2B approach. Since the PA-FG beads were not covalently linked to their target
in this approach we were unable to wash as stringently as in the 2B approach. Subsequently we
identified 175 proteins in the three bands that were excised (figure 1 D and supplemental table
1).
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Figure 1.

Figure 1. A) Normalized luciferase signal from Forkhead Response Element (FHRE) Luciferase after treatment with PA or PA
derivative compounds. All PA derivatives retain the ability to induce FHRE activity. B) Identification of discrete protein targets of PA

59

by 2B labeling (HEK lysates and C. elegans lysates) and C) pull down with PA-FG beads (HEK lysates). D) Representation of PA
candidate list identified by two parallel approaches.

Based on our two parallel approaches we generated a list of 207 candidate targets of
PA, with five proteins identified by both approaches. Although an overlap of five proteins was
significantly less than we had expected, there were functional similarities in the proteins
purified by the two approaches. A bioinformatics analysis of the purified proteins indicated that
both approaches identified proteins which were highly enriched for RNA processing (i.e.
stability, splicing, metabolism, posttranscriptional gene expression) (Table 1). This also
potentially helped explain the large number of proteins that we purified. While the FG beads
are designed to have very few non-specific interactions, if the target of PA is a member of a
large ribonucleo protein (RNP) complex we may have pulled down a macromolecular complex of
proteins interacting with the specific target of PA.
Table 1.

Gene Ontology for 2B Purified
Proteins
Gene Ontology Term

Count

%

GO:0008380~RNA splicing

14

13.9

GO:0016071~mRNA metabolic process

15

14.9

GO:0006397~mRNA processing

13

12.9

GO:0006396~RNA processing

15

14.9

PValue
1.73E12
2.71E12
1.52E10
4.92E10

GO:0000375~RNA splicing, via
transesterification reactions

10

9.9

GO:0000398~nuclear mRNA splicing, via
spliceosome

10

9.9
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Fold
Enrichment

8.63

FDR
2.34E09
3.66E09
2.05E07
6.65E07

7.75E10

20.56

1.05E06

7.75E10

20.56

1.05E06

15.51
12.75
12.74

GO:0000377~RNA splicing, via
transesterification reactions with bulged
adenosine as nucleophile

10

9.9

7.75E10

20.56

1.05E06

Gene Ontology for PA-FG Purified
Proteins
Gene Ontology Term

Count

%

PValue

Fold Enrichment

GO:0006396~RNA processing
GO:0016071~mRNA metabolic
process
GO:0006397~mRNA
processing

44

23.7

1.26E-25

7.35

37

19.9

1.56E-24

9.14

34

18.3

3.03E-23

9.68

GO:0008380~RNA splicing

32

17.2

1.25E-22

10.30

FDR
1.99E22
2.47E21
4.79E20
1.97E19

22

11.8

1.31E-17

13.14

2.08E14

2.08E14

GO:0000375~RNA splicing, via
transesterification reactions
GO:0000377~RNA splicing, via
transesterification reactions
with bulged adenosine as
nucleophile
GO:0000398~nuclear mRNA
splicing, via spliceosome
GO:0043489~RNA stabilization
GO:0048255~mRNA
stabilization
GO:0010608~posttranscriptio
nal regulation of gene
expression
GO:0043488~regulation of
mRNA stability
GO:0043487~regulation of
RNA stability

22

11.8

1.31E-17

13.14

22

11.8

1.31E-17

13.14

6

3.2

3.89E-07

36.56

6

3.2

3.89E-07

36.56

14

7.5

4.96E-07

6.06

6

3.2

3.21E-06

24.93

6

3.2

5.09E-06

22.85

2.08E14
6.16E04
6.16E04
7.84E04
5.08E03
8.05E03

We began screening candidates from our list with a specific focus on the overlapping
proteins. Due to the large number of candidates, we adopted a multi-pronged approach to
identifying the PA target. To screen candidates we obtained plasmids for recombinant
expression, over expression or knockdown of candidate proteins and then screened lysates
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using the 2B TAMRA coupling assay. We screened 14 targets by this method (supplemental
table 2) before identifying a positive hit. In a bacterial expression system, induction of HNRNPK
expression with Isopropyl β-D-1 thiogalactopyranoside (IPTG) yielded a strong band which is not
present in un-induced lysates (figure 2 A). This band has approximately the same molecular
weight as the smallest band identified in HEK293 lysates.
The target purification with 2B and PA-FG beads had suggested some other
characteristics of the target of PA which HNRNPK fit. HNRNPK is an RNA binding protein known
to be involved in numerous aspects of RNA processing, including translation, mRNA stability, and
splicing. This makes HNRNPK a good fit for the types of processes that we suspect PA is involved
in based on our bioinformatics analysis of candidate proteins. Secondly HNRNPK is thought to
be a “hub” protein, interacting with numerous protein partners and acting to integrate various
signaling cascades. HNRNPK is known to have over 100 interacting proteins51. This is thought to
be facilitated by its highly unstructured KI domain. This breadth of protein-protein interactions
might help explain the high number of candidates identified by our purification methods. An
analysis of the literature suggested that of the 37 proteins identified by 2B purification followed
by on bead digest 12 were previously described as HNRNPK binding partners.
Characterization of the PA interaction with HNRNPK by Surface Plasmon Resonance
In order to better characterize the interaction between PA and HNRNPK we attempted
to demonstrate specificity and characterize the Kd of PA binding to HNRNPK by surface plasmon
resonance. We began by comparing PA binding to GST-HNRNPK versus GST. We were unable to
identify saturable binding in this paradigm (figure 2 B), indicative of a non-specific interaction.
We speculated that because HNRNPK participates in such a wide variety of protein, RNA and
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DNA binding events, many aspects of its native structure may not be recapitulated during
recombinant expression and purification. This may be particularly true of domains like KI which
are thought to derive their 3D structure from partner binding51. Without these secondary
structural features, a non-specific interaction may be occurring between PA and HNRNPK.
Although it would be impractical to try and introduce all of the potential HNRNPK interacting
proteins into the system to see if they allowed for specific PA binding to HNRNPK, it was feasible
to introduce RNA.
We began by observing whether RNA could be stably bound to HNRNPK. We applied
whole cell RNA extracts over the GST-HNRNPK and GST surfaces and found a saturable and
stable binding of RNA to GST-HNRNPK but not GST alone (data not shown). We then repeated
the PA binding experiment and were now able to generate a saturable binding curve (figure 2 C).
In addition to the interaction now being saturable, concentrations of 50, 100 and 150uM PA
elicited a significantly higher response when HNRNPK was pre-bound with RNA. This suggested
that the structure of HNRNPK was modified by RNA binding in such a way that its affinity for PA
was increased.
In order to control for the possibility that PA was interacting with RNA rather than RNA
bound HNRNPK, and to further demonstrate specificity of PA for HNRNPK, we used a second
RNA binding protein as a control. We compared PA binding to GST-HNRNPK versus GST-HNRNPI
(PTBP1). We considered HNRNPI to be a good control based on the fact that it binds pyrimidine
rich tracts. HNRNPK binds cytosine rich domains so there is potentially some overlap in the
RNAs that the two proteins will bind. In this paradigm we were again able to show specific,
saturable binding of PA to HNRNPK after saturating both proteins with RNA (figure 2 D). From
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these measurements we were able to generate a binding curve and estimate the Kd of PA for
HNRNPK at 166 uM. Based on our work with 2B, we suspect that this Kd is not truly indicative of
PA binding to HNRNPK in vivo. We are able to visualize PA interactions with HNRNPK in bacterial
lysates with concentrations as low as 100 nM and PA binding appears saturated at 5 uM in
HEK293 lysates (data not shown). This discrepancy may be due to the absence of HNRNPK
binding partners or lack of post-translational modifications to the GST-HNRNPK used in the
surface plasmon resonance system. Never the less these data support a specific interaction of
PA with HNRNPK.
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Figure 2.

Figure 2. A) 2B binding and TAMRA visualization of PA binding to HNRNPK in induced and un-induced bacteria expressing an IPTG
inducible HNRNPK construct. B) Surface plasmon resonance analysis of PA binding to HNRNPK.

65

PA Increases the Abundance of a Disulfide Linked HNRNPK Complex
As a first step in characterizing the mechanism of action of PA we began by monitoring
any changes in HNRNPK abundance after PA treatment. We were unable to identify any
changes in the total abundance of HNRNPK or its nuclear versus cytoplasmic localization after
PA treatment (figure 3 C). Interestingly, on non-reducing western blots, we found a high
molecular weight species using anti-HNRNPK antibodies which was lost under reducing
conditions (figure 3 A). The abundance of this complex did appear to be PA responsive (figure 3
B). In order to better characterize the composition of this putative HNRNPK containing complex
we immunoprecipitated HNRNPK, then resolved it by SDS PAGE and stained with coomassie
brilliant blue under reducing and non-reducing conditions. Using this approach, we were able to
visualize the high molecular weight complex under non-reducing conditions and excise the
complex as well as the corresponding area in the reduced lane and analyze them by LC MS/MS.
Based on semi-quantitative analysis, the complex appeared to be made up of HNRNPK, DDX17,
and Lamin B1 (supplemental table 2). The combined molecular weight of these three proteins is
consistent with the molecular weight of the non-reduced HNRNPK complex.
Immunoprecipitation of HNRNPK from HEK293 lysates confirmed a strong interaction between
HNRNPK and DDX17 as well as Lamin B1 (figure 3 D). While PA appears to increase the
abundance of this high molecular weight HNRNPK containing complex, it is unclear what role
this complex plays in normal cellular function or what the functional consequences of increasing
the abundance of this complex are.
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Figure 3.

Figure 3. A) Detection of a high molecular weight HNRNPK containing complex in non-reducing cell lysates B) PA treatment increases
the abundance of this high molecular weight HNRNPK containing complex in a dose-dependent manner. C) PA treatment does not
alter total abundance or subcellular distribution of HNRNPK. D) HNRNPK co-immunoprecipitates with DDX17 and Lamin B1

PA Has No Effect on Numerous Functions of HNRNPK Biology
HNRNPK plays a role in a multitude of biological processes. We attempted to focus our
investigation on PA induced changes in HNRNPK biology based on the knowledge that PA is
neuroprotective, and the observation that PA seems to increase the abundance of an HNRNPKDDX17-LaminB1 disulfide linked complex.
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HNRNPK is known to act on κB enhancer elements and affect their transcriptional
activities134. Abnormalities in NF-κB signaling have recently been implicated in forms of
inherited ALS135,136 so we wanted to determine whether PA might be modifying NF-κB signaling.
We used two separate NF-κB luciferase constructs to monitor possible interactions between PA
treatment and NF-κB signaling. We monitored normalized luciferase activity in PA and vehicle
treated cells in an IL-1 stimulated and un-stimulated state (figure 4 A). PA did not have a
significant effect on either basal or stimulated NF-κB activity.
HNRNPK is known to play an important role in p53 induced apoptosis54. Under
conditions of p53 activation there is an increase in the abundance of the long intergenic noncoding (LINC) p21. LINCp21 then interacts with HNRNPK and facilitates the repression of
numerous pro-survival genes, thus facilitating cell death55. We hypothesized that PA could
disrupt this interaction and thereby increase cell survival. To test this, we generated
biotinylated LINCp21 in vitro. Cells were treated with various doses of PA, lysed and then
incubated with biotinylated LINCp21. Biotinylated LINCp21 was purified with avidin beads and
then boiled in loading buffer to release associated proteins. We were able to clearly identify
HNRNPK by western blot. All three HNRNPK bands were observed under non-reducing
conditions, but there abundance was not influenced by PA treatment (figure 4 B).
DDX17 is part of the DROSHA microprocessor complex137. Based on our observation
that PA appears to increase the interaction between HNRNPK and DDX17, we wanted to know
whether PA was modifying miRNA biogenesis. Interestingly other components of the
microprocessor were identified in our PA target purification including: DROSHA, DDX1, DDX3X,
DDX5, DHX15, HNRNPH1, HNRNU-like1 and FUS. The DROSHA microprocessor complex cleaves
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pri-miRNAs into pre-miRNAs which are then exported into the cytoplasm and undergo a final
cleavage step to become mature miRNAS138. As important regulators of gene expression, any
changes in miRNA abundance due to association/dissociation of HNRNPK with DDX17 as part of
the microprocessor complex could be an important function of PA. In order to explore this
possibility, cells were transfected with flag-DROSHA and treated with PA or vehicle. Cells were
then lysed and immunoprecipitated for flag tag to assess the abundance of HNRNPK and DDX17
associated with the microprocessor complex. No changes in the abundance of co-precipitated
HNRNPK or DDX17 with DROSHA were detected after treatment with PA (figure 4 C).
Both HNRNPK and DDX17 are known to be involved in alternative splicing. Venables et.
al. previously described an assay for monitoring multiple alternative splicing events of genes
involved in apoptosis and found a broad effect of HNRNPK knockdown which they were able to
replicate in multiple cell lines62. We used this assay to monitor alternative splicing events under
6 conditions: 1) mock transfected with HNRNPK, 2) over expressing HNRNPK, 3) treated with PA,
4) treated with vehicle, 5) HNRNPK knockdown, or 6) HNRNPK knockdown with PA trearment.
While we identified splicing events which were influenced by HNRNPK knock down or
overexpression, PA treatment did not result in significant changes in any alternative splicing
events (figure 4 D for representative examples, see supplemental figure 2 for heatmap of entire
dataset). This suggested that PA was not acting to modulate alternative splicing.
While none of these assays is a definitive proof that the neuroprotective activity of PA is
not mediated by one of these processes, we found the lack of a robust effect in any of these
assays sufficiently compelling to suggest that the neuroprotective properties of PA are operating
through a different mechanism.
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Figure 4.

Figure 4. A) PA does not alter NFκB signaling. B) PA does not alter the association between HNRNPK and Linc p21. C) PA treatment
does not alter the abundance of DDX17 or HNRNPK associated with DROSHA. D) PA treatment does not alter alternative splicing.

PA treatment decreases rRNA Abundance
A recent study in Xenopus laevis by Liu et. al. used a RIP-Chip approach to characterize
RNA targets of HNRNPK in the developing Xenopus brain56. They identified numerous neuron
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specific cytoskeletal components important for axonogenesis that interact with HNRNPK. In
order to analyze whether PA was changing the abundance or distribution of any of these
transcripts we treated cortical cultures with PA and then performed qPCR to monitor message
abundance. We analyzed our data using the ∆∆CT method for relative quantitation and found
that when normalizing to 5.8s rRNA all other messages appeared to increase, while when
normalizing to beta actin or GAPDH we found no change. This led us to suspect that there may
be alterations in the abundance of rRNAs upon treatment with PA.
HNRNPK was recently described as playing an important role in stabilizing rRNAs against
stress dependent degradation60. Another potential link between PA and rRNA abundance lies in
the fact that the DEAD box RNA helicases are the largest family of rRNA processing proteins and
DDX17 has been characterized as playing a role in rRNA biogenesis. We investigated this further
by analyzing the abundance of 28s, 18s, 5.8s and 5s rRNAs in both cortical cultures and HEK293
cells after PA treatment (figure 5A). Interestingly we found a statistically significant interaction
between message and PA treatment by two way ANOVA in both groups (p<0.01 in both groups),
with a specific reduction in the 5.8s and 5s rRNAs in both cortical neurons and HEK293 cells after
PA treatment (F(5,6)=7.93 and F(5,6)=11.08 in HEK cells and F(7,6)=7.02 and F(7,6)=6.15 in CT neurons
respectively by Tukey’s post hoc). We did not detect a significant difference in RNA levels of
HNRNPK targets identified by Liu et. al. in cortical neurons, or in beta or gamma actin in HEK293
cells. Wen et al specifically describe a role for HNRNPK in protection of rRNAs after stress. In
order to determine if HNRNPK has an effect on rRNA levels in unstressed cells we transfected
HEK cells with GFP or GFP tagged HNRNPK and assessed rRNA levels 48 hours post transfection
(figure 5B). We found that overexpression of HNRNPK significantly increased the abundance of
the 5.8s and 5s rRNAs, the same rRNAs which were negatively regulated by PA in both HEK cells
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and cortical neurons (Two way ANOVA shows significant interaction of HNRNPK overexpression
on rRNA abundance, p<0.01 and F(3,4)=10.57 and F(3,4)=4.06 respectively by Tukey’s post hoc).
This leads to the hypothesis that PA acts to inhibit HNRNPK dependent promotion of rRNA
stability.

PA Treatment does not Alter Global Levels of Translation
Reductions in translation through knockdown of ribosomal proteins, rRNA processing
proteins or changes in the abundance of ribosomal subunits have all been linked to lifespan
extension in worms, and yeast139-141. This suggested that the neuroprotective properties of PA
could potentially be mediated through its capacity to decrease rRNA abundance by inhibiting
HNRNPK dependent stabilization of rRNA, potentially leading to decreased translation. We
wanted to determine if changes in rRNA abundance that occur after PA treatment were
affecting the abundance of ribosomes and/or levels of global translation. First we generated
polysome profiles from cells treated with PA or vehicle (figure 5 D). An overlay of representative
polysome profiles from PA and vehicle treated cells is shown as well as the quantification of six
PA treated and six vehicle treated profiles. No significant changes were observed in the
polysome profiles after treatment with PA. Overall abundance of monomeric 40s and 60s
ribosomal subunits was unchanged, as was the abundance of the 80s dimer. No change in the
abundance of polysomes was observed.
To confirm whether our polysome observations were of functional significance, we
monitored global protein translation after PA treatment using [35S]-methionine with
cyclohexamide treated cells as a positive control. No changes in global protein synthesis were
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observed after PA treatment (Figure 5 C). It is possible that modulation of rRNA abundance by
PA results in changes that are subtle and below the sensitivity of this assay.

Figure 5.

Figure 5. A) PA treatment reduces 5s and 5.8s rRNA abundance in HEK293 cells as well as cortical neurons. B) Overexpression of
HNRNPK increases 5s and 5.8s rRNA abundance in HEK293 cells. C) PA treatment does not decrease rate of total translation. D) PA
treatment does not alter the cellular polysome profile.

PA Increases 5.8s rRNA Abundance in Stressed Cells
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While the majority of our screening for an effect of PA on HNRNPK activity was
undertaken in HEK293 cells, our previous characterization of PA’s neuroprotective action was
characterized in mixed spinal cord cultures under conditions of stress associated with motor
neuron disease. Now that we had characterized an alteration in rRNA abundance in HEK293
cells we wanted to explore PA’s activities on rRNA abundance in mixed spinal cord cultures
under conditions of stress. To do this we infected cultures overnight with HSV- LacZ, WT SOD1,
and MutSOD1. The next day cultures were treated with 250nM PA for 24 hours and then total
rRNA was collected and analyzed by qPCR for the abundance of 5.8s rRNA. We found that when
culutures expressed an innocuous gene such as LacZ, PA had no effect on rRNA abundance after
24 hours, similar to what we had previously seen at 24 hours in HEK293 cells (Figure 6A and data
not shown). Interestingly, expression of wild type SOD1, which is mildly stressful to motor
neurons, elicited a significant increase in the abundance of 5.8s rRNA; treatment with PA
significantly further increased the abundance of 5.8s rRNA (figure 6A). Expression of mutant
SOD1, a very stressful insult, led to even greater 5.8s rRNA expression which was again
significantly enhanced by PA (figure 6A). This effect appears to be specific to rRNA and most
robust in the 5.8s rRNA (figure 6B).
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Discussion:
Using two parallel purification methods to identify candidate targets of PA followed by a
secondary screen for direct interaction, we identified HNRNPK as a likely direct physical target of
the neuroprotective compound PA. Follow up analysis of this interaction by surface plasmon
resonance confirmed saturable binding of PA to HNRNPK and suggested that the interaction is
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likely to be dependent on HNRNPK binding to RNA. Our original characterization of PA as being
neuroprotective focused heavily on models of motor neuron disease, including ALS. The
identification of FUS, TDP-43, and a hexa-nucleotide repeat expansion in the first intron of
C9orf72 as causative gene mutations in ALS has put a recent focus on potential dysregulation of
RNA processing as a mechanism of toxicity37,39,49. For this reason, we were particularly intrigued
by the fact that HNRPK is an RNA binding protein involved in many aspects of RNA metabolism.
Interestingly, we find that treatment of cells with PA leaves many HNRNPK dependent
processes unaffected, suggesting a high level of specificity in PA’s activity. We do find a
significant effect of PA on the ability of HNRNPK to influence the abundance of specific rRNAs.
Although our analysis of total translation and polysome profiles did not show any significant
differences in PA treated cells; it is possible that while no overt changes in translation are
detectable, the cell is able to sense reduced rRNA levels and initiates a prosurvival response
accordingly. Work by Li and Gu suggests that this could be the case. They find that RNAi
knockdown of 5s rRNA in U2OS cells has no overt effect on translation or the generation of the
large ribosomal subunit. They do observe a decrease in 5s rRNA associated with Mdmx and a
subsequent decrease in Mdmx abundance. Mdmx is a negative regulator of p53 transcriptional
activity and they find that knockdown of 5s rRNA leads to increased expression of p53 targets
such as p21142. These observations as well as previous studies showing that 5.8s rRNA is
covalently linked to p53 suggest that the rRNAs form non-ribosomal complexes that are
potentially involved in stress signaling outside of translation143. While we find a reduction in
rRNA after PA treatment in unstressed cells, possibly the more biologically relevant observation
is the fact that stressed spinal cord cultures treated with PA show increased rRNA abundance.
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Another possibility is that a subtle reduction in translation exists upon treatment with
PA that our methods are simply not sensitive enough to detect. Knockdown of numerous
ribosomal proteins (rps-3,6,8,10,11,15,22,26 and rpl-4,6,9,19,30) and translation initiation
factors (ifg-1, iftb-1, eif-3.B, inf-1, eif-3.F, egl-45) in the worm lead to enhanced lifespan and
resistance to stress139,141. The lifespan and stress resistance phenotype of many of these
knockdowns is dependent on the worm ortholog of FOXO, daf-16. PA may be initiating a similar
cellular response through reduction in rRNA abundance and this may explain our previous
observation that PA’s neuroprotective activities were FOXO dependent in a Drosophila model of
SBMA124.
Translation inhibition is a common response to a variety of cellular stresses. One way
the cell inhibits translation is through rRNA degradation. rRNA degradation and subsequent
translation inhibition could have prosuvival effects by allowing the cell to save energy under
adverse conditions. Another potential mechanism of protection relies on the fact that certain
apoptotic pathways require de novo protein synthesis, inhibition of protein synthesis slows
translation of apoptosis inducing proteins and therefore allows time for the cell to cope with
stressful stimuli. It is possible that PA’s neuroprotective properties stem from the ability to
disrupt HNRNPK stabilization of rRNAs, thus allowing the cell to inhibit translation upon stress
more quickly, and or efficiently.
Conversely, apoptotic stimuli have been shown to induce extensive degradation of 5.8s
rRNA in yeast144. Reductions in rRNA are thought to potentially represent a turning point where
cells commit to apoptosis as opposed to cellular repair. In neurons degradation of rRNA may act
as a signal to activate p53145. Our data from stressed neurons demonstrates that under
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conditions of neuronal stress PA acts to enhance rRNA abundance, this may in turn act to
prevent apoptosis. It is interesting to note that neurons seem to increase their abundance of
5.8s rRNA when stressed with wild type or mutant SOD1 suggesting that increases in 5.8s rRNA
may represent an endogenous pro-survival response to stress. Assuming increased 5.8s rRNA is
a consequence of stress, the fact that PA does not change 5.8s rRNA abundance in LacZ infected
cells suggests that PA is specifically modifying a stress signal, likely associated with HNRNPK, and
not simply stressing neurons.
Unfortunately, due to the plethora of functions of HNRNPK it was difficult for us to
perform a complete analysis of every HNRNPK activity for PA dependent changes. Therefore it
remains possible that PA impacts some of the HNRNPK functions that we considered to be
unchanged. Based on our observation that PA alters rRNA abundance differently under
conditions of stress, it is also possible that PA specifically alters a stress induced change in one of
the HNRNPK activities that we considered to be unchanged. For example PA might alter the
interaction between HNRNPK and other target RNAs such as those described by Liu et al under
conditions of stress. Although we did not detect any changes in the abundance of these mRNAs
after PA treatment, they may simply not be targeted for degradation under basal conditions.
Many of these analyses lent themselves to being done in HEK293 cells as opposed to
neurons. We can not rule out the possibility that cell type specific HNRNPK activities, or
complexes, exist in neurons and that we are unable to recapitulate some PA activities in HEK293
cells.
In our current analysis we identify a novel function of the small molecule PA as a
modifier of rRNA abundance. Based on the role of HNRNPK in rRNA stability, we favor the view
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that PA alters rRNA abundance through its interaction with HNRNPK. The extent to which this
action of PA accounts for its neuroprotective activity is not entirely clear at this time.

Methods:

Luciferase Assays: HEK293 cells were transfected with pGL3-FHRE and pRL-TK plasmids for
monitoring FOXO activity or pBIIx-firefly luciferase and pRL-TK for monitoring NFκB activity.
24hrs after transfection cells were trypsinized and replated into a 96-well plate in drug or
vehicle treated media, cells were re-dosed at 48 hours. 72 hours after drug treatment, the ratio
of firefly to renilla luciferase was determined using a Veritas Microplate Luminometer
(Promega) in conjunction with the Dual-Luciferase Reporter Assay Kit (Promega).
Psammaplysene A and Derivatives: For synthesis of PA see: Georgiades, S. N. & Clardy, J. Total
synthesis of psammaplysenes A and B, naturally occurring inhibitors of FOXO1a nuclear export.
Organic letters 7, 4091-4094, doi:10.1021/ol0513286 (2005). PA derivatives used for covalent
crosslinking and purification were generated from reaction intermediaries. For schematic of
synthesis of the PA derivative used for FG bead coupling see supplemental figure 3.
Preparation of psammaplysene A-immobilized polymer-coated affinity magnetic beads (FG
beads): Polymer-coated affinity magnetic beads with amine groups (FG beads: Nishio, K. et al,
2008; Sakamoto, et al, 2009; TAS8848 N1130 (Tamagawa Seiki Co. Ltd., Iida, Japan)), stocked in
pure water, were suspended in ethanol. Prior to immobilization step, ethanol was removed by
centrifugation (15000 rpm, room temperature) of the beads. Then, ethanol, Nmethylmorpholine in ethanol, PA derivative solution in ethanol, EDC•HCl (1-ethyl-3-(3dimethylaminopropyl)carbodiimide hydrochloride) solution in ethanol, and 179

hydroxybenztriazole in DMF (N,N-dimethyformamide) were added to centrifuged beads. After
the beads were dispersed well into the medium, the suspension was incubated for 1 day at
room temperature. This immobilization step gave psammaplysene A-immobilized FG beads with
unreacted amine groups. Then, the beads were washed with ethanol once and suspended in
DMF. Masking of unreacted amine groups on the beads was performed by incubation with 1%
acetic anhydride in DMF for 3 hours at room temperature. DMF was removed and the PA-FG
beads were resuspended in distilled water. Finally, suspension of PA-FG beads in pure water was
kept at 4°C.
PA Target Identification with 2B: Cell lysates were prepared from HEK293 cells or C. elegans in
Triton-X 100 buffer (50mM Tris pH 7.8, 150mM NaCl, 1% Triton-X 100, complete protease
inhibitor cocktail). Lysates were incubated with 250nM of the PA derivative 2B for 1hr at 4⁰ C
with rotation. The lysate was then UV illuminated to activate the photo-affinity tag.
Crosslinking was performed with 365nm UV illumination using a Spectroline 6 watt UV lamp on
ice. Crosslinked lysates were then processed using the Click-iT protein reaction buffer kit
(Molecular Probes) to attach either TAMRA-azide or biotin-azide (Molecular Probes) to the
alkyene group on 2B. TAMRA tagged lysates were run on a 4-15% gradient gel and then
visualized by in gel laser scanning with the Typhoon 9400 imaging system (GE life sciences).
Biotin tagged lysates were incubated with hydrophilic streptavidin magnetic beads (New
England Biolabs) at 4⁰ C for 1 hr with rotation. Beads were washed three times with high
stringency wash buffer (PBS with 1 M KCl and 500mM Urea) to decrease pulldown of indirect
binding partners. Beads were submitted for mass spec analysis to identify binding partners.
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Purification of PA Targets with PA-FG Beads: HEK293 lysates were incubated with 0x, 1x, and
5x PA-FG beads for 1 hr at 4⁰ C. Beads were then washed 3x in PBS, moved to a new tube and
washed 2 additional times in PBS. The beads were then resuspended in 1x SDS-PAGE loading
buffer and boiled for 5 min. These samples were then run on a 4-15% gradient gel and
visualized with coomassie stain. The bands indicated in figure 1 were excised and submitted for
mass spec.
Surface Plasmon Resonance: PA binding to GST-HNRNPK was analyzed using a CM5 sensor chip
on a BIACORE 3000. Anti GST antibody was immobilized on the sensor chip using the GST
Capture Kit (GE). A capture/crosslink strategy was used to prevent dissociation of GST and GST
fusions from the GST antibody over time. The anti GST antibody was saturated with GST or GST
fusion protein and then briefly pulsed (60 sec) with NHS/EDC followed by a brief pulse (60 sec)
of ethanolamine. The buffer used for dissolving PA and washing the surface was composed of
5% DMSO and 0.05% Tween-20 in PBS. PA was injected at a flow rate of 30uL per minute for 60
seconds followed by a 120 second wash before administration of the next drug concentration.
In Vitro Transcription and Purification of Biotinylated Transcripts: Plasmid DNA containing the
non-coding RNA of interest downstream from a T7 promoter element was linearized by
overnight restriction enzyme digest. Linearized plasmid was recovered by gel purification using
the QIAquick Gel Extraction kit (Qiagen). Biotinylated transcripts were then generated using the
Ampliscribe T7-Flash Biotin-RNA Transcription Kit (Epicentre) with linearized plasmid as the
template. Biotinylated RNA was purified by ammonium acetate precipitation and resuspended
in rnase free water. Biotinylated RNAs were incubated with cell lysates for 1 hour and then
pulled down with hydrophilic streptavidin magnetic beads (New England Biolabs). Beads were
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washed 3x in TBS-T and then boiled in 1x SDS-PAGE loading buffer. Samples were run on an
SDPS-PAGE gel and western blots were performed to identify associated proteins.
Alternative Splicing Event Assay: Total RNA was isolated from HEK293 cells using the RNeasy
Plus Mini Kit (Qiagen). RNA was then analyzed for changes in alternative splicing events as
described in: Venables, J. P. et al. Multiple and specific mRNA processing targets for the major
human hnRNP proteins. Molecular and cellular biology 28, 6033-6043, doi:10.1128/MCB.0072608 (2008).
qPCR: Total RNA was isolated from HEK293 cells using the RNeasy Plus Mini Kit (Qiagen). RNA
yield was quantified by A260 and 1ug of total RNA was used as template for reverse trascription
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). RNA abundance
was then quantified by qPCR using Power SYBR Green Master Mix (Applied Biosystems) on a
Step One Plus Real Time PCR System (Applied Biosystems). All quantification was done using the
∆∆CT method to determine realtive fold changes compared to GAPDH. Primers used were as
follows:
5s rRNA forward 5’ GTC TAC GGC CAT ACC ACC 3’, reverse 5’ AAG CCT ACA GCA CCC G 3’
5.8s rRNA forward 5’ GGT GGA TCA CTC GGC TCG T 3’, reverse 5’ GCA AGT GCG TTC GAA GTG TC
3’
18s rRNA forward 5’ GAT ATG CTC ATG TGG TGT TG 3’, reverse 5’ AAT CTT CTT CAG TCG CTC CA
3’
28s rRNA forward 5’ TTG AAA ATC CGG GGG AGA G 3’, reverse 5’ ACA TTG TTC CAA CAT GCC AG
3’
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GAPDH forward 5’ AAT GAA GGG GTC ATT GAT GG 3’, reverse 5’ AAG GTG AAG GTC GGA GTC AA
3’
Beta actin forward 5’ ATA GCA CAG CCT GGA TAG CAA CGT AC 3’, reverse CAC CTT CTA CAA TGA
GCT GCG TGT G 3’
Gamma actin forward 5’ GCA AAA CCA GCT TTG CAC AT 3’, reverse CTC GCA CTC TGT TCT TCC G
3’
NCOR1 forward 5’ TTG TGA CGA GCA GTG AGA CAC G 3’, reverse 5’ TCA GCT TTG GTT TGC ACA
CTC CTG 3’
RAB5A forward 5’ GGC TGC CTT TCT AAC CCA AAC TG 3’, reverse 5’ TAC ACA ACT ATG GCGGCT
TGT G 3’
APP forward 5’ AAC CAG CAT TGC CAC CAC TAC C 3’, reverse 5’ AGC TTG TTC AGA GCA CAC CTC
TC 3’
NF-M forward 5’CAG TCC TCT TCG CTG CTT AAC G 3’, reverse 5’CTG CAG CTG CTC TTT CTC GTT
TG 3’

Immunoprecipitation: Cells were lysed in Triton-X 100 buffer (50mM Tris pH 7.8, 150mM NaCl,
1% Triton-X 100, complete protease inhibitor cocktail) and sonicated at 20% amplitude for 5
seconds with a Branson sonicator. Lysates were cleared of insoluble material by centrifugation
at max speed ~13,000 g for 10 min at 4⁰ C. Antibodies were prebound to Dynobead protein G
(Invitrogen) and then incubated with cell lysates for 1hr at room temperature. Beads were
washed 3x in PBS, transferred to a new tube and washed 2x in PBS. Beads were then
resuspended in 1x SDS-PAGE buffer and boiled for 5 minutes. Samples were resolved on an SDSPAGE gel and western blotted for the protein of interest.
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Polysome Profiling: Two 100mm dishes of HEK cells were used for each sample. Cells were
treated for 72 hours with PA or vehicle prior to polysome profiling. Cells were treated for 15
minutes with 100 µg/ml cyclohexamide. Cells were then washed twice with PBS + 100 µg/ml
cyclohexamide and then scraped from the plate in this same solution. Cells were spun for 2
minutes at 1,000 x g to pellet cells. Supernatant was aspirated and cells were lysed in 20 mM
Hepes pH 7.4, 100 mM KCl, 15 mM MGCl2, 0.5% NP-40, 2 mM DTT, 100 µg/ml cyclohexamide,
100 U/ml RNasin plus (Promega) and 1x complete protease inhibitor cocktail by passage through
a 26 gauge needle. Lysates were layered onto 15-45% continuous sucrose gradients containing
100 µg/ml cyclohexamide, 100 U/ml RNasin plus (Promega) prepared with DEPC treated water.
Samples were spun in a SW-41 Ti rotor (Beckman) for 2.5 hours at 38,000 rpm with no brake. A
peristaltic pump was used to through a UV monitor at 800 µl/min and A260 was plotted using
Labview Signal Express.
Incorporation of [35S]-methionine: Cells were treated for 72 hours with PA prior to translation
assay. Cells were washed two times in DMEM before replacing the media with cysteine and
methionine free media for 1 hour with PA or vehicle. After 20 minutes, [35S]-methionine was
added to the media at a concentration of 100 µCi/ml and translation was allowed to occur for
1hr. After labeling, media was removed and cells were washed once with PBS. Cells were lysed
in TNNB (50mM Tris-HCl pH 8.0, 250 mM NaCl, 0.5% NP-40, 0.5 mM PMSF, 0.1% BSA) with
100mM iodoacetamide at a final volume of 1 ml. 3 µl of each lysate was spotted onto filter
paper and dried. Filters were incubated in 10% TCA at 4⁰ C overnight. Incorporation of [35S]methionine was quantified on a Wallac 1409 DSA liquid scintillation counter (Perkin Elmer).
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Figure S1. PA derivative compounds
Suplemental Table 1

Protein names
2B Pulldown

Gene names

Actin, beta (Actin, beta, cytoplasmic)
cDNA FLJ37875 fis, clone BRSSN2018771, highly similar to
Poly(A)-binding protein 1
cDNA FLJ39996 fis, clone STOMA2002166, highly similar to
Splicing factor 3B subunit 4
cDNA FLJ52880, highly similar to Malate dehydrogenase,
mitochondrial (EC 1.1.1.37)
cDNA FLJ75163, highly similar to Homo sapiens heterogeneous
nuclear ribonucleoprotein U-like 1 (HNRPUL1), transcript
variant 4, mRNA
cDNA FLJ75556, highly similar to Homo sapiens ribosomal
protein L14, mRNA
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Actb mCG_23209

cDNA, FLJ92798, highly similar to Homo sapiens annexin A7
(ANXA7), transcript variant 2, mRNA
cDNA, FLJ93744, highly similar to Homo sapiens keratin 6E
(KRT6E), mRNA
D-3-phosphoglycerate dehydrogenase (3-PGDH) (EC 1.1.1.95)
DNA-directed RNA polymerase II subunit RPB1 (RNA
polymerase II subunit B1) (EC 2.7.7.6) (DNA-directed RNA
polymerase II subunit A) (DNA-directed RNA polymerase III
largest subunit) (RNA-directed RNA polymerase II subunit RPB1)
(EC 2.7.7.48)
EIF4G1 protein
Elongation factor 1-alpha
Elongation factor 2 (EF-2)
Ewing sarcoma breakpoint region 1 (Uncharacterized protein)
Fused in sarcoma
Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1)
(Helix-destabilizing protein) (Single-strand RNA-binding protein)
(hnRNP core protein A1)
Heterogeneous nuclear ribonucleoprotein H3 (hnRNP H3)
(Heterogeneous nuclear ribonucleoprotein 2H9) (hnRNP 2H9)
Heterogeneous nuclear ribonucleoprotein K
Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP
A2/B1)
Inducible heat shock protein 70
Keratin, type I cytoskeletal 10 (Cytokeratin-10) (CK-10) (Keratin10) (K10)
Keratin, type I cytoskeletal 14 (Cytokeratin-14) (CK-14) (Keratin14) (K14)
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9)
(K9)
Keratin, type II cytoskeletal 1 (67 kDa cytokeratin) (Cytokeratin1) (CK-1) (Hair alpha protein) (Keratin-1) (K1) (Type-II keratin
Kb1)
Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e) (CK2e) (Epithelial keratin-2e) (Keratin-2 epidermis) (Keratin-2e)
(K2e) (Type-II keratin Kb2)
MCG9909 (Small nuclear ribonucleoprotein B)
Peptidyl-prolyl cis-trans isomerase (EC 5.2.1.8)
Phosphoglycerate kinase (EC 2.7.2.3)
Profilin-1 (Profilin I)
Putative MAPK activating protein
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PHGDH PGDH3

POLR2A POLR2
EIF4G1
EEF2 EF2
EWSR1 AC002059.7-007
FUS

HNRNPA1 HNRPA1
HNRNPH3 HNRPH3
Hnrnpk Hnrpk
Hnrnpa2b1 Hnrpa2b1
Hspa1a
KRT10 KPP
KRT14
KRT9

KRT1 KRTA

KRT2 KRT2A KRT2E
Snrpb mCG_9909 RP2320A6.3-001
PPIA
PGK1 hCG_20034
PFN1

Pyruvate kinase isozymes M1/M2 (EC 2.7.1.40) (Cytosolic
thyroid hormone-binding protein) (CTHBP) (Opa-interacting
protein 3) (OIP-3) (Pyruvate kinase 2/3) (Pyruvate kinase muscle
isozyme) (Thyroid hormone-binding protein 1) (THBP1) (Tumor
M2-PK) (p58)
RNA-binding motif protein, X chromosome (Glycoprotein p43)
(Heterogeneous nuclear ribonucleoprotein G) (hnRNP G)
[Cleaved into: RNA-binding motif protein, X chromosome, Nterminally processed]
RNA-binding protein 14 (Paraspeckle protein 2) (PSP2) (RNAbinding motif protein 14) (RRM-containing coactivator
activator/modulator) (Synaptotagmin-interacting protein) (SYTinteracting protein)
Splicing factor, proline- and glutamine-rich (DNA-binding
p52/p100 complex, 100 kDa subunit) (Polypyrimidine tractbinding protein-associated-splicing factor) (PSF) (PTBassociated-splicing factor)
Tubulin alpha-1A chain (Alpha-tubulin 3) (Tubulin B-alpha-1)
(Tubulin alpha-3 chain)
Uncharacterized protein (cDNA FLJ77026, highly similar to
Homo sapiens ataxin 2-like (ATXN2L), transcript variant E,
mRNA)
Zinc finger protein 207

PKM2 OIP3 PK2 PK3 PKM

RBMX HNRPG RBMXP1

RBM14 SIP

Sfpq
TUBA1A TUBA3

ATXN2L
ZNF207

PA Nanobead Pulldown
60S ribosomal protein L6
78 kDa glucose-regulated protein (GRP-78) (Endoplasmic
reticulum lumenal Ca(2+)-binding protein grp78) (Heat shock 70
kDa protein 5) (Immunoglobulin heavy chain-binding protein)
(BiP)
A-kinase anchor protein 8 (AKAP-8) (A-kinase anchor protein 95
kDa) (AKAP 95)
Amyloid beta A4 protein-binding family B member 1 transcript
variant 3 (cDNA FLJ53829, highly similar to Amyloid beta A4
protein-bindingfamily B member 1) (cDNA FLJ61679, highly
similar to Amyloid beta A4 protein-binding family B member 1)
AP-3 complex subunit delta-1 (AP-3 complex subunit delta)
(Adapter-related protein complex 3 subunit delta-1) (Deltaadaptin)
Apoptosis-inducing factor 1, mitochondrial (EC 1.-.-.-)
(Programmed cell death protein 8)
ATPase family AAA domain-containing protein 3A
ATPase family AAA domain-containing protein 3B
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HSPA5 GRP78
AKAP8 AKAP95

APBB1

AP3D1 PRO0039
AIFM1 AIF PDCD8
ATAD3A
ATAD3B KIAA1273

ATP-binding cassette, sub-family F (GCN20), member 2 (ATPbinding cassette, sub-family F (GCN20), member 2, isoform
CRA_b) (Putative uncharacterized protein ABCF2)
ATP-dependent RNA helicase A (RHA) (EC 3.6.4.13) (DEAH box
protein 9) (Leukophysin) (LKP) (Nuclear DNA helicase II) (NDH II)
ATP-dependent RNA helicase DDX1 (DEAD (Asp-Glu-Ala-Asp)
box polypeptide 1, isoform CRA_d) (DEAD box polypeptide 1)
(cDNA, FLJ94573, Homo sapiens DEAD (Asp-Glu-Ala-Asp) box
polypeptide 1 (DDX1), mRNA)
ATP-dependent RNA helicase DDX3X (EC 3.6.4.13) (DEAD box
protein 3, X-chromosomal) (DEAD box, X isoform) (Helicase-like
protein 2) (HLP2)
ATP-dependent RNA helicase DHX29 (EC 3.6.4.13) (DEAH box
protein 29) (Nucleic acid helicase DDXx)
Bcl-2-associated transcription factor 1 (Btf)
BMP-2-inducible protein kinase (BIKe) (EC 2.7.11.1)
CD55 molecule, decay accelerating factor for complement
(Cromer blood group)
cDNA FLJ10686 fis, clone NT2RP3000252, highly similar to
Nucleolar GTP-binding protein 1
cDNA FLJ10711 fis, clone NT2RP3000917, highly similar to 5'-3'
exoribonuclease 2 (EC 3.1.11.-)
cDNA FLJ16043 fis, clone BRCAN2028355, highly similar to
Calcium/calmodulin-dependent protein kinasetype II gamma
chain (EC 2.7.11.17)
cDNA FLJ32131 fis, clone PEBLM2000267, highly similar to
Tubulin alpha-ubiquitous chain
cDNA FLJ36409 fis, clone THYMU2010448, highly similar to
Regulator of nonsense transcripts 3B
cDNA FLJ46863 fis, clone UTERU3011558
cDNA FLJ50778, highly similar to Protein flightless-1 homolog
cDNA FLJ53353, highly similar to ATP-binding cassette subfamily D member 3
cDNA FLJ54081, highly similar to Keratin, type II cytoskeletal 5
cDNA FLJ54345, highly similar to Homo sapiens neuropathy
target esterase (NTE), mRNA
cDNA FLJ54552, highly similar to Heterogeneous nuclear
ribonucleoprotein K
cDNA FLJ55635, highly similar to pre-mRNA-splicing factorATPdependent RNA helicase DHX15 (EC 3.6.1.-)
cDNA FLJ55671, highly similar to Ubiquitin-associated protein 2like
cDNA FLJ56474, highly similar to Histone deacetylase 6
cDNA FLJ58171, moderately similar to Melanoma-associated
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ABCF2 hCG_1643314
DHX9 DDX9 LKP NDH2

DDX1 hCG_15914

DDX3X DBX DDX3
DHX29 DDX29
BCLAF1 BTF KIAA0164
BMP2K BIKE HRIHFB2017
CD55 RP11-357P18.1-003

antigen D2
cDNA FLJ58398, highly similar to A-kinase anchor protein 8
cDNA FLJ61214, highly similar to Acid sphingomyelinase-like
phosphodiesterase 3b (EC 3.1.4.-)
cDNA FLJ75163, highly similar to Homo sapiens heterogeneous
nuclear ribonucleoprotein U-like 1 (HNRPUL1), transcript
variant 4, mRNA
cDNA FLJ75871, highly similar to Homo sapiens staufen, RNA
binding protein (STAU), transcript variant T3, mRNA
cDNA FLJ76871, highly similar to Homo sapiens DEAH (Asp-GluAla-His) box polypeptide 38 (DHX38), mRNA
cDNA FLJ76888, highly similar to Homo sapiens RNA binding
motif protein 6 (RBM6), mRNA
cDNA FLJ77037, highly similar to Homo sapiens RNA polymerase
II associated protein 1, mRNA (Fragment)
cDNA FLJ77404, highly similar to Homo sapiens small nuclear
ribonucleoprotein 70kDa polypeptide (RNP antigen) (SNRP70),
transcript variant 1, mRNA
cDNA FLJ78268, highly similar to Homo sapiens fusion (involved
in t(12;16) in malignant liposarcoma), transcript variant 1,
mRNA
cDNA FLJ78677, highly similar to Homo sapiens splicing factor
3b, subunit 3, 130kDa (SF3B3), mRNA
cDNA, FLJ92684, highly similar to Homo sapiens IK cytokine,
down-regulator of HLA II (IK), mRNA
cDNA, FLJ95128, highly similar to Homo sapiens sorting nexin 9
(SNX9), mRNA
cDNA, FLJ96507
cDNA, FLJ96901, highly similar to Homo sapiens Rac GTPase
activating protein 1 (RACGAP1), mRNA
Coatomer subunit alpha (Alpha-coat protein) (Alpha-COP) (HEPCOP) (HEPCOP) [Cleaved into: Xenin (Xenopsin-related peptide);
Proxenin]
COPA
Coiled-coil domain-containing protein 138
CCDC138
Coilin (p80)
COIL CLN80
Condensin complex subunit 1
CRNKL1 CRN CGI-201
Crooked neck-like protein 1 (Crooked neck homolog) (hCrn)
MSTP021
CTP synthase 1 (EC 6.3.4.2) (CTP synthetase 1) (UTP--ammonia
ligase 1)
CTPS
CWF19-like protein 1
CWF19L1
CYTSA KIAA0376
CYTSA protein (KIAA0376 protein, isoform CRA_a)
hCG_1811992
DBH-like monooxygenase protein 1 (EC 1.14.17.-)
MOXD1 MOX
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(Monooxygenase X)
DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 (DEAD box
polypeptide 17 isoform p82 variant) (Fragment)
DEAD (Asp-Glu-Ala-Asp) box polypeptide 52
Desmoglein-2 (Cadherin family member 5) (HDGC)
DNA repair protein RAD50 (hRAD50) (EC 3.6.-.-)
DNA-binding protein A (Cold shock domain-containing protein
A) (Single-strand DNA-binding protein NF-GMB)
DNA-dependent protein kinase catalytic subunit (DNA-PK
catalytic subunit) (DNA-PKcs) (EC 2.7.11.1) (DNPK1) (p460)
DNA-directed RNA polymerase III subunit RPC1 (RNA
polymerase III subunit C1) (EC 2.7.7.6) (DNA-directed RNA
polymerase III largest subunit) (DNA-directed RNA polymerase
III subunit A) (RNA polymerase III 155 kDa subunit) (RPC155)
(RNA polymerase III subunit C160)
Double-stranded RNA-binding protein Staufen homolog 2
Dynactin 1
EMILIN-2 (Elastin microfibril interface-located protein 2) (Elastin
microfibril interfacer 2) (Protein FOAP-10)
Eukaryotic translation initiation factor 3, subunit D (cDNA
FLJ53917, highly similar to Eukaryotic translation initiation
factor 3 subunit 7)
Eukaryotic translation initiation factor 3, subunit E interacting
protein (Uncharacterized protein)
Extracellular sulfatase Sulf-2 (hSulf-2) (EC 3.1.6.-)
Fanconi anemia group D2 protein (Protein FACD2)
Far upstream element (FUSE) binding protein 3 (HCG31253,
isoform CRA_a) (cDNA FLJ58115, highly similar to Far upstream
element-binding protein 3)
Fragile X mental retardation protein 1 (FMRP) (Protein FMR-1)
G patch domain-containing protein 4
Golgi apparatus protein 1 (CFR-1) (Cysteine-rich fibroblast
growth factor receptor) (E-selectin ligand 1) (ESL-1) (Golgi
sialoglycoprotein MG-160)
Guanine nucleotide-binding protein-like 3 (E2-induced gene 3
protein) (Novel nucleolar protein 47) (NNP47) (Nucleolar GTPbinding protein 3) (Nucleostemin)
Heat shock 70kDa protein 1A (Heat shock 70kDa protein 1B)
(cDNA FLJ75127, highly similar to Homo sapiens heat shock
70kDa protein 1A, mRNA)
Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein
8)
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UNQ2493/PRO5780
DDX17
DDX52
DSG2 CDHF5
RAD50
CSDA DBPA
PRKDC HYRC HYRC1

POLR3A
STAU2
DCTN1
EMILIN2

EIF3D
EIF3EIP EIF3L AL022311.1001
SULF2 KIAA1247
UNQ559/PRO1120
FANCD2 FACD
FUBP3 hCG_31253 RP1157C19.3-002
FMR1
GPATCH4 GPATC4

GLG1 CFR1 ESL1 MG160

GNL3 E2IG3 NS

HSPA1A HSPA1B
HSPA8 HSC70 HSP73
HSPA10

Heterogeneous nuclear ribonucleoprotein H (hnRNP H)
[Cleaved into: Heterogeneous nuclear ribonucleoprotein H, Nterminally processed]
Heterogeneous nuclear ribonucleoprotein L (hnRNP L)
Heterogeneous nuclear ribonucleoprotein M (hnRNP M)
Heterogeneous nuclear ribonucleoprotein Q (hnRNP Q)
(Glycine- and tyrosine-rich RNA-binding protein) (GRY-RBP)
(NS1-associated protein 1) (Synaptotagmin-binding, cytoplasmic
RNA-interacting protein)
Heterogeneous nuclear ribonucleoprotein R (hnRNP R)
Histone deacetylase (EC 3.5.1.98)
Insulin receptor substrate 4 (IRS-4) (160 kDa phosphotyrosine
protein) (py160) (Phosphoprotein of 160 kDa) (pp160)
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2
mRNA-binding protein 1) (IMP-1) (Coding region determinantbinding protein) (CRD-BP) (IGF-II mRNA-binding protein 1)
(VICKZ family member 1) (Zip code-binding protein 1) (ZBP-1)
(Zipcode-binding protein 1)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2
mRNA-binding protein 2) (IMP-2) (Hepatocellular carcinoma
autoantigen p62) (IGF-II mRNA-binding protein 2) (VICKZ family
member 2)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2
mRNA-binding protein 3) (IMP-3) (IGF-II mRNA-binding protein
3) (KH domain-containing protein overexpressed in cancer)
(hKOC) (VICKZ family member 3)
Isoleucine--tRNA ligase, cytoplasmic (EC 6.1.1.5) (Isoleucyl-tRNA
synthetase) (IRS) (IleRS)
Junction plakoglobin (Catenin gamma) (Desmoplakin III)
(Desmoplakin-3)
Kelch-like protein 21
Keratin, type I cytoskeletal 10 (Cytokeratin-10) (CK-10) (Keratin10) (K10)
Keratin, type I cytoskeletal 16 (Cytokeratin-16) (CK-16) (Keratin16) (K16)
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9)
(K9)
Keratin, type II cytoskeletal 1 (67 kDa cytokeratin) (Cytokeratin1) (CK-1) (Hair alpha protein) (Keratin-1) (K1) (Type-II keratin
Kb1)
Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e) (CK2e) (Epithelial keratin-2e) (Keratin-2 epidermis) (Keratin-2e)
(K2e) (Type-II keratin Kb2)
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HNRNPH1 HNRPH HNRPH1
HNRNPL HNRPL P/OKcl.14
HNRNPM HNRPM NAGR1

SYNCRIP HNRPQ NSAP1
HNRNPR HNRPR
HDAC1
IRS4

IGF2BP1 CRDBP VICKZ1
ZBP1

IGF2BP2 IMP2 VICKZ2

IGF2BP3 IMP3 KOC1
VICKZ3
IARS
JUP CTNNG DP3
KLHL21 KIAA0469
KRT10 KPP
KRT16 KRT16A
KRT9

KRT1 KRTA

KRT2 KRT2A KRT2E

KH domain-containing, RNA-binding, signal transductionassociated protein 1 (GAP-associated tyrosine phosphoprotein
p62) (Src-associated in mitosis 68 kDa protein) (Sam68) (p21
Ras GTPase-activating protein-associated p62) (p68)
KTN1 protein (cDNA FLJ61494, highly similar to Kinectin)
La-related protein 1 (La ribonucleoprotein domain family
member 1)
La-related protein 1B (La ribonucleoprotein domain family
member 1B) (La ribonucleoprotein domain family member 2)
(La-related protein 2)
La-related protein 7 (La ribonucleoprotein domain family
member 7) (P-TEFb-interaction protein for 7SK stability) (PIP7S)
Lectin, galactoside-binding, soluble, 3 binding protein
(Uncharacterized protein) (cDNA FLJ53478, highly similar to
Galectin-3-binding protein)
Melanoma-associated antigen D1 (MAGE tumor antigen CCF)
(MAGE-D1 antigen) (Neurotrophin receptor-interacting MAGE
homolog)
Mov10, Moloney leukemia virus 10, homolog (Mouse) (Mov10,
Moloney leukemia virus 10, homolog (Mouse), isoform CRA_a)
(Uncharacterized protein)
Myb-binding protein 1A
Myelin expression factor 2 (MEF-2) (MyEF-2) (MST156)
MYH10 protein
Myosin phosphatase Rho-interacting protein (M-RIP) (Rhointeracting protein 3) (RIP3) (p116Rip)
Myosin-14 (Myosin heavy chain 14) (Myosin heavy chain, nonmuscle IIc) (Non-muscle myosin heavy chain IIc) (NMHC II-C)
Myosin-9 (Cellular myosin heavy chain, type A) (Myosin heavy
chain 9) (Myosin heavy chain, non-muscle IIa) (Non-muscle
myosin heavy chain A) (NMMHC-A) (Non-muscle myosin heavy
chain IIa) (NMMHC II-a) (NMMHC-IIA)
Nuclear pore complex protein Nup160 (160 kDa nucleoporin)
(Nucleoporin Nup160)
Nucleolar protein 58 (Nucleolar protein 5)
Nucleolin, isoform CRA_c (cDNA FLJ10452 fis, clone
NT2RP1000966, highly similar to NUCLEOLIN)
PABPC4 protein (Poly(A) binding protein, cytoplasmic 4
(Inducible form)) (Poly(A) binding protein, cytoplasmic 4
(Inducible form), isoform CRA_c) (Uncharacterized protein)
Pentatricopeptide repeat domain 1 (cDNA FLJ76276, highly
similar to Homo sapiens pentatricopeptide repeat domain 1
(PTCD1), mRNA)
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KHDRBS1 SAM68
KTN1
LARP1 KIAA0731 LARP

LARP1B LARP2
LARP7 HDCMA18P

LGALS3BP
MAGED1 NRAGE PRO2292
PP2250
MOV10 hCG_38463 RP11426L16.2-003
MYBBP1A P160
MYEF2 KIAA1341
MYH10
MPRIP KIAA0864 MRIP
RHOIP3
MYH14 KIAA2034 FP17425

MYH9
NUP160 KIAA0197 NUP120
NOP58 NOL5 NOP5
HSPC120
NCL hCG_33980
PABPC4 hCG_2031827
RP11-69E11.6-002
PTCD1 hCG_2023422
tcag7.1151

Pentatricopeptide repeat-containing protein 3, mitochondrial
(Transformation-related gene 15 protein) (TRG-15)
Periodic tryptophan protein 1 homolog (Keratinocyte protein
IEF SSP 9502)
Poly(U)-binding-splicing factor PUF60 (60 kDa poly(U)-bindingsplicing factor) (FUSE-binding protein-interacting repressor)
(FBP-interacting repressor) (Ro-binding protein 1) (RoBP1)
(Siah-binding protein 1) (Siah-BP1)
Polyadenylate-binding protein 1 (PABP-1) (Poly(A)-binding
protein 1)
Prelamin-A/C [Cleaved into: Lamin-A/C (70 kDa lamin) (Renal
carcinoma antigen NY-REN-32)]
Probable ATP-dependent RNA helicase DDX41 (EC 3.6.4.13)
(DEAD box protein 41) (DEAD box protein abstrakt homolog)
Probable ATP-dependent RNA helicase DDX5 (EC 3.6.4.13)
(DEAD box protein 5) (RNA helicase p68)
Probable ATP-dependent RNA helicase DHX36 (EC 3.6.4.13)
(DEAH box protein 36) (MLE-like protein 1) (RNA helicase
associated with AU-rich element ARE)
Probable ATP-dependent RNA helicase YTHDC2 (EC 3.6.4.13)
Protein angel homolog 1
Protein angel homolog 2
Protein C16orf88 (Testis-specific gene 118 protein)
Protein FAM98A
Protein LYRIC (3D3/LYRIC) (Astrocyte elevated gene-1 protein)
(AEG-1) (Lysine-rich CEACAM1 co-isolated protein)
(Metadherin) (Metastasis adhesion protein)
Protein phosphatase 2 (Formerly 2A), regulatory subunit A (PR
65), alpha isoform (cDNA FLJ78455, highly similar to Homo
sapiens protein phosphatase 2 (formerly 2A), regulatory subunit
A (PR 65), alpha isoform (PPP2R1A), mRNA) (cDNA, FLJ96799,
Homo sapiens protein phosphatase 2 (formerly 2A), regulatory
subunit A (PR 65), alpha isoform (PPP2R1A), mRNA)
Protein transport protein Sec16A (SEC16 homolog A)
Putative ATP-dependent RNA helicase DHX57 (EC 3.6.4.13)
(DEAH box protein 57)
Putative protein FAM90A7
Putative RNA helicase Ski2w
Putative uncharacterized protein DKFZp686A13234 (Fragment)
RBM39 protein (Uncharacterized protein) (cDNA FLJ59214,
highly similar to RNA-binding region-containing protein 2)
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PTCD3 TRG15
PWP1

PUF60 FIR ROBPI SIAHBP1
PABPC1 PAB1 PABP1
PABPC2
LMNA LMN1
DDX41 ABS
DDX5 G17P1 HELR HLR1
DHX36 DDX36 KIAA1488
MLEL1 RHAU
YTHDC2
ANGEL1 KIAA0759
ANGEL2 KIAA0759L
C16orf88 TSG118
FAM98A

MTDH AEG1 LYRIC

PPP2R1A hCG_19686
SEC16A KIAA0310 SEC16
SEC16L
DHX57
FAM90A7
SKI2W
DKFZp686A13234
RBM39

Regulator of nonsense transcripts 1 (EC 3.6.4.-) (ATP-dependent
helicase RENT1) (Nonsense mRNA reducing factor 1) (NORF1)
(Up-frameshift suppressor 1 homolog) (hUpf1)
Ribonuclease 3 (EC 3.1.26.3) (Protein Drosha) (Ribonuclease III)
(RNase III) (p241)
RNA-binding protein 14 (Paraspeckle protein 2) (PSP2) (RNAbinding motif protein 14) (RRM-containing coactivator
activator/modulator) (Synaptotagmin-interacting protein) (SYTinteracting protein)
RSL1D1 protein (Fragment)
SAFB protein (Scaffold attachment factor B)
Scaffold attachment factor B2 (SAF-B2)
SNW domain-containing protein 1 (Nuclear protein SkiP)
(Nuclear receptor coactivator NCoA-62) (Ski-interacting protein)
Splicing factor 3A subunit 2 (SF3a66) (Spliceosome-associated
protein 62) (SAP 62)
Splicing factor 3B subunit 1 (Pre-mRNA-splicing factor SF3b 155
kDa subunit) (SF3b155) (Spliceosome-associated protein 155)
(SAP 155)
SRP72 protein (Fragment)
Stress-70 protein, mitochondrial (75 kDa glucose-regulated
protein) (GRP-75) (Heat shock 70 kDa protein 9) (Mortalin)
(MOT) (Peptide-binding protein 74) (PBP74)
Structural maintenance of chromosomes protein 1A (SMC
protein 1A) (SMC-1-alpha) (SMC-1A) (Sb1.8)
Synembryn-A (Protein Ric-8A)
TAF15 RNA polymerase II, TATA box binding protein (TBP)associated factor, 68kDa (TAF15 RNA polymerase II, TATA box
binding protein (TBP)-associated factor, 68kDa, isoform CRA_b)
(cDNA, FLJ94920, Homo sapiens TAF15 RNA polymerase II, TATA
box binding protein(TBP)-associated factor, 68kDa (TAF15),
transcript variant 1, mRNA)
TBC1 domain family, member 9B (With GRAM domain)
T-complex protein 1 subunit alpha (TCP-1-alpha) (CCT-alpha)
T-complex protein 1 subunit epsilon (TCP-1-epsilon) (CCTepsilon)
T-complex protein 1 subunit gamma (TCP-1-gamma) (CCTgamma) (hTRiC5)
Tetratricopeptide repeat protein 37 (TPR repeat protein 37)
(Thespin)
THO complex subunit 2 (Tho2) (hTREX120)
Titin (EC 2.7.11.1) (Connectin) (Rhabdomyosarcoma antigen
MU-RMS-40.14)
Transcription factor 25 (TCF-25) (Nuclear localized protein 1)
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UPF1 KIAA0221 RENT1
DROSHA RN3 RNASE3L
RNASEN

RBM14 SIP
RSL1D1
SAFB
SAFB2 KIAA0138
SNW1 SKIIP SKIP
SF3A2 SAP62

SF3B1 SAP155
SRP72

HSPA9 GRP75 HSPA9B
SMC1A DXS423E KIAA0178
SB1.8 SMC1 SMC1L1
RIC8A

TAF15 hCG_1992163
TBC1D9B
TCP1 CCT1 CCTA
CCT5 CCTE KIAA0098
CCT3 CCTG TRIC5
TTC37 KIAA0372
THOC2 CXorf3
TTN
TCF25 KIAA1049 NULP1

FKSG26
Trifunctional enzyme subunit alpha, mitochondrial (78 kDa
gastrin-binding protein) (TP-alpha) [Includes: Long-chain enoylCoA hydratase (EC 4.2.1.17); Long chain 3-hydroxyacyl-CoA
dehydrogenase (EC 1.1.1.211)]
Tubulin beta chain (Tubulin beta-5 chain)
Tubulin beta-4B chain (Tubulin beta-2 chain) (Tubulin beta-2C
chain)
Twinkle protein, mitochondrial (EC 3.6.4.12) (Progressive
external ophthalmoplegia 1 protein) (T7 gp4-like protein with
intramitochondrial nucleoid localization) (T7-like mitochondrial
DNA helicase)
U2 small nuclear RNA auxiliary factor 2 isoform b
U2 snRNP-associated SURP motif-containing protein (140 kDa
Ser/Arg-rich domain protein) (U2-associated protein SR140)
U4/U6.U5 tri-snRNP-associated protein 2 (Inactive ubiquitinspecific peptidase 39) (SAD1 homolog) (U4/U6.U5 tri-snRNPassociated 65 kDa protein) (65K)
Unc-84 homolog B (C. elegans) (Uncharacterized protein)
Uncharacterized protein
Uncharacterized protein (cDNA FLJ44920 fis, clone
BRAMY3011501, highly similar to Heterogeneous nuclear
ribonucleoprotein U)
Uncharacterized protein (cDNA FLJ50109, highly similar to
CDC45-related protein)
Uncharacterized protein (cDNA FLJ54150, highly similar to
Heterogeneous nuclear ribonucleoprotein D0)
Uncharacterized protein (X-ray repair complementing defective
repair in Chinese hamster cells 6 (Ku autoantigen, 70kDa))
Unconventionnal myosin-X (Unconventional myosin-10)
UTP18 small subunit (SSU) processome component homolog
(yeast) (cDNA, FLJ95176, Homo sapiens CGI-48 protein (CGI-48),
mRNA)
Uveal autoantigen with coiled-coil domains and ankyrin repeats
Versican core protein (Chondroitin sulfate proteoglycan core
protein 2) (Chondroitin sulfate proteoglycan 2) (Glial
hyaluronate-binding protein) (GHAP) (Large fibroblast
proteoglycan) (PG-M)
Vigilin (High density lipoprotein-binding protein) (HDL-binding
protein)
Voltage-dependent calcium channel subunit alpha-2/delta-1
(Voltage-gated calcium channel subunit alpha-2/delta-1)
[Cleaved into: Voltage-dependent calcium channel subunit
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HADHA HADH
TUBB TUBB5 OK/SW-cl.56
TUBB4B TUBB2C

PEO1 C10orf2
U2AF2
U2SURP KIAA0332 SR140
USP39 CGI-21 HSPC332
PRO2855
UNC84B SUN2 RP3508I15.15-002
GNL3L

HNRNPU
CDC45
HNRNPD
XRCC6 CTA-216E10.7-005
MYO10 KIAA0799

UTP18
UACA KIAA1561

VCAN CSPG2
HDLBP HBP VGL
CACNA2D1 CACNL2A
CCHL2A MHS3

alpha-2-1; Voltage-dependent calcium channel subunit delta-1]
Zinc finger protein 326

ZNF326

Suplemental Table 2

Screened PA Target Candidates
Ataxin 2-like (ATXN2L)
DEAH box polypeptide 57 (DHX57)
DEAH box polypeptide 9 (DHX9)
DEAD box helicase 17 (DDX17)
KH domain-containing, RNA-binding, signal
transduction-associated protein 1 (KHDRBS1,
SAM68)
Histone deacetylase 6 (HDAC6)
Heterogeneous nuclear ribonucleoprotein K
(HNRNPK)
Heterogeneous nuclear ribonucleoprotein L
(HNRNPL)
Heterogeneous nuclear ribonucleoprotein Q
(HNRNPQ, SYNCRIP)
Heterogeneous nuclear ribonucleoprotein Ulike 1 (HNRNPUL1)
La ribonucleoprotein domain family member
1 (LARP1)
La ribonucleoprotein domain family member
7 (LARP7)
MYB binding protein (MYBBP1A)
YTH domain containing 2 (YTHDC2)
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Suplemental Figure 2
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Figure S2. Heat map of alternative splicing events.
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Chapter 5
Future Directions:
Effects of IIS Signaling on SOD1 Toxicity in C. elegans

Are the Beneficial Effects of Reduced IIS on SOD1 Toxicity Cell Autonomous?
Our work with the Psnb-1::G85R::YFP; sid-1(pk3321)[Punc119::sid-1] strain suggested a
specific requirement of reduced IIS in the nervous system in order to rescue G85R induced
toxicity. While this approach allowed us to preferentially direct RNAi to the nervous system it
did not provide us with cell specific activation of DAF-16. This prevented us from definitively
determining whether increased DAF-16 activity was required cell autonomously to rescue
mutant SOD1 toxicity. If so this finding would be in contrast to effects of reduced IIS on
longevity. Reduced IIS in specific tissues has been found to coordinate organismal aging and
provide much of the same benefits on longevity as reducing IIS in the entire organism17. This
observation was made by mosaic analysis. Similar studies have not been performed to analyze
the effects of reduced IIS on stress resistance or more specifically, beneficial effects on
proteotoxicity in a tissue/lineage specific fashion. One potential approach to answering this
question would be to rescue daf-16 function in the Psnb-1::G85R::YFP;daf-2(e1370);daf100

16(mgDf50) background using tissue specific promoters. Using the snb-1 promoter to rescue
daf-16 function in this background, one could determine if restoration of DAF-16 activity
exclusively in neurons that express G85R is sufficient to rescue locomotor function in these
worms. If expression of daf-16 under the snb-1 promoter offered similar protection against
G85R toxicity as daf-2(e1370) does in a wild type daf-16 background, this would suggest that the
beneficial effects of reduced IIS on proteotoxicity are being mediated in a cell autonomous
manner. Similarly, this approach would allow you to selectively restore daf-16 in any tissue of
the Psnb-1::G85R::YFP;daf-2(e1370);daf-16(mgDf50) worm in order to determine if this was
beneficial to locomotion. If Psnb-1::daf-16 rescued locomotor function in the Psnb1::G85R::YFP;daf-2(e1370);daf-16(mgDf50) worm but expression of daf-16 in other tissues did
not this would suggest a cell autonomous effect of decreased IIS reducing SOD1 toxicity. An
alternative interpretation could be that snb-1 expressing neurons act to coordinate an
organismal response to SOD1 toxicity. In order to control for this possibility, one could develop
a SOD1 toxicity assay in a non-snb1 expressing tissue and ensure that rescue of daf-16 function
under control of the snb-1 promoter does not affect SOD1 toxicity in this assay. This would
ensure that the effects of increased DAF-16 activity on G85R toxicity are truly cell autonomous
and not coordinated by snb-1 expressing cells. A cell autonomous effect of decreased IIS on
SOD1 toxicity could be further validated through cell specific knockdown of daf-16 on the
G85R;daf-2(e1370) background. A daf-16 RNAi driven by Psnb-1 would be predicted to
eliminate the rescue typically seen in these worms if the benefits of daf-2(e1370) are mediated
cell autonomously.
Developing an accurate model of the cell autonomous versus nonautonomous effects of
reduced IIS on stress resistance is of clinical importance due to the potential for reduced IIS to
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ameliorate toxicity associated with a broad range of neurodegenerative diseases. Reduced IIS
might have adverse effects in certain tissues. If this were true therapies could be developed
that target reductions in IIS to specific tissues or potentially even regions within the brain.
Conversely if tissues or brain regions were found that were able to coordinate organismal stress
response, as certain cell types regulate aging in the worm, reduced IIS in these cell types could
be exploited to ameliorate disease globally.

Molecular Mechanisms of PA Neuroprotection
Although we were able to identify the target of PA as HNRNPK and determine that PA alters
rRNA abundance presumably through HNRNPK, a number of questions remain.
Are Reductions in rRNA Abundance Neuroprotective?
Reductions in rRNA abundance after stress are well documented, and are typically
thought to be associated with apotosis144,146. Consistent with these observations our data
demonstrates an ability of PA to increase rRNA abundance under stressful conditions. By
preventing decreases in rRNA abundance PA may be acting to prevent apoptosis. The fact that
stressed neurons not treated with PA increase their abundance of rRNA suggests that increasing
rRNA may be an endogenous mechanism for coping with cellular stress. Increased rRNA
abundance may facilitate increased translation that allows for translation of pro-survival factors.
Alternatively increased rRNA could function in a translation independent fashion. Non-coding
RNAs are capable of having signaling pathways and the 5s rRNA has been shown to act as a
brake on p53 activation by stabilizing mdmx142. Possible pro-survival activities of rRNAs could be
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investigated through overexpression of rRNA. A Herpes Simplex Virus (HSV) could be
engineered to expresss 5s, 5.8s, 18s or 28s rRNA and the neuroprotective capacity of
overexpression of rRNA could be monitored in motor neuron cultures exposed to various
stressors.
A potential role for decreased rRNA in survival has not been investigated. Knockdown of
components necessary for translation, such as ribosomal proteins and translation initiation
factors, is not only tolerated in C. elegans, such manipulations can significantly extend
lifespan139,141. Due to the proven record of knockdown of transcriptional machinery in worms, C.
elegans might be an optimal system to begin investigating the effects of knockdown of 5s, 5.8s,
18s, and 28s rRNAs. It would be interesting to determine if knockdown of any of the rRNAs is
tolerated and, if so, if this knockdown increases longevity or stress resistance. If knockdown of
rRNA is tolerated it would also be interesting to determine the effect of rRNA knockdown on
daf-16::GFP reporter worms. These worms show robust nuclear accumulation of DAF-16::GFP
upon exposure to stimuli which activate DAF-16. If RNAi to rRNAs increases stress resistance
and DAF-16 activation in worms this would suggest that reduction of rRNA stability might
represents the neuroprotective mechanism of PA. Some manipulations in the worm that extend
lifespan through inhibition of translation are not daf-16 dependent139, therefore it would be
informative to determine whether daf-16 is necessary to mediate any lifespan extending or
stress resistance effects of rRNA knockdown. A positive result in the worm would suggest follow
up experiments to determine if rRNA knockdown can be protective in mammalian cells as well.
A HSV could be generated to knockdown rRNAs in neurons and its protective effects could be
screened in the neuroprotection assays for which PA has already been determined to be
effective.
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Does Altered rRNA Abundance Represent the Only Functionally Significant Change in HNRNPK
After PA Treatment?
Although we were unable to find an effect of PA on many other HNRNPK functions, such
as alternative splicing, activation of NFκB, or abundance of HNRNPK target mRNAs, our assays
were somewhat limited in scope and therefore do not represent absolute evidence that PA is
not altering these functions. Our investigation into HNRNPK’s role as a transcription factor was
limited to effects on NFκB. HNRNPK effects the transcription of a number of other genes which
we did not investigate54. Similarly HNRNPK is known to effect alternative splicing of a number of
the genes in the alternative splicing assay we performed, but these do not represent all of the
HNRNPK mediated alternative splicing events. In order to further investigate potential effects of
PA on HNRNPK mediated splicing and gene expression, total RNA sequencing could be
performed on PA treated cells and compared to vehicle. This approach would allow for
simultaneous quantification of changes in transcript abundance as well as alternative splicing.
The ability to quantify non-coding RNA is another important advantage of this approach. Since
we already know that PA alters rRNA abundance, other non-coding RNAs might be important
targets of HNRNPK which are altered by PA as well. Alternatively this could be accomplished
with an exon array, although the ability to quantify non-coding RNAs would be lost.
Another important experiment would be to identify all of the RNAs whose binding to
HNRNPK is modified by PA treatment. We know that PA decreases rRNA stability. Work by Jiaqi
Shi and colleagues suggests that HNRNPK binds to and is an important stabilizer of rRNAs and
displacement of HNRNPK from rRNA leads to its degradation60. Based on this model, PA’s ability
to decrease rRNA abundance could potentially be mediated by a displacement of HNRNPK from
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rRNA resulting in decreased rRNA stability. There could be numerous other RNAs which are
displaced, or preferentially bound, by HNRNPK after PA treatment. One might be able to
identify some of these transcripts simply by changes in transcript abundance, but they may be
difficult to identify if they are not being actively targeted for degradation. If they are not
actively being degraded their abundance may be similar whether they are HNRNPK bound or
not. Stress or other stimuli may target these RNAs for degradation, at which point the effect of
PA would become biologically significant, but the PA effect may be masked under basal
conditions. One way to identify all the RNAs whose binding to HNRNPK are altered by PA would
be through Immunoprecipitation of HNRNPK followed by sequencing of HNRNPK bound
transcripts under vehicle and PA treated conditions. This would give a quantitative analysis of
all the transcripts which are dissociated or preferentially bound to HNRNPK after PA treatment.
Another limitation of our analysis of PA activity was the use of HEK293 cells for most
screening assays. The neuroprotective properties of PA were described in spinal cord cultures
which raises the possibility of cell type specific effects of PA. It may be important to perform the
experiments described above in neurons and, it may even be necessary to repeat some of the
previously performed assays in neurons as well.
Does PA Alter Other HNRNPK Activities in a Stress Dependent Fashion?
A number of studies have shown that HNRNPK plays an important role in p53 biology,
both as a transcriptional co-activator of p53 targets and as a transcriptional repressor of genes
downregulated by LINCp21 upon p53 activation54,55. This is of particular interest in light of work
implicating p53 in neurodegeneration and preclinical data suggesting that p53 inhibitors may be
effective therapeutics for neurodegenerative disease147. Based on our observations regarding
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rRNA and the fact that PA is neuroprotective, it is possible that PA plays a role in modifying
other stress specific functions of HNRNPK. For this reason it may prove important to do many of
the experiments we already performed, as well as some of the ones described above, under
basal as well as stressed conditions. Unfortunately adding stress to the analysis of HNRNPK
function after PA treatment makes data interpretation significantly more difficult; as you now
have to tease apart what changes in HNRNPK function are cause by stress, and which are caused
by PA under conditions of stress.
Can Functional Data be Inferred by Determining the Structure of PA Bound HNRNPK?
Another potential direction to take this project would be to try to determine where PA
binds HNRNPK. Several approaches could be considered to answering this question. 1) The
BIACORE analysis that was performed on GST-HNRNPK could be repeated using overlapping
truncated versions of the protein in order to define a minimal binding domain. 2) A truncated
overlapping HNRNPK constructs could also be transfected into cells and analyzed using the 2B
binding assay. 3) One could also attempt to crystalize PA bound to HNRNPK. These approaches
could be used to determine where PA is binding HNRNPK. Many of the domains of HNRNPK are
well characterized and knowing which domains PA is interacting with might give insight into its
activity. If PA is acting to occlude a KH domain this might suggest which HNRNPK might be
displaced by PA binding. If PA binds in or near the KI domain, this might suggest that PA is
disrupting an HNRNPK protein-protein interaction. Similarly, binding on or near a site of known
post-translational modification might suggest a role for that residue in stabilizing rRNA, or
interaction with an important protein partner.
Could PA Have Therapeutic Potential Against Cancer?
106

While we set out trying to identify the neuroprotective mechanism of PA, we may have
identified a cancer fighting activity of PA. PA was originally described as potentially having
cancer fighting properties based on its ability to relocalize FOXO1 to the nucleus in PTEN
deficient cells. Our work potentially suggests another cancer fighting property of PA. Work by
Jiaqi Shi, and colleagues, has described a significant reduction in eIF3f in various human cancers,
including pancreatic cancer and melanoma148-150. eIF3f appears to play an important role in
decreasing translation by increasing rRNA degradation. The molecular mechanism by which this
is achieved is by dissociating HNRNPK from rRNA, thus decreasing their stability and facilitating
their degradation60. As we have found that PA decreases rRNA abundance, it is conceivable that
administration of PA to eIF3f deficient cells might act to correct dysregulated translational
control in these cells. This could be of therapeutic benefit. Shi and colleagues describe
numerous cell growth and proliferation assays used to characterize cells that are transformed by
a loss of eIF3f. Monitoring changes in these assays in PA treated cells could be informative
about whether PA treatment could be of therapeutic potential.
Screening for Compounds with Similar Properties as PA.
The intent of this study was to identify the mechanism of action of PA so that
compounds with more “drug-likeness” than PA could eventually be identified. Assuming it can
be verified that altering the abundance of rRNA is PA’s protective mechanism, then a screen for
rRNA modulating compounds could be undertaken. This could be done by high throughput
qPCR. A potentially confounding aspect of this approach is that PA appears to change rRNA
abundance in different ways under stressed and unstressed conditions. It may be necessary to
determine which represents the neuroprotective activity before undertaking this screen.
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A more technically challenging but potentially more informative approach could be to
utilize a fluorescent RNA aptamer to monitor the interaction between HNRNPK and rRNA. Since
HNRNPK binding to rRNA has been suggested to increase rRNA stability, PA might be changing
HNRNPKs binding to rRNA. Paige et al recently described an RNA aptamer, called spinach, which
mimics GFP upon addition of the cell permeable fluorophore DFHBI. In their work they attach
spinach to 5s rRNA and are able to monitor its cellular localization and abundance in live cells in
real time151. While they do not perform any FRET experiments, it is possible that FRET between
spinach and a fluorescently tagged protein (such as HNRNPK) could be used to monitor protein
RNA interactions. A screen could be designed where fluorescence from a fluorophore on
HNRNPK excites 5s rRNA spinach and spinach fluorescence is used to monitor their interaction in
the presence of various drugs. This could be set up as a high throughput imaging screen looking
for compounds that modify FRET between 5s rRNA and HNRNPK.
Summary: Our work has identified HNRNPK as the target of the neuroprotective compound PA.
We have described a role for PA in modifying HNRNPKs ability to regulate rRNA abundance. We
show that neurons endogenously upregulate the abundance of the 5.8s rRNA when stressed and
PA acts to enhance this effect. rRNA degradation has been associated with apoptosis and the
ability of PA to upregulate rRNA may represent PA’s mechanism of neuroprotection.
Alternatively PA appears to decrease rRNA abundance when chronically administered under
non-stressed conditions. This may also represent a potential neuroprotective activity as
disruption of translation machinery has been shown to increase lifespan in various model
organisms.
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Abstract
The Forkhead Box O (Foxo) proteins represent an evolutionarily conserved family of
transcription factors that play an important role in regulating processes including metabolism,
longevity, and cell death/survival. How is it that a single transcription factor can initiate such
divergent cellular responses? We will review the evidence that specific patterns of posttranslational modifications play a key role in directing Foxo into various transcriptional readouts.
This regulation appears to take on a two tiered regulatory model; with a group of well defined
post-translational modifications regulating nuclear localization and transcriptional activity while
a second set of modifications regulate the transcriptional specificity of Foxo.

Introduction
The Forkead Box O (Foxo) transcription factors are members of the Forkhead
superfamily of winged helix transcription factors. The Foxo family regulates cellular processes
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including metabolism, stress response, DNA damage repair and cell death. The Foxo family is
highly conserved evolutionarily, with Foxo orthologs exhibiting similar physiological functions in
model organisms such as Caenorhabditis elegans, Drosophila melanogaster, and in vertebrates.
There are four mammalian Foxos, FOXO1, FOXO3, FOXO4 and FOXO6. FOXO2 is identical to
FOXO3 and FoxO5 is the fish ortholog of FOXO3. While all Foxo members are capable of
binding the same core DNA sequence, 5’-TTGTTTAC-3’, the expression of individual Foxos is
tissue specific. In addition, some Foxos undergo specific regulation or lack the regulatory
interactions of other isoforms. In most cases groups study the regulation of a single Foxo
isoform. Frequently regulatory pathways that are discovered in a single Foxo isoform are
conserved between isoforms, therefore, for the sake of simplicity, the general term Foxo will be
used in this article instead of listing each individual isoform.
While much is known about signaling pathways that influence its nuclear localization,
the necessary antecedent for transcriptional activity of Foxo, less is known about signaling
pathways that control Foxo transcription of specific genes in specific contexts. The ability of
Foxo to regulate so many cellular processes would suggest that such signaling pathways exist in
order to integrate cellular context and direct Foxo to specific targets. For example nuclear
localization of Foxo through Paclitaxel treatment causes cell death in breast cancer cells152, while
nuclear localization of Foxo through Psammaplysene A treatment is neuroprotective in multiple
models of motorneuron disease124. Even within the same cell type Foxo can have opposing
actions (mediating either apoptosis or survival of neurons100,124 depending on the cellular
context), raising the question of how its opposing activities are regulated. One mechanism of
regulating Foxo transcriptional output is through its pattern of posttranslational modifications
(i.e. phosphorylation, acetylation and ubiquitination). We will review the evidence that these
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patterns of posttranslational modification are responsible for regulating both transcriptional
specificity and transcriptional activation. In order to fully understand Foxo signaling it is
important to consider both pathways – those that generally activate or inhibit Foxo (by
regulating its subcellular localization), and those that direct Foxo to transcribe specific genes.

Foxo Inhibitory Kinases
The following kinases are known, general inhibitors of Foxo signaling. Their signaling
activities are responsible for promoting translocation of Foxo out of the nucleus and regulating
its degradation. Because of their ability to turn off Foxo transcription, and therefore repress, for
example, Foxo’s pro-apototic activity, these kinases are often considered in terms of Foxo’s role
in cancer biology. While it is clear that these signaling pathways play a role in controlling Foxo’s
subcellular localization, the extent to which these posttranslational modifications (at any of
these sites) play a role in the specificity of Foxo transactivation is unclear.
PI3’K Regulates Foxo Activation through Its Downstream Kinases AKT and SGK
The Phosphoinositide 3 Kinase (PI3’K) pathway is a major regulator of Foxo activation.
Activation of PI3’K leads to phosphorylation and activation of downstream targets including
Protein Kinase B (also known as AKT) and Serum and Glucocorticoid inducible Kinase(SGK). AKT
and SGK are both capable of recognizing the same motifs for substrate phosphorylation,
RXRXXS/T, and are responsible for phosphorylation of Foxo at 3 key residues: Thr32, Ser253 and
Ser315 (of Foxo3a). When Foxo is phosphorylated at these residues it associates with 14-3-3
proteins and is exported from the nucleus, where it is transcriptionally inactive97,153,154.
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While AKT and SGK are capable of phosphorylating the same residues, there does seem
to be some preference for specific sites between these two kinases. In particular, the C-terminal
most phosphorylation site, Ser315, seems to be preferentially phosphorylated by SGK, while
Ser253 is preferentially phosphorylated by AKT155. The N-terminal Thr32 is efficiently
phosphorylated by both kinases. Experiments using dominant negative forms of these two
kinases have demonstrated that disruption of either AKT or SGK kinase activity leads to nuclear
Foxo, suggesting a non-redundant role for these kinases in efficiently phosphorylating Foxo at
these three sites and targeting it to the cytoplasm.
Each of these three phosphorylation sites appears to mediate its own important
function in the nuclear export of Foxo. The most N-terminal phosphorylation site, Thr32, is
involved in Foxo association with 14-3-3, which is essential for Foxo nuclear export. The central
phosphorylation site at Ser253 is located in the Foxo Nuclear Localization Sequence (NLS) and
acts to disrupt NLS activity by introducing a negative charge to the basic NLS region. This
prevents re-entry of Foxo into the nucleus. The C-terminal most phosphorylation site, Ser315,
plays a key role in the rate of nuclear export. Phosphorylation of Ser315 unmasks the Foxo
Nuclear Export Sequence (NES) thus increasing its rate of nuclear export. The importance of this
residue is demonstrated by Foxo6, which lacks this phosphorylation site, and unlike the other
three Foxos, is predominantly nuclear156. Nuclear export of Foxo is an active process that
depends on the association between CRM1 and Foxo. Treatment of cells with the CRM1 specific
inhibitor leptomycin B (which covalently modifies the CRM1 NES binding domain) results in a
robust nuclear localization of Foxo even when Foxo is phosphorylated at Thr32, Ser253, and
Ser315153.
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Acetylation of Foxo influences AKT phosphorylation at Ser-253. Foxo mutants that are
acetylation-mimetic at Foxo lysine residues 242, 245, and 262 become highly phosphorylated
under basal growth conditions. Similarly, phosphorylation of wild type Foxo (Ser253) increases
with deacetylase inhibitor treatment, while phosphorylation at Ser253 of non-acetylatable
mutants is unaffected by deacetylase inhibitors157. Acetylation of Foxo by the histone acetyl
transeferases CBP and p300 inhibit Foxo DNA binding capacity in vitro. Phosphorylation of Foxo
at Thr32 disrupts the interaction between Foxo and CBP/p300. These data suggest a model in
which acetylation inhibits Foxo transcription in a sequential manner. Once Foxo is acetylated on
lysine 242, 245, and 262, its DNA binding capacity decreases. Acetylated Foxo, which does not
interact with DNA, is a superior substrate for phosphorylation by AKT at nuclear export sites.
Phospho Thr32/Ser253 Foxo loses the interaction between Foxo and CBP/p300 and thus negates
the favorable chromatin remodeling that this interaction promotes.
The ability of PI3’K to activate AKT and SGK is negatively regulated by the lipid
phosphatase, phosphatase and tensin homolog (PTEN) which degrades PIP3 thus inhibiting
PI3’K. Inactivation of PTEN is common in glioblastomas and prostate cancer158,159. Similarly,
decreased PTEN activity has been characterized in breast cancer160,161. The ability of this
pathway to robustly control Foxo nuclear localization helps explain the oncogenic properties of
PTEN. Normally, PTEN hydorlyzes PIP3, the product of PI3’K, and therefore decreases the
activity of AKT and SGK. PTEN deficiency results in a constitutively cytoplasmic Foxo. The lack of
nuclear Foxo in these cells could contribute to oncogenic transformation through a loss of the
cell cycle arrest and proappototic capabilities of Foxo.
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Phosphorylation of Ser315 by SGK Primes Foxo for CK1 Phosphorylation and Increases the
Rate of Nuclear Export
Casein Kinase 1 (CK1) plays a role in cell differentiation and circadian rhythm control and
its dysregulation can contribute to neurodegeneration and cancer development162. CK1 can
phosphorylate Ser318 and Ser321 but only after phosphorylation of Ser315 by SGK.
Phosphorylation of Ser315 by SGK creates a consensus sequence for CK1 phosphorylation,
S/T(P)XXS/T, at Ser318 which in turn creates a CK1 consensus sequence at Ser321. Ser to Ala
mutations and phosphospecific antibodies have been used to demonstrate that phosphorylation
at these residues is, in fact, hierarchical, with phosphorylation of Ser315 by SGK being necessary
for the subsequent phosphorylation of Ser318 and Ser321 by CK1. As mutations at any of these
sites have no effect on nuclear import rates; they probably function by increasing nuclear
export. It is thought that in conjunction with Ser325 this grouping of highly phosphorylated
residues creates an acidic patch that increases Foxo’s association with its nuclear export
complex163.
Dual Specificity Tyrosine Phosphorylated and Regulated Kinase 1A (DYRK1A) Increases Nuclear
Export of Foxo
DYRK1A is a serine/threonine kinase found in both the nuclear and cytoplasmic
compartments. While some DYRK1A targets are known, a detailed understanding of its cellular
functions is lacking. Decreased levels of the Drosphila ortholog, MiniBrain Kinase, results in
decreased brain size suggesting a role in the regulation of neurogenesis. Based on its
chromosomal location, and the role of MiniBrain, DYRK1A has been implicated in the
pathogenesis of Down syndrome164. DYRK1A has been shown to phosphorylate Foxo at Ser325.
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Phosphorylation at this residue decreases the amount of Foxo in the nuclear fraction and
accordingly decreases Foxo transcriptional activity. DYRK1A activity is SGK-and-CK1independent and a Ser to Ala mutation at Ser325 increases the amount of nuclear Foxo165.
Although DYRK1A activity is PI3’K independent, phosphorylation of Foxo at Ser325 by DYRK1A
seems to have a synergistic effect with SGK and CK1 perhaps by enhancing the acidic patch
effect that promotes Foxo to interact with its nuclear export complex.
IKK Regulates Foxo Inactivation and Degradation in an AKT Independent Fashion
The IкB Kinase (IKK) is best known for its regulation of the Nuclear Factor-κB family of
transcription factors166. Activation of the IKK has also been shown to inactivate Foxo.
Constitutive activation of IKK has been linked to breast carcinoma, suggesting a model where
constitutive activation of IKK increases pro-survival factor expression and inhibits the proapoptotic functions of Foxo. Hu et.al. demonstrated that the ability of IKK to induce cytoplasmic
localization of Foxo is AKT independent167. This AKT independence was characterized using
mutant forms of Foxo that are non-phosphorylatable at the three AKT/SGK sites described
above, as well as cell lines lacking AKT activity. Activation of IKK has been shown to induce
phosphorylation of Foxo at ser644. Phosphorylation at this residue results in both nuclear
exclusion and degradation of Foxo. Phosphorylation at ser644 has been shown to induce
ubiquitination of Foxo and a subsequent decrease in Foxo levels that can be inhibited using the
proteasomal inhibitor MG132.
ERK Inhibits and Degrades Foxo
The RAS-ERK pathway is a signaling cascade that regulates cellular proliferation and
survival168. Many tumors are RAS overexpressors or express a mutant, constitutively active,
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form of RAS. When this is the case, ERK activity is upregulated and there is an accompanying
decrease in Foxo transcriptional activity in two ways. First, ERK has been shown to
phosphorylate Foxo (at Ser294, Ser344, and Ser425 on Foxo3a) and this phosphorylation results
in increasing amounts of cytoplasmic Foxo. Second, Foxo phosphorylated at these three
residues is less stable, and is degraded in a proteasome dependent fashion. This decreased
stability may be based on its increased interaction with the E3-ligase, MDM2169.

Foxo Activating Kinases

Stressors Induce Nuclear Accumulation of Foxo
A number of different kinases (MST1, JNK, and CDK1) are capable of promoting
translocation of Foxo into the nucleus under conditions of cellular stress. Once localized to the
nucleus, Foxo seems to execute either a pro-survival or pro-death transcriptional pattern
dependent on the cellular context and severity of the insult. While phosphorylation at any of
the sites described bellow seems to be sufficient to induce nuclear localization, little is known
about the consequences of activating these pathways together. Do these multiple stress
dependent kinases represent redundant pathways of Foxo activation, thus ensuring that Foxo
responds to stressors, or might they act to integrate data to help determine the severity of the
stressor and thus signal the appropriate transcriptional pattern to execute?
Oxidative Stress Activates JNK which Activates Foxo
c-Jun N-terminal Kinase (JNK) is a kinase which is activated by cell stress, including
inflammatory signals, ultraviolet light and Reactive Oxygen Species (ROS), and upon activation
can increase Foxo transcription. ROS activate the small GTPase Ral, and Ral, in turn activates
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JNK. JNK then phosphorylates Foxo at Thr447 and Thr451 leading to an increase in its
transcriptional activity170. The JNK dependent effect on Foxo transcription appears to be
antagonized by the AKT/SGK signaling pathway. ROS are known to induce nuclear localization
of Foxo even in the presence of serum (when AKT is active and would otherwise lead to
cytoplasmic localization of Foxo). Nevertheless, Foxo proteins which are phosphomimetic at the
JNK sites show similar association with 14-3-3 upon insulin treatment as wild type Foxo, and
undergo cytoplasmic localization. This suggests that the nuclear localization of Foxo after ROS
treatment is not regulated by JNK. While Foxo is regulated normally by PI3’K after JNK
phosphorylation, JNK phosphorylation of Foxo makes Foxo transcriptionally more active.
CDK1 Activates Foxo as a Key Check in the Cell Cycle
Cyclin Dependent Kinase 1 (CDK1) phosphorylates Foxo in the forkhead domain at
Ser249. CDK1 is a kinase associated with cell cycle progression, predominantly the G2/M
transition. As opposed to the PI3’K/AKT pathway, phosphorylation at Ser249 by CDK1 disrupts
the interaction between Foxo and 14-3-3, thus leading to its nuclear localization.
Phosphorylation at this site varies with the cell cycle, with Foxo being highly phosphorylated at
Ser249 during the G2/M transition (when CDK1 is most active) and relatively unphosphorylated
during the G0/G1 transition. The ability of CDK1 to increase Foxo transcription likely correlates
with Foxo’s ability to induce expression of DNA damage repair genes such as GADD45 and genes
that eliminate ROS. These genes are turned on at the G2/M transition and ensure the cell is in
an optimal state before the cell cycle continues171.
Another interesting aspect of this pathway is that aberrant activation of the cell cycle
has been associated with cell death in post-mitotic neurons. For example depriving cerebellar
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granule neurons of action potential firing (through blockage of calcium flux) causes cell death.
This activity deprivation is also associated with an increase in CDK1 activity, leading to Foxo
activation171. Foxo-dependent cell death is mediated by the expression of pro-apoptotic factors
such as Bim. There is some disagreement about this as some have suggested that
phosphorylation at Ser249 results in inhibition of Foxo potentially leading to tumorogenesis172.
MST1 Phosphorylates Foxo Leading to its Activation
Mammalian Sterile 20-like kinase 1 (MST1) is known to control cell proliferation, survival
and morphology173. The fly ortholog of MST1, Hippo, is a known tumor suppressor and it is
suspected that MST1 has a tumor suppressor capacity as well. MST1 is capable of
phosphorylating Foxo at Ser207174. Once phosphorylated at this site the interaction between
Foxo and 14-3-3 is disrupted and Foxo localizes to the nucleus. Phosphorylation at this site can
be initiated by ROS or activity/trophic factor deprivation in neurons. Neuronal death induced by
trophic factor/activity withdrawal or ROS exhibit a dependence on MST1 and Foxo175. While not
characterized, it is likely that this signaling pathway may also be adaptive allowing for survival
depending on the severity of the insult. Insults resulting in cell death are generally studied due
to the fact that they result in an easily quantifiable phenotype (i.e. death/survival). For this
reason it is difficult to say definitively that this pathway is adaptive when less severe insults are
administered, but the Foxo transcriptome would suggest that this is the case176.

Kinases That Dictate a Transcriptional Profile

Foxo is the transcriptional regulator of a group of proteins whose cellular functions,
when considered as a whole, are not directed towards a single purpose. For example Foxo is the
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regulator of GADD45a and manganese superoxide dismutase, which are involved in DNA
damage repair and ROS scavenging respectively. Yet Foxo also regulates expression of FASligand and BIM which are involved in apoptosis177. These four proteins would likely never be
activated in unison as there is no clear purpose in clearing cellular ROS and repairing DNA in a
cell which has initiated an apoptotic pathway. This suggests that Foxo is capable of integrating
cellular signals in order to select the transcriptional profile suited to affect a specific outcome.
This is analogous to the cellular function of the transcription factor p53, which acts to initiate
cell survival and DNA damage repair in the case of mild insults but initiates cell death when
insults are severe178.
It is clear that post-translational modifications play an important role in specifying the
transcriptional outputs of Foxo. It has been technically challenging thus far to profile the Foxo
transcriptome in the case of every post translational modification due to the sheer number of
potential modifications and pathways that act upon Foxo. While it is likely that some of the
aforementioned inhibitory and activating kinases are specifying more than an on/off type signal,
AMPK is the only kinase whose effect on Foxo’s transcriptional profile has been well
characterized.
AMPK acts to Integrate Data on Energy Levels into Foxo Transcriptional Activity
The AMP-activated Protein Kinase (AMPK) is a key regulator of energy homeostasis in
cells. It is regulated by the ratio of AMP to ATP in a cell, with higher AMP/ATP ratios resulting in
AMPK activation. AMPK can phosphorylate Foxo at six sites. While phosphorylation at these
sites appears not to have any effect on the localization or overall activity of Foxo, these sites do
influence the transcriptional profile of Foxo. Microarray studies of cells expressing mutant Foxo
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that is non-phosphorylatable at the six AMPK sites has revealed a transcript profile in which
genes involved in ROS resistance are up regulated179. Simultaneously, others are turned down
and many remain unchanged. This is particularly interesting because it represents a second
layer of control dictated by post translational modification. AMPK does not regulate Foxo in a
binary manner (i.e. transcriptionaly active versus inactive) instead it is dictating a specific
transcriptional output. The mechanism by which phosphorylation at these sites alters Foxo’s
transcriptional pattern been well explored. Potential mechanisms for AMPK’s control of Foxo
dependent transcription include: recruitment of additional proteins to a transcriptional complex
or direction of Foxo to specific promoter regions.

Figure 1. Numerous residues on Foxo are regulated via phosphorylation. These sites influence
Foxo’s subcellular localization, transcriptional potency and specify gene targets for activation.
*This SGK site is not present in Foxo6. ** This JNK site is only present in Foxo4.

Acetylation of Foxo
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The effect of acetylation on Foxo activity represents a complex balance between histone
deacetylases (hDACs) such as Silent Information Regulator 2 (SIRT1) and (SIRT2) and the Histone
Acetyl Transfreases (HATs) CREB Binding Protein (CBP) and p300. The histone acetyltransferase
activity of the coavtivators CBP/p300 could enhance Foxo transcription indirectly through their
ability to acetylate histones and favorably remodel chromatin. In contrast, acetylation of Foxo
has been shown to inhibit its DNA binding capacity157. This negative feedback mechanism is
most likely offset by the activity of SIRT1 and 2 which are capable of deacetylating Foxo.
Monoubiquitination of Foxo lysines which can prevent acetylation, should both keep Foxo nonacetylated and extend its association with DNA promoter regions.
SIRT1 and 2
SIRT1 and SIRT2 are members of the sirtuin family of decacetylases and are the
mammalian homologs of the yeast deacetylase Sir2. In yeast, Sir2 plays an important role in
oraganismal longevity through histone deacetylation and gene silencing. Deacetylation of other
contributory proteins by Sir2, such as acetyl-coenzyme A, may also play a role in longevity
through regulation of intermediary metabolism180. In mammals, SIRT1 and SIRT2 interact with
Foxo in a ROS-dependent manner. ROS promotes nuclear localization of Foxo and nuclear
localization of Foxo is necessary for the Foxo SIRT1 interaction since SIRT1 is constitutively
nuclear. Yet, nuclear localization alone is not sufficient to initiate the Foxo-SIRT1 interaction;
cells must be exposed to increased levels of ROS to induce this protein-protein interaction.
SIRT2 on the other hand shuttles between the nucleus and the cytoplasm, so it is conceivable
that SIRT2 could deacetylate Foxo in the nucleus or the cytoplasm.
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Based on the work of several groups, it appears that deacetylation of Foxo by SIRT1
imparts transcriptional specificity, shifting Foxo’s transcriptional profile away from apoptosis
and towards expression of survival promoting genes181-184. This is consistent with findings that
inhibition of SIRT1 or disruption of its interaction with Foxo promotes the expression of
apoptotic genes controlled by Foxo in prostate cancer derived cell lines185,186. Experiments in
mouse embryonic fibroblasts that are null for SIRT1 suggest that deacetylation of Foxo by SIRT1
selectively increases the expression of ROS resistance genes while having little effect on proapoptotic gene expression181. SIRT1 deacetylation of Foxo also seems to increase the ability of
Foxo to induce cell cycle arrest. These two findings taken together suggest the role for
deacetylation of Foxo, by SIRT1, is to pause the cell cycle in order to allow cells to repair DNA
damage and remove ROS prior to cell division. SIRT2 has also been reported to upregulate
transcription of Foxo targets that allow cells to cope with ROS, such as p27kip and manganese
superoxide disumatase187. In addition over expression of SIRT2 is capable of inducing
transcription of the pro-apoptotic factor Bim188. This scenario is quite reminiscent of p53178.
CBP/p300
The HATs CBP and p300 have two distinct activities on Foxo transcription. Acetylation of
Foxo by CBP/p300 results in a decrease in Foxo transcriptional activity. CBP is able to acetylate
Foxo at Lys242, 245 and 262157. These residues are all located in the DNA binding domain of
Foxo, and in vitro experiments using mutants which mimic the acetylated state at these residues
(by replacing the basic lysine residues with Alanines or Glutamines) have severely diminished
DNA binding capacity in vitro157. This is a mechanism through which CBP/p300 can act to inhibit
Foxo-dependent transcription.
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The second activity of CBP/p300 is to acetylate histones in a manner that allows Foxo
increased access to promoter regions189. One example of this activity is during treatment of
cells with ROS. Treatment with ROS has been shown to increases the association of CBP/p300
with Foxo. This interaction has been shown to be mediated by a redox sensitive disulfide bridge
that covalently links Foxo to CBP/p300 through Cys477 on Foxo190. This could potentially lead to
acetylation of Foxo and decreased levels of Foxo transcription, yet ROS are known to increase
the expression levels of many Foxo regulated genes. The most probable explanation for this
result is that CBP/p300 acetylation of histones favorably remodels chromatin while SIRT1/2
prevents acetylation of Foxo and allows it to bind DNA. Thus while CBP/p300 can act as
repressors of Foxo through their protein acetyltransferase activity, they also act as coactivators,
increasing Foxo transcription through their histone acetyltransferase activity. A structural
representation of how CBP/p300 binds Foxo and acts as a coactivator to increase Foxo
transcription has recently been solved189.

Ubiquitination of Foxo

Ubituitination plays a key role in the regulation of Foxo proteins. Foxo, like many other
proteins, is targeted for proteasomal degradation through polyubiquitination. In addition to this
canonical role for ubiquitination in protein degradation, monoubiquitination also plays a role in
Foxo response to ROS. This is achived by controlling transcriptional activity and localization of
Foxo. This suggests a complex role for ubiquitination in Foxo signaling. Monoubiquitination of
Foxoleads to activation of its transcriptional activity. This is balanced by polyubiquitination
which leads to degredation – essentially depression of Foxo transcription through degradation.
Therefore, from the monoubiquitinated state, polyubiquitination can be used for long term
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inactivation of Foxo transcription or deubiquitination can occur, allowing for quick reactivation
of Foxo if necessary.
Monoubiquitination by MDM2
Exposure of cells to ROS results in monoubiquitination of Foxo at multiple sites. This
monoubiquitination is lost upon treatment of cells with MDM2 siRNA suggesting this E3 ligase
directly ubiquitinates Foxo. Expression of Foxo-ubiquitin fusion constructs suggest that
monoubiquitination of Foxo results in an increase in nuclear localization of Foxo as well
enhancement of Foxo transcriptional activity. While MDM2 likely acts as a monoubiquitinating
E3 ligase for Foxo, this event probably primes Foxo for branching ubiquitination by SKP2. This is
suggested by the observation that very high levels of MDM2 expression (or phosphorylation of
Foxo by ERK), which increases MDM2-Foxo interaction, results in decreased levels of Foxo
protein191.
Mutant Foxo constructs and treatment with deacetylase inhibitors suggests that the
lysine residues that are ubiquitinated are the same residues that are acetylated by CBP/p300192.
Under some circumstances a competition exists between the ubiquitin ligases and acetylases for
these residues. This is potentially important as it suggests a posttranslationaly modified state of
Foxo where acetylases could interact with Foxo as cofactors (allowing optimal chromatin
structure) without acetylating Foxo (which would inhibit its transcriptional activity). It is
important to note that this state is independent of SIRT deacetylation.
Deubiquitination by USP7
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Deubiquitination of Foxo is mediated by the deubiquitinating enzyme USP7. Foxo has
been shown to interact with USP7 both through yeast two hybrid and immunoprecipitation
experiments. This interaction is enhanced by increased levels of ROS with kinetics which are
slower than the monoubiquitination of Foxo192. These observations suggest that Foxo exists in a
dynamic equilibrium: Foxo monoubiquitination by MDM2 is induced by ROS, and this
monoubiquitination is offset by USP7-dependent deubiquitination. Deubiquitinated Foxo is less
transcriptionally active, thus USP7 acts as a negative regulator on Foxo transcription. While
USP7 inhibits Foxo through deubiquitination it has no effect on protein levels of Foxo reinforcing
the view that monoubiquitination of Foxo acts independent of protein degradation.
Polyubiquitination by SKP2
SKP2 physically interacts with Foxo in a phosphorylation-dependent manner.
Phosphorylation of Foxo at Ser253 (preferentially phosphorylated by AKT) is required for Foxo
SKP2 interaction and its subsequent ubiquitination193. SKP2 polybuiquitinates Foxo after binding
and the ability of SKP2 to decrease Foxo protein levels is proteasome-dependent (it is abolished
by MG132 treatment194). Elevated SKP2 levels are found in a wide variety of human cancers,
and overexpression of this protein in mice leads to tumor formation. The ability to degrade
Foxo (and thus eliminate its pro-apoptotic activity) may help explain the oncogenic properties of
SKP2. This is also consistent with the oncogenic properties of PTEN deficiency. The loss of PTEN
activity enhances AKT signaling and phosphorylation of Foxo at Ser253. This not only promotes
nuclear exclusion of Foxo but polyubiquitination by SKP2 which leads to degradation of Foxo.
This link between SKP2 and AKT phosphorylation also helps to explain the capacity of PTEN
deficiency to induce tumorogenesis.
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Figure 2. The acetylases CBP and p300 play an important role in chromatin remodeling, allowing
Foxo to effectively transcribe its targets. Interestingly CBP/p300 also have an inhibitory effect
on Foxo DNA binding through acetylation of the Foxo DNA binding domain. This negative
regulatory effect is counteracted by the histone deacetylases SIRT1 and SIRT2. Foxo acetylation
can also potentially be prevented through monoubiquitination of the lysines in Foxo’s DNA
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bidning domain. Monoubiquitinaiton also primes Foxo for potential polyubiquitination and
eventual degredation.

Foxo Cofactors and Foxo as a Cofactor

Foxo transcriptional activity can be affected by cofactors. These cofactors may have a
general effect on Foxo transcriptional activity or they may confer Foxo transcriptional specificity.
In addition, Foxo acts as a cofactor for a number of other transcription factors, affecting their
transcriptional activity independently of Foxo’s own DNA binding activity. This increases the
scope of Foxo activity beyond the already impressively large number of Foxo transcriptional
processes.
β-Catenin Increases Foxo Transcriptional Activity
β-Catenin directly binds to Foxo and increases its transcriptional activity. ROS increase
the interaction between β-catenin and Foxo195. This interaction may play a role in determining
whether cells progress through the cell cycle or arrest. In the absence of ROS, β-catenin
interacts with members of the T cell factor (TCF) family of transcription factors, which act to
promote progression of the cell cycle. In contrast, increased Foxo transcription results in higher
levels of cell cycle inhibitors such as p27kip. In this way the ROS dependent interaction between
Foxo and β-catenin may act like a switch, allowing cells to pause and clear harmful ROS when
Foxo and β-catenin interact. When oxidative stress subsides, β-catenin preferentially interacts
with TCF, allowing cells to proceed through the cell cycle.
127

Foxo acts as a Corepressor of HIF1
As mentioned before, PTEN deficiency results in a lack of nuclear Foxo and is associated
with tumorogenesis. PTEN-deficient tumors are known to be quite aggressive and highly
vascular. This knowledge led to a study of the effects of PTEN on Hypoxia Inducible Factor 1
(HIF1) a key transcription factor controlling the expression of many angiogenic genes. PTEN
alters HIF1 transcriptional activation via Foxo’s cellular localization196. Even in PTEN deficient
cells, if Foxo is localized to the nucleus, then HIF1 transactivation is inhibited. This is
accomplished by Foxo complexing with HIF1 and interfering with HIF1’s interaction with its
coactivator p300196. This discovery adds to the complexity of Foxo’s anticancer properties. In
addition to affecting cell cycle progression, clearing ROS, and proappoptotic capacity, Foxo also
seems to act as a repressor of the HIF1 transcription factor and neovascularization.
Foxo is a Corepressor of the Androgen Receptor
Much like its effect on HIF-1, Foxo is capable of repressing the transcriptional activity of
the Androgen Recptor (AR). This inhibition is not dependent on the transcriptional capacity of
Foxo but simply on its nuclear localization. Transcriptionally inactive Foxo (mutant in its DNA
binding domain) inhibits AR as robustly as the wild type protein197. Much like HIF-1, Foxo and
the AR form a complex on AR promoter regions. HDAC3 is also a part of this complex and seems
to play an important role in Foxo’s ability to inhibit AR transcription. Foxo inhibition of the AR
prevents both adrenergic and non-adrenergic activation of the AR197.
Foxo Acts as a Coactivator of Ets-1
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There are 15 consensus phosphorylation sites on Foxo which are predicted to be
regulated by members of the Mitogen Activated Protein Kinase (MAPK) family. Nine of the
serine residues are capable of being phosphorylated in vivo by ERK and of these, five can also be
phosphorylated by p38. Mutational analysis has revealed that phosphorylation at these sites
can influence Foxo interaction with another transcription factor, Ets-1. Foxo interaction with
Ets-1 leads to an increase in Ets-1 transcriptional activity as assessed by Ets-1 activity on the Flk1 promoter, which promotes angiogensis. Foxo has no activity at the Flk-1 promoter region but
Ser to Ala mutations at the putative ERK/p38 sites that disrupt the Foxo-Ets-1 interaction greatly
diminish Ets-1 interaction with Flk-1198. This suggests that Foxo can act as a cofactor for other
transcription factors indicating an even broader role of Foxo in transcriptional regulation. As
discussed previously, phosphorylation of Foxo by ERK decreases Foxo stability potentially acting
as a negative regulator of this signaling pathway.

Foxo Signaling as a Potential Therapeutic Target for Disease

As of yet, the only clinical use of drugs that target the Foxo signaling pathway is in
cancer. Inactivation of Foxo through aberrant PTEN, AKT, IKK or ERK signaling have all been
shown to promote tumorogenesis. A number of chemotherapeutic drugs have been shown to
mediate their activity at least in part through restoring Foxo activity to cells, inducing Foxo proapoptotic target genes such as Bim. For example, Paclitaxel is known to increase Foxo activity
through repression of AKT and induction of JNK signaling which cooperatively lead to nuclear
localization and activation of Foxo152. While no drugs that function through the Foxo signaling
pathway are currently available for treating diseases other than cancer, some research has
suggested that under certain circumstances promoting Foxo signaling may be used in a pro129

survival manner as well. The marine sponge compound Psammaplysene A has been shown to
be neuroprotective both in vitro and in vivo against neurotoxic insults124. This reinforces the
observation that induction of Foxo can have varying activity based on the cellular context of
Foxo activation. This raises the intriguing possibility of developing drugs in the future which act
on Foxo to modulate its transcriptional profile. Current drug strategies take advantage of the
fact that Foxo, through the integration of various posttranslational modifications, is able to
activate pro-survival or pro-death genes depending on the state of cell. If we fully understood
the signaling pathways that mediate Foxo gene expression choice, we could develop more
potent drugs that not only activate Foxo, but ensure that it is transcribing only those genes
which will give the greatest benefit in a specific disease state.
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Abstract:
Aging is a risk factor for the development of adult-onset neuro-degenerative diseases.
While some of the molecular pathways regulating longevity and stress resistance in lower
organisms are defined (i.e., those activating the transcriptional regulators DAF-16 and HSF-1 in
C. elegans), their relevance to mammals and disease susceptibility are unknown. We studied
the signaling controlled by the mammalian homolog of DAF-16, FOXO3a, in model systems of
motor neuron disease. Neuron death elicited in vitro by excitotoxic insult or the expression of
mutant SOD1, mutant p150glued or polyQ-expanded androgen receptor was abrogated by
expression of nuclear-targeted FOXO3a. We identify a compound (Psammaplysene A, PA) that
increases nuclear localization of FOXO3a in vitro and in vivo and show that PA also protects
against these insults in vitro. Administration of PA to invertebrate model systems of
neurodegeneration similarly blocked neuron death in a DAF-16/FOXO3a-dependent manner.
These results indicate that activation of the DAF-16/FOXO3a pathway, genetically or
pharmacologically, confers protection against the known causes of motor neuron diseases.

Introduction:
Although motor neuron diseases due to single gene mutations are unusual (~10% of
cases), the affected genes have been successfully used to model these diseases in experimental
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systems 87. Rare, genetic forms of motor neuron disease that arise from mutations in
superoxide dismutase (SOD) or p150glued have a disease phenotype that strongly resembles
sporadic ALS with lower motor neuron predominance 88. Another predominantly lower motor
neuron disease, called spinobulbar muscular atrophy (SBMA or Kennedy’s Disease) is due to a
polyglutamine expansion in the androgen receptor 89. Despite identification of the “disease
protein”, the underlying pathogenic mechanism(s) remain incompletely understood.
In most cases of sporadic ALS, motor neuron death is triggered by the interaction of a
genetic pre-disposition and environmental factors 90. Genome-wide association studies have
failed to reveal consistent susceptibility loci 91,92. Correlative evidence suggests that aging is a
risk factor for the development of ALS as well as other adult-onset neurodegenerative disorders
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. Studies from a variety of experimental systems have provided insight into the genetic factors

controlling aging, in particular, the insulin/insulin-like growth factor signaling pathway 94,95. In
Caenorhabditis elegans, hypomorphic alleles of the daf-2 gene (mammalian homolog,
insulin/insulin-like growth factor receptor) and the downstream signaling molecule age-1
(mammalian homolog, phosphotidylinositol-3’-kinase, PI3’K) promote longevity and lifespan
extension. These effects require the activity of the DAF-16 transcription factor (mammalian
homolog, FOXO3a)96.
DAF-16/FOXO3a shuttles between the cytoplasm (where it is inactive) and the nucleus
in a process that is controlled by its phosphorylation state 97. Phosphorylation of DAF16/FOXO3a by the PI3’K substrate kinases Akt and SGK 98 leads to the 14-3-3 protein-dependent
export of nuclear DAF-16/FOXO3a and re-entry into the nucleus requires dephosphorylation and
release of 14-3-3 98,99. Within the nucleus, DAF-16/FOXO3a leads to the expression of a number
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of genes that have context-dependent effects on cellular physiology. Expression of a
constitutively nuclear FOXO3a can promote the death of purified motor neurons and cerebellar
granule cells and this has been linked to the expression of FasL 97,100. In contrast, active FOXO3a
protects a variety of quiescent cells against death evoked by oxidative stress or glucose
deprivation and this has been linked to the expression of manganese superoxide dismutase
(MnSOD) and catalase 101,102. Thymocyte survival and differentiation is FOXO3a-dependent 103.
Differences in beneficial versus harmful effects of FOXO3a probably relate to cell-circumstancespecific level of activation and post-translational modifications 104.
Some of the stresses that contribute to motor neuron death in ALS include
excitotoxicity, reactive oxygen species, accumulation of insoluble aggregates of neurofilaments,
and defects in axonal transport 87,105-107. Since DAF-16/FOXO3a-dependent gene transcription, in
some contexts, combats cellular stresses, we inquired whether manipulating FOXO3a signaling
protected neurons from insults relevant to motor neuron diseases. We show FOXO3a activation
is neuroprotective across phyla and identify a toxicity-sparing pharmacological approach for
enhancement of DAF-16/FOXO3a signaling activation.

Methods:
Source of Reagents: Trophic factors (ciliary neuronotrophic factor (CNTF), brain-derived
neurotrophic factor (BDNF), neurotrophin 4 (NT 4), cardiotrophin 1 (CT 1) and glial-derived
neurotrophic factor (GDNF)) were obtained from Alomone Labs (Jerusalem, Israel).
Psammaplysene A was synthesized as described 110. All other reagents were obtained from
Sigma (St. Louis, MO) and were of the highest grade available.

133

Tissue Culture: Embryonic Sprague-dawley rat spinal cord neurons were grown on confluent
monolayers of cortical astrocytes, as previously described 120. The substratum was acid washed
glass coverslips when imaging was performed and Primaria tissue culture plasticware (Falcon,
Becton-Dickinson) when biochemistry was performed. Culture media consisted of astrocyteconditioned media supplemented with 10 ng/ml CNTF, BDNF, NT 4, CT 1 and GDNF and 50% of
media was replaced with fresh media every 3 days.
Male SBMA mice transgenic for the prion protein promoter-driven androgen receptor
cDNA containing an expanded (112) CAG repeat tract were mated with non-transgenic C57Bl/6
female mice 121. Dissociated, mixed spinal cord cultures obtained from 13.5-day embryos were
grown for 3 weeks in conditioned medium (conditioned on normal mouse astrocytes) containing
charcoal-stripped serum to remove hormones. At 3 weeks, motor neurons were well
differentiated and distinguishable from other neurons, including sensory neurons, by size and
morphology. At this time, cultures were treated with indicated conditions for 7 days; cells were
then fixed with 4% paraformaldehyde and immunostained using antibodies to neurofilament
heavy chain (NF-H) (SMI32; Sternberger Monoclonal Inc.). Motor neurons were visualized using
a Leica DMR fluorescence microscope, photographed, and analyzed using IP Labs software.
Statistical analyses of results were carried out using Student's t-test (viral infections) or ANOVA
(compound treatments; SigmaStat).

Recombinant HSV: cDNAs were cloned into the PrpUC amplicon plasmid to generate
recombinant HSV as previously described 122. The titer of virus used in these studies was
routinely 3-5 x 107 plaque-forming units/ml. The sources of constructs were: Michael
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Greenberg, Harvard University (HA-tagged wild type and triple mutant human FOXO3a), David
Borchelt, University of Florida (WT and G85R mutant SOD), Erika Holzbaur, University of
Pennsylvania (WT and mutant p150glued) and Anne Brunet (3xFHRE-luciferase).

Excitotoxicity Assay: After 14 days in vitro (DIV), culture media was removed (and saved) and
cells were exposed to 100 µM kainic acid (KA) for 1 hour. Subsequently they were washed three
times in Locke’s buffer not containing KA, the original media was replaced and incubated for
another 24 hours at 37 oC. in 5% CO2 before fixation in 4% paraformaldehyde. Motor neurons
were identified in mixed culture by immunostaining for nonphosphorylated neurofilaments and
counting only labeled cells with cell body diameter of 25 µm or greater. We have previously
validated this method as a means of specifically recognizing motor neurons (Figure 1 in 123). In
experiments involving recombinant HSV, 1 µL of viral stock was added to 1mL of culture media
24 hours or more prior to the next manipulation. Tubes containing viruses were color coded so
that the operator was blinded to the specific virus used.

Quantification of motor neurons: The # of immunostained cells were counted in 3 randomly
selected fields/coverslip and the mean value obtained. In each experiment 3+ independent
coverslips were used per condition and the results presented were obtained for 4+ independent
cultures and experiments.

135

Immunocytochemistry: Tissue culture cells were fixed in freshly prepared 4% paraformaldehyde
in 0.1 M pH 7.4 phosphate buffer for 30 minutes prior to extensive washing in phosphate
buffered saline. Overnight incubation with primary antibody was performed at room
temperature and after washing, coverslips were incubated with Alexafluor conjugated
secondary antibody (2 – 4 hrs.). When double labeling experiments were performed, speciesspecific secondary antibodies with distinct emission spectra were employed. Coverslips were
washed prior to mounting in PermaFluor (Thermo Electron Corporation) and viewing on an
Olympus FV300 Fluoview laser confocal microscope.

Western Blots and quantification: Cultures were lysed in NP-40 lysis buffer (1% NP-40, 40 mM
Tris pH = 7.4, 0.15 M NaCl, 10% glycerol, 0,1% SDS, 0.1% deoxycholate + protease inhibitors and
phosphatase inhibitors), sonicated, particulate matter removed by centrifugation and subjected
to PAGE-SDS prior to transfer to nitrocellose. Equal amounts of protein (determined using BCA
reagents from Pierce) were loaded in each lane. After blocking in 5% milk in phosphate buffer
saline, membranes were incubated in primary antibody overnight, washed, incubated with
secondary antibody, washed and visualized to GE Healthcare (Buckinghamshire, U.K.)
chemiluminescent substrate according to the manufacturers directions. Densitometric analysis
of films was obtained using TINA (Isotopenmegeräte, GmbH) from 4+ independent
experiments, the results averaged and mean values ± S.E. formed the basis of the statistical
comparisons. Quantitative data on band intensity was expressed as the fold change in
comparison with values of HSV-LacZ infected cultures. The displayed western blot data are
representative of the results obtained from at least 4 independent cultures. In some
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experiments the LI-COR Odysseus system was used for visualizing and quantifying western blot
bands. Secondary antibodies were from LI-COR Biosciences (IR 800 or 680 goat anti-mouse IgG
or anti-rabbit IgG).The source of primary antibodies was: (Calbiochem, Oncogene Research
Products, rabbit anti- MnSOD (Stressgen Bioreagents, Victoria, British Columbia, Canada), rabbit
anti- FKHRL1/FOXO3a and anti-phospho FKHRL1/FOXO3a (T32) (Upstate, Lake Placid, NY), antiphosphoFOXO3a (S253) (Abcam) and rabbit anti-HA (Santa Cruz Biotechnology, Santa Cruz, CA).
Species-specific HRP-conjugated secondary antibodies were from Amersham (GE Healthcare,
Buckinghamshire, U.K.) and Alexa 488-conjugated anti rabbit secondary antibody from
Molecular Probes, Invitrogen (Eugene, OR).

Subcellular fractionation
Nuclear protein lysate was prepared using Sigma N-Xtract Tm kit. Briefly, cells collected from
one 60 mm dish were suspended in 150 ul hypotonic lysis buffer (10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, and 10 mM KCl). After incubating on ice for 10 minutes, 10% IGEPA CA-630 was added to
final concentration of 0.6%. Vortexed vigorously for 10 seconds and centrifuged immediately at
10,000-11,000g for 30 seconds. The supernatant is cyoplasmic fraction and the pellet is nuclear
fraction.

Luciferase reporter assay
Human embryonic kidney 293 cells were grown to approximately 80% confluence and then
transfected either 3x Fork Head Response Element Luciferase (FHRE), the parent vector lacking
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the FHREs (pGL3), or pGL3 vector containing 3x Retinoic Acid Response Element (RAREluciferase from Addgene). In all cases, the Renilla luciferase reporter construct, driven by the
thymidine kinase promoter (pRL-TK), was co-transfected as an internal control for transfection
efficiency and cell death. After 24 hrs the cells were trypsinized and replated into media
containing the appropriate concentration of PA or vehicle. After 48 hrs the cells were
trypsinized again and replated into a 96 well plate in fresh media containing PA or vehicle (12
replicates per condition). Twenty four hours later the plates were analyzed using the Dual-Glo
Luciferase Assay System (Promega) on the Xenogen In Vitro Imaging System. The ratio of
Luciferase signal to Renilla signal for each well was calculated and the various treatment groups
were compared to vehicle.

Bioinformatics
In order to identify genes that were differentially expressed in ALS we accessed the NCBI
GEO database and searched the available data sets for ALS-related microarray data. Five data
sets were identified and these were analyzed using the two-tailed t-test analysis with a 0.050
significance level, as provided on the GEO site, to compare the control group to the ALS group in
each of the data sets. The data from these differentially expressed genes was then downloaded
into a spreadsheet and searched for genes that were previously determined to be controlled by
FOXO 176. Genes that were present in both lists were added to the Supplement Table and their
direction of regulation was indicated.

Study of mice. B6SJL-Tg(SOD1-G93A)1Gur/J mice were obtained from Jackson labs and were
bred to the F1 generation of C57Bl/6 x SJL mice. The offspring of this cross was used for all of
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the biochemical studies (n=4 in each experimental group). Lumbar spinal cord was obtained at
P87, frozen on dry ice until use. The spinal cord segments were homogenized with a dounce in
NP-40 buffer as above (10:1 volume to weight). All other manipulation of the lysates was as
described tissue culture cells.

Study of Drosophila
Drosophila stocks were crossed on standard cornmeal agar media at 29°C. Food was
supplemented with DHT (Steraloids) and Psammaplysene A once it had cooled to <50 °C, to final
concentrations of 1 mM and 0.5 mM, respectively. Eye phenotypes of female flies of each
condition were examined and blindly scored according to the criteria described with one scoring
modification to increase sensitivity to differences in affected eye areas 111.
Flies haploinsufficient for dFOXO were generated by mating GMR-GAL4, AR52Q flies to
the following fly stock lines: foxoBG01018 (Bloomington stock 12530); foxo21, foxo25 114 and
foxoc01841 (Exelixis, Harvard).

Study of C. elegans
The following C. elegans strains were obtained from the C. elegans Genetic Center
(biosci.umn.edu/CGC) or constructed by us: ∆glt-3: ZB1096 glt-3(bz34) IV; nuIs5: KP742[glr1::gfp; glr-1::Gs(Q227L) V; lin-15(+)]; ∆glt-3; nuIs5: ZB1102 glt-3(bz34) IV; nuIs5 V; age-1; ∆glt3; nuIs5 Strain ZB1102 glt-3(bz34) IV; nuIs5 V was crossed with strain BE13 sqt-1(sc13)II. sqt-1
was then kicked out and replaced by age-1 using strain TJ1052 age-1(hx546) II. Pmyo-3:daf-16::gfp
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Strain ZB2283 was produced by Jian Xue and Carolina Ibanez-Ventoso by making transgenic
animals carrying an extra-chromosomal array containing Pmyo-3:daf-16:gfp.
For PA treatment, we soaked the diluted drug into standard NGM culture plates. We
transferred freshly growing nematode cultures to these plates and allowed them to grow for 2
days before assessing the effect. To determine the ratio of nuclear vs. cytoplasmic DAF-16 levels
we used a strain transgenic for Pmyo-3:daf-16::gfp, where the DAF-16::GFP reporter is expressed
in body wall muscle cells. We compared the intensity of GFP labeling in the nucleus and adjacent
cytoplasm using NIH-Image. We monitored the effect of PA or age-1 on nematode excitotoxicity
by measuring the extent of neurodegeneration in ∆glt-3; nuIs5 animals ± PA or ± age-1
mutation. We observed free-moving animals with an inverted scope under Nomarski DIC optics
with no anesthetics. Swollen cells in the nerve-ring region were counted as head necrotic figures
indicative of neurodegeneration.

Statistics. Pairwise comparisons employed two-tailed Students’s t-test and when three or more
groups were compared we used Analysis of Variance (ANOVA) and post hoc analysis with
significance set at p< 0.05.

Results:
In fibroblasts, expression of FOXO3a with alanine substitutions at three phosphorylation
sites (Threonine 32, “T32”; Serine 253, “S253” and Serine 315, “S315”) leads to nuclear
retention of the transcriptionally active protein 98. Cultures of rat spinal cord neurons were
infected with recombinant HSV engineered to express the triple mutant (TM) or wild type (WT)
FOXO3a. Immuno-staining for the transgene demonstrated that the WT-FOXO3a is restricted to
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the neuronal cytoplasm and the TM-FOXO3a is largely nuclear (Figure 1A). The transgene
products were detectable in all neurons for >5 days without any apparent toxicity. To
determine if these transgenes influenced the susceptibility of motor neurons to excitotoxic
insult, 14 days in vitro (DIV) mixed spinal cord cultures were infected with HSV- WT-FOXO3a,
HSV- TM-FOXO3a, HSV-LacZ or no virus, the following day exposed to an excitotoxic challenge
(100 µM kainic acid (KA) or vehicle for 1h) and the number of surviving motor neurons
determined 24 hours later 199,200. While approximately 45% of motor neurons were killed by KA
in the HSV-LacZ and HSV-WT-FOXO3a infected cultures, no KA-induced motor neuron death
occurred in the HSV-TM-FOXO3a infected cultures (Figure 1B). ANOVA using transgene
expression as the between-group factor and survival as the within-group factor demonstrated a
significant difference between groups (F(5,12) = 15.68; p< 0.001, ANOVA). The post-hoc
comparisons between groups using Scheffé’s F test with significance set at p < 0.05 showed that
significant motor neuron death only occurred in the cultures expressing the WT-FOXO3a or LacZ.
Thus expression of the TM-FOXO3a protects cultured motor neurons from excitotoxic insult.
Next we explored the capacity of TM-FOXO3a to protect motor neurons in vitro from a
variety of proteotoxic insults relevant to motor neuron diseases. In spinobulbar muscular
atrophy a polyglutamine expansion in the androgen receptor (AR) leads to testosteronedependent motor neuron death 121. We made cultures from spinal cord of mutant ARexpressing mice and found that a 7 day treatment with dihydrotestosterone (DHT) led to the
loss of approximately 25% of motor neurons compared with the vehicle-treated cultures (p <
0.05) (Figure 1C). We observed an equivalent rate of DHT-dependent motor neuron death in
cultures treated with HSV-WT-FOXO3a (p < 0.05). Infection of cultures with HSV-TM-FOXO3a,
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however, completely blocked DHT-dependent death of motor neurons, with all motor neurons
surviving in the presence of DHT (Figure 1C).
Proteotoxic motor neuron death can also be precipitated by expression of mutant forms
of human superoxide dismutase or p150glued 201. We asked if treating cultures expressing these
mutant proteins with TM-FOXO3a affected motor neuron death. We began these studies by
determining concentrations of viruses that led to co-expression of both transgenes in neurons
but did not lead to toxicity owing to the viral burden. We established that infection of spinal
cord neurons with ~8 x 104 pfu of HSV-mutant SOD/ml culture media reliably induced 50%
motor neuron loss 7 days post infection. Addition of ~8 x 104 more pfu of HSV-LacZ to these
wells did not exacerbate motor neuron death. Immunocytological localization studies revealed
that 97 ± 2 % of motor neurons expressing mutant SOD also expressed ß-galactosidase (Figure
1D). In all subsequent studies we confirmed a >95% co-expression of the toxicity-inducing
mutant protein (SOD or p150glued) and LacZ or TM-FOXO3a. We also established that coexpression of LacZ with either WT SOD or WT p150glued had no adverse effect on motor neuron
survival. We previously have shown that this concentration of HSV-mutant SOD infects all
motor neurons at this plating density 120,201.
We compared next the outcome of cultures infected with HSV-mutant SOD + HSV-LacZ
or HSV-TM-FOXO3a as well as cultures infected with HSV- mutant p150glued + HSV-LacZ or HSVTM-FOXO3a (Figure 1 E). The ANOVA indicates that statistically significant differences between
groups existed (F(5,12) = 70.14, p < 0.0001). Infection of cultures with HSV-mutant SOD + HSVLacZ led to significantly lower motor neuron numbers when compared with cultures infected
with HSV-mutant SOD + HSV-TM-FOXO3a (35.0 ± 4.0 versus 69.0 ± 2.0, p < 0.05 in post hoc
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analysis). Similarly motor neuron numbers from cultures infected with HSV- mutant p150glued +
HSV-LacZ were significantly lower than motor neuron numbers from cultures infected with
mutant p150glued + HSV-TM-FOXO3a (36.0 ± 4.0 versus 68.0 ± 3.0, p < 0.05 in post hoc analysis)
(Figure 1E). Thus the toxicity of three different mutant proteins that cause motor neuron
disease can be blocked by expression of a version of FOXO3a that constitutively resides in the
nucleus.

Figure 1. Triple-mutant FOXO3a is retained in the nucleus and protects against excitotoxic and proteotoxic insults. Panel A. Mixed
spinal cord neurons were transfected using Lipofectamine 2000 (Invitrogen) with HA-tagged wild type FOXO3a (WT-FOXO3a) or
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triple mutant FOXO3a (TM-FOXO3a) and 24 hours later fixed and immunostained with anti-HA antibody and Alexa-488 conjugated
secondary antibody. In the left frame, WT-FOXO3a is present in neurites and the soma cytoplasm while the nucleus appears devoid
of immunoreactivity. In the right frame, TM-FOXO3a is seen largely concentrated in the nucleus while soma and neurite staining is
weak. Calibration bar = 24 microns. Panel B., Mixed spinal cord cultures were maintained for 14 DIV before infection with HSV-LacZ,
HSV-WT-FOXO3a, or HSV-TM-FOXO3a. 24 hrs later, the cultures underwent a 1 hr excitotoxic insult and after 24 hrs, the cultures
were fixed and stained for SMI-32. The number of SMI32(+) motor neurons surviving each treatment is noted on the ordinate axis.
A statistically significant reduction in motor neuron number is seen in all groups except the cultured treated with HSV-TM-FOXO3a.
Panel C., 14 DIV mixed spinal cord cultures from mice engineered to express polyQ expanded AR were infected with HSV-LacZ, HSV,
WT-FOXO3a, or HSV-TM-FOXO3a and then treated with DHT or vehicle. After 7 days, fixed cultures were stained and the number of
motor neurons surviving was determined. A statistically significant, DHT-dependent death was found in the uninfected group and
the HSV-WT-FOXO (but not HSV- TM-FOXO3a) group. Panel D., Cultures were infected with HSV-mutant SOD (green) and HSV-LacZ
(red) and subsequently stained with specific antibodies. A high degree of co-localization is evident (yellow, merge image).
Calibration bar = 40 microns. Panel E., The number of motor neurons surviving each treatment was determined after infecting 14
DIV cultures with combinations of HSV-LacZ, TM-FOXO3a, mutant SOD, mutant p150glued, WT-SOD or WT p150glued. Mutant SOD and
mutant p150glued motor neuron death is blocked when TM-FOXO3a is expressed.

Inhibition of PI3’K should lead to accumulation of FOXO3a dephosphorylated at T32,
S253 and S315 and enhanced partitioning of FOXO3a into the nucleus. Given this, we wondered
if PI3’K inhibition would confer neuroprotection. We began these experiments by determining
that application of the PI3’K inhibitor LY294002 (final concentration, 20 µM) every other day for
six days, did not adversely affect motor neuron survival under our culture conditions (data not
shown). Next we examined the biochemical effects of LY294002. For this set of experiments,
the culture media was supplemented with CNTF, CT-1, NT4 and GDNF but lacked BDNF.
Neurons were pre-treated with LY294002 or vehicle for 30 minutes prior to acute stimulation
with BDNF (50 ng/ml) or vehicle and then lystates were prepared 30 minutes later (Figure 2A).
In the absence of LY294002, BDNF evoked an increase in the phosphorylation of AKT, MAPK and
T32 and S253 of FOXO3a. No changes in the abundance of the non-phosphorylated species
were noted. In cultures pre-treated with LY294002, application of BDNF evoked an increase in
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MAPK phosphorylation but there were no changes in the phosphorylation of AKT and T32 and
S253 of FOXO3a. No changes in the abundance of the non-phosphorylated species were noted.
These results suggest that LY294002 selectively inhibit the PI3’K signaling pathway and
phosphorylation of FOXO3a. Next we investigated the effects of chronic LY294002 application
to cultures supplemented with all five of the above trophic factors. Twenty-four hour
incubation with LY-294002, in comparison with vehicle treated cultures, led to a decrease in the
abundance of phosphoAKT and phosphorylation at the S253 site on FOXO3a (Figure 2B). No
other changes were noted in the phosphorylated proteins studied and no changes were
detected in the abundance of the non-phosphorylated species. Next we looked at the effects of
6 day incubation with LY294002 (fresh drug applied every other day – Figure 2 C). We found
that incubation with LY-294002, in comparison with vehicle treated cultures, led to a decrease in
the abundance of phosphoAKT, phosphoMAPK and phosphorylation of T32 and S253 of FOXO3a.
In sum, these experiments indicate that inhibition of PI3’K has the desired effect of decreasing
the abundance of phosphorylated FOXO3a.
To determine if LY294002 was neuroprotective, cultures were infected with either WT
or mutant SOD expressing viruses and LY294002 or vehicle added to the culture media every
other day for 6 days (Figure 2D). In the presence of WT SOD, equivalent levels of motor neuron
survival was found in the presence or absence of LY294002. In addition, in the presence of
mutant SOD, equivalent levels of motor neuron death were found in the presence or absence of
LY294002. These results indicate that LY294002 is not toxic on its own and does not protect
motor neurons from mutant SOD toxicity. Since LY294002 reduces FOXO3a phosphorylation but
is not neuroprotective, it may be that phosphorylation of other PI3’K targets in mammalian cells
offset any potential beneficial actions of dephosphorylated FOXO3a.
145

Figure 2. Inhibition of PI3’K reduces FOXO3a phosphorylation but does not protect against mutant SOD toxicity. Mixed spinal cord
cultures were grown in the absence of BDNF and pretreated with LY294002 or vehicle prior to acute stimulation with BDNF. Thirty
minutes after application of BDNF, lysates were prepared for western blot analysis. Panel A shows that LY294002 blocks the BDNF
stimulated increase in P-AKT, P-MAPK and phosphorylation of FOXO3a onT32 and S253. Panel B shows the effect of a 24 hours
treatment with LY294002 of cultures chronically grown in 5 trophic factors including BDNF. By western blot analysis, LY294002
suppresses P-AKT and phosphorylation of FOXO3a on S253. Panel C shows the effect of a 6 day treatment with LY294002 of cultures
chronically grown in 5 trophic factors including BDNF. By western blot analysis, LY294002 suppresses P-AKT, P-MAPK and
phosphorylation of FOXO3a on T32 and S253. Panel D shows the number of motor neurons surviving 6 days of infection with HSVWT-SOD or HSV-mutant SOD grown in the presence or absence of chronic LY294002. Mutant SOD led to approximately 50% motor
neuron loss and LY294002 did not abrogate the process.

A chemical-genetic screen recently reported the identification of a series of compounds
that can inhibit FOXO1a nuclear export. Compounds fell into two classes: 1) inhibitors of
general nuclear export machinery and 2) inhibitors specific to the FOXO1a pathway 108. We
inquired whether compounds in the second class would also block the nuclear export of FOXO3a
since they would be predicted (based on the results above) to display neuro-protective activity.
We focused on Psammaplysene A (PA), which was isolated from a marine sponge, because it
was the most potent of the class 2 inhibitors (Figure 3A) 109. In addition PA was reported to have
no effect on AKT phosphorylation suggesting it acted either downstream of AKT or in a
synergistic pathway.
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We began by looking at the effect of a synthetic sample of PA (for synthesis see 110) on
the distribution of FOXO3a endogenously expressed by neurons. We biochemically isolated
nuclei from spinal cord cultures treated with PA or vehicle (Figure 3B). Based on the distribution
of the nuclear envelope protein lamin, it is clear that our subcellular fractionation procedure
greatly enriched nuclei. There was an ~ 2.5 fold increase in the nuclear FOXO3a/nuclear lamin
ratio in the PA treated cultures in comparison to vehicle-treated cultures. Total FOXO3a and
lamin levels were unaffected by drug treatment. These observations indicate that PA promotes
the sequestration of FOXO3a into nuclei.
We next tested the ability of PA to promote FOXO-dependent transcription. HEK 293
cells were transfected with a plasmid containing a minimal promoter containing 3x Fork Head
Response Elements (3x FHRE) driving luciferase expression and then treated with various
concentrations of PA or vehicle for 72 hours. As a control for a non-specific action of PA on
transcription, a parallel set of cells were transfected with the parent plasmid (pGL3) that lacked
the 3x FHRE. In all experiments, an internal control plasmid expressing Renilla luciferase was
cotransfected and all results are expressed as the ratio Luciferase/Renilla fluorescence. PA
treatment led to a dose-dependent increase in luciferase signal in 3x FHRE, but not pGL3, expressing cells (Figure 3C). As an added control for specificity we looked at the ability of PA to
enhance transcription from a 3x retinoic acid response element (RARE) luciferase construct and
found that PA had no effect on this promoter. These results indicate that PA can promote FOXO
transcriptional activity.
To determine if PA had neuroprotective activity, spinal cord cultures were treated with
the drug (10 nM) for two days and then subjected to an excitotoxic challenge (Figure 3D). The
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percent of KA-induced cell death was ~50 % in vehicle-treated cultures (65 ± 2 versus 35 ± 3
vehicle versus KA, p < 0.01, Student’s t-test) and ~3 % in PA treated cultures (67 ± 3 versus 65 ± 2
vehicle versus KA, p < 0.6, Student’s t-test) indicating that PA protected motor neurons from
excitotoxic challenge. Next we looked at mutant AR proteotoxicity (Figure 3D). Significant
differences between groups (F(2,6) = 18.84, by ANOVA) were found in the three-way comparison
of 1) No DHT, 2) DHT + vehicle, and 3) DHT + PA). The post hoc analysis demonstrated a DHTdependent ~25 % loss of motor neurons in vehicle-treated cultures (p < 0.01) and
neuroprotection in the PA treated cultures (P > 0.05 in the comparison of no DHT versus DHT +
PA).
We followed up these observations by asking if PA blocked the proteotoxicity of SOD or
p150glued. Spinal cord cultures were infected with HSV engineered to express the WT or mutant
forms of SOD or the WT or mutant forms of p150glued and received PA (or vehicle) every other
day for 4 days. The drug treatment had no effect on transgene expression (not shown). After 4
days, the cultures were fixed and motor neuron number was determined. ANOVA revealed
statistically significant differences between groups in LacZ versus WT SOD versus mutant SOD (±
PA) comparisons (F(5,12) = 18.41, p < 0.001) as well as LacZ versus WT p150glued versus mutant
150glued (± PA) comparisons (F(5,12) = 19.26, p < 0.001) (Figure 3E). The post hoc analysis revealed
that statistically significant protection against the toxicity of mutant SOD or p150glued was
conferred by PA treatment on motor neuron survival. PA had no adverse effect on survival of
motor neurons expressing LacZ or wild type versions of SOD or p150glued. Thus PA is non-toxic
on its own, but can protect against four different insults in vitro that are directly relevant to
motor neuron diseases.
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Figure 3. Psammaplysene A (PA) drives FOXO3a into the neuronal nucleus, promotes FOXO-dependent transcription and protects
against the proteotoxicity of mutant SOD and mutant p150glued . Panel A. The chemical structure of PA. Panel B. Subcellular
fractionation of DIV14 spinal cord culture lysates treated with PA or vehicle. Nuclear fraction (enriched for the nuclear marker,
lamin) contains more FOXO3a in PA- versus vehicle-treated cultures. The abundance of total FOXO3a, lamin or actin is the same
under both conditions. Quantification of band intensities show that PA treatment leads to a statistically significant increase in
nuclear FOXO3a/nuclear lamin in comparison with vehicle treated cultures. Panel C. PA promotes transcription from a 3x FHREluciferase reporter in a dose-dependent manner. PA affected neither transcription from the parent vector (pGL3 that lacks the
FHREs) nor from a 3x RARE luciferase reporter. There was a statistically significant difference between vehicle treatment of 3xFHRE
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versus PA concentrations 10 nM (*, p < 0.05), 50 nM (**, p< 0.01) and 100nM (***, p < 0.001). Panel D. Pretreatment of mixed
spinal cord cultures with PA (+PA) protected motor neurons from excitotoxic insult (left bar graph) and DHT-dependent death of
polyQ expanded AR toxicity (right bar graph). Panel E. One set of 14 DIV mixed spinal cord cultures was infected with HSV-LacZ, HSVWT-SOD or HSV-mutant SOD and a second set of cultures was infected with HSV-LacZ, HSV-WT-p150glued or HSV-mutant p150glued.
Survival of SMI-32 stained motor neurons was determined 4 days later. Infected cultures were either treated with Vehicle (“- PA”)
or PA (“+ PA”). Mutant SOD led to a statistically significant reduction in motor neuron number (by ANOVA, see text for details) and
this was prevented in PA-treated cultures. Similarly mutant p150glued led to a statistically significant reduction in motor neuron
number and this was prevented in PA-treated cultures. * p < 0.05.

Although the direct molecular target of PA is unknown, we examined the effect of PA on
some candidate biochemical and cell biological processes that have previously been implicated
in neuron death. Neurotrophins (such as brain-derived neurotrophic factor, BDNF) can promote
neuronal survival by activating its receptor, TrkB, both during development and after insult (202204

, but see 201,205) and so we wondered if PA had demonstrable effects on this signaling pathway.

Spinal cord cultures grown for 14 DIV were infected with HSV-mutant SOD and then PA or
vehicle was added to the cultures. Under these conditions, in the absence of BDNF, the level of
active, phosphoTrk receptor is very low (Figure 4A). Similarly, downstream signaling involving
AKT and MAPK are only modestly active. In response to BDNF addition to the media, there is a
rapid and robust activation of the Trk receptor (as monitored by assaying for the
phosphorylated form of the receptor) as well as phosphoAKT and phosphoMAPK. The temporal
pattern of receptor activation and downstream signaling in our cultures conforms to previous
observations 120,200 (Figure 4A). Identical results were obtained in cultures uninfected with
viruses (not shown). Thus we find no evidence that pre-treatment of cultures with PA has any
effect on the magnitude or duration of BDNF-TrkB signaling.
Insoluble aggregates of mutant SOD are detectable within cells from transgenic mice
engineered to express mutant SOD 206,207. We wondered if WT or mutant SOD aggregated in
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neurons in vitro and if treating cultures with PA influenced the cellular distribution of human
transgene SOD. Immunocytological location of human SOD in cultures infected with HSV-WTSOD revealed that the protein is homogeneously distributed throughout the cytoplasm and
extends centrifugally for >100 microns into axons and dendrites (Figure 4B). In contrast, in
cultures infected with HSV- mutant SOD immunoreactivity is concentrated into puncta (the
cytological signature of insoluble aggregated proteins) in the soma cytoplasm and neurites.
Double labeling studies reveal that mutant SOD puncta are present in motor neurons (identified
by SMI32 immunoreactivity) as well as non-motor neurons in our cultures (Figure 4B).
Treatment of cultures with PA had no effect on the subcellular distribution of human SOD in
cultures infected with either of the recombinant HSVs. Although the pathophysiological
significance of aggregated protein is controversial, these results indicate that the
neuroprotective action of PA is dissociable from the accumulation of aggregated mutant SOD. A
similar observation has been made in C. elegans wherein DAF-16 protects against A1-42 toxicity
but does not influence the accumulation of protein aggregates 15.
Since the neuroprotection conferred by PA does not seem to be linked to alterations in
trophic factor signaling or the generation of macroscopic mutant SOD aggregates, perhaps PA
action is linked to its capacity to promote nuclear localization of FOXO3a. This would be
consistent with the observations that PA causes nuclear partitioning of FOXO3a in neurons and
constitutive localization of FOXO3a in the nucleus is broadly neuroprotective. We began with
biochemical studies of spinal cord neurons in vitro expressing WT SOD or mutant SOD. In the
absence of PA, the abundance of phosphorylated FOXO3a at T32 (or its ratio to the nonphosphorylated species) is the same in mutant- versus WT-SOD, expressing cultures (Figure 4C).
The same was true when we assayed phosphorylation of S253 (not shown). On the other hand,
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one transcriptional target of FOXO3a is MnSOD and the abundance of this protein is markedly
depressed in mutant SOD, in comparison with WT-SOD-expressing cultures. Expression of
neither mutant- nor WT-SOD led to measurable changes in total FOXO3a or actin. In the
presence of PA treatment, the abundance of phosphorylated FOXO3a (or its ratio to the nonphosphorylated species) is the same in mutant- versus WT-SOD, expressing cultures (Figure 4C).
Interestingly, PA treatment rescued the mutant SOD effect on the level of MnSOD such that
MnSOD abundance was equal in the mutant- versus WT-SOD expressing cultures. PA had no
effect on the abundance of total FOXO3a or actin. These findings suggest that mutant SOD
proteotoxic stress in vitro is not associated with a change in the state of phosphorylation of
FOXO3a at sites that regulate it subcellular distribution. On the other hand, mutant SOD
expression results in a reduction in the abundance of a FOXO3a transcriptional target (MnSOD)
raising the possibility that proteotoxic stress might influence FOXO3a signaling pathway. How
PA treatment reverses the mutant SOD-dependent effect on MnSOD expression, and if it is
linked to FOXO3a, will require further study.
Given these in vitro observations, we wondered if a similar phenomenon occurs in
mutant SOD mice. We examined lysates from spinal cords of mice expressing the G93A mutant
form of human SOD or wild type controls for the expression of phosphoFOXO3a and target
genes. The mice were 87 days old, a time when they are asymptomatic in terms of weakness,
but do manifest other subtle abnormalities 208-210. A consistent increase in the phosphorylation
of T32 of FOXO3a (and the ratio of phosphoFOXO3a to the non-phosphorylated species) was
seen in the G93A mice in comparison with the wild type animals (n=4 in each experimental
group) (figure 4D). This was associated with a reduction in MnSOD in the G93A mice in
comparison to the wild type animals. No differences were noted in the abundance of actin in
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the mutant versus wild type animals. Thus in both in vitro and in vivo experiments, mutant SOD
expression is associated with a reduction in MnSOD expression. The effect of mutant SOD
expression on FOXO3a phosphorylation differed in the in vitro versus in vivo paradigms.

Figure 4. Effects of PA on the distribution of WT and mutant SOD in vitro and biochemical consequences of WT and mutant SOD in
vitro and in vivo. Panel A. Mixed spinal cord cultures infected with HSV-WT-SOD or HSV-G87R-SOD were treated with PA or vehicle
overnight prior to stimulation with 50 ng/ml BDNF. Lysates of unstimulated cells or stimulated cells at the given time points were
subjected to Western blot analysis. The kinetics and degree of TrkB pathway stimulation is the same in PA- versus vehicle-treated
cells. Panel B. Mixed spinal cord cultures infected with HSV-WT-SOD or HSV-G85R-SOD were treated with PA or vehicle for 3 days
prior to fixation and immunostaining for human SOD. WT-SOD is homogenously distributed throughout the cytoplasm in the
neuronal soma and processes in the absence of PA (“- PA”) and in the presence of PA (“+ PA”). In contrast, G87R SOD assumes a
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punctate pattern of expression indicative of aggregates of the protein, both in the absence of PA (“- PA”) and in the presence of PA
(“+ PA”). Calibration bar = 20 microns. Below, using cultures infected with HSV-G85R-SOD, motor neurons are stained with SMI-32
(left panel) and anti-human SOD (middle panel). Aggregated mutant SOD is localized within motor neurons (yellow in right panel).
Calibration bar = 15 microns. Panel C. In the absence of PA (“-PA”) treatement, spinal cord cultures expressing mutant SOD or WT
SOD have the same abundance of phosphoFOXO3a (T32) and the non-phosphorylated species. In addition, mutant SOD expressing
cultures have decreased abundance of MnSOD. In the presence of PA (“+PA”), there is no difference in the abundance of phosphoor non-phosphorylated FOXO3a in cultures expressing WT or mutant SOD. In addition, the level of expression of MnSOD is no longer
suppressed by mutant SOD expression in PA treated cultures. Panel D. Western blots of lumbar spinal cord lysates from 2 wild type
(labeled 1 and 2) and G93A mutant SOD mice (labeled 1 and 2). Representative western blots show an increase in the abundance of
T32 phosphoFOXO3a in the lysates from the mutant mice as well as a decrease in the abundance of MnSOD. Quantification of these
results are shown in the histograms below.

To further explore this issue we employed bioinformatics tools to query existing
microarray profiles for a potential connection between motor neuron disease and FOXO3adependent transcription. We identified five microarray datasets located in the National Center
for Biotechnology Information Gene Expression Omnibus (NCBI GEO) server that are relevant to
motor neuron disease. These datasets come from studies of postmortem tissue from ALS
patients and mutant SOD mouse or rat tissues at various stages of disease. To our knowledge
the only description of the FOXO3a transcriptome comes from a study of PTEN null 786-O renal
carcinoma cells 176. This study identified 198 transcripts whose level of expression is changed
2-fold when a DNA binding-competent, constitutively nuclear (triple mutant) FOXO3a is
expressed in these cells. When we asked how many genes in the motor neuron disease data set
were also components of the FOXO3a transcriptome, we identified 22 transcripts in both
datasets (Supplemental Table). Even given the disparate experimental platforms employed in
these studies, the presence of any overlapping dataset is intriguing. A better-controlled
prospective study is required to obtain a more full understanding of the potential importance of
FOXO3a in motor neuron disease pathogenesis.
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In light of the neuroprotective effect of PA in vitro, we examined the effects of the drug
in two in vivo model systems of neuronal degeneration. Expression of polyglutamine-expanded
AR in the Drosophila eye leads to DHT-dependent degeneration 111,112. We found that flies
reared on food supplemented with 0.5 mM PA had a reduced degenerative phenotype when
compared with vehicle treated flies (Figure 5a, b). These in vivo results complement the
observations made in spinal cord cultures from mice expressing polyglutamine-expanded AR
wherein we found expression of TM-FOXO or treatment with PA blunts DHT-dependent mutant
AR toxicity.
We next asked if the neuroprotective action of PA depended on FOXO. To this end, we
examined the efficacy of PA in flies that both expressed the polyglutamine expanded AR and
were haploinsufficient for Drosophila Foxo (dFOXO) (Figure 5c, d). In a dFOXO-deficient
background (foxoBG01018 allele)113, PA lost its ability to protect against DHT-dependent
degeneration. To corroborate these observations, we studied two additional dFOXO loss-offunction alleles (foxo21 and foxo25) and one predicted loss-of function allele (foxoC01841) 114,115. As
above, on all of these dFOXO-deficient backgrounds, PA lost its ability to protect against DHTdependent degeneration. Using a quantitative rating score, we found that PA led to a
statistically significant mitigation of polyglutamine-expanded AR degeneration but this was lost
in the dFOXO haploinsufficient flies (Figure 5 bar graph). Variation in the baseline (no PA
provided) level of neurodegeneration phenotype among the studied fly lines is likely due to
differences in the background genotype. These observations indicate that PA confers protection
against mutant AR proteotoxicity in a FOXO-dependent manner.
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Figure 5: PA suppresses degeneration in a Drosophila model of SBMA in a dFOXO-dependent manner. Right panel of each diptych
shows higher magnification of the posterior margin of the eye, where degeneration is concentrated. Panel a, flies expressing
polyglutamine-expanded human androgen receptor (GMR, AR52Q) show degeneration when reared on food containing 1 mM
dihydrotestosterone (+DHT). Panel b, this degeneration is suppressed when food is supplemented with 0.5 mM PA. Panels c and d,
PA fails to rescue AR52Q-mediated degeneration in a dFoxo-deficient background. Bar graph below - Quantification of the
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degenerative eye phenotype (scored according to Pandey et al. 111) shows that the neuroprotective effect of PA is lost when flies are
haploinsufficient for dFOXO. Number of eyes scored: GMR, AR52 – DMSO n=34, PA n = 41; GMR, AR52; foxoBG01018 DMSO n=37, PA n
= 47; GMR, AR52; foxo21 DMSO n=20, PA n=16; GMR, AR52; foxo25 DMSO n=8, PA n=14; GMR, AR52; foxoC01841 DMSO n=28, PA n=20.
Mean values are indicated with standard error. P value was determined using Student's t-test. * - p < 0.05

We developed a C. elegans model system of neurodegeneration by combining a null
mutation in the glutamate transporter GLT-3 (∆glt-3) with a transgenic strain (nuIs5 - 116) in
which the glr-1 promoter drives expression of an activated form of Gs (abbreviated Gs*) and
GFP in glutamatergic neurons 117. The ∆glt-3; nuIs5 double mutants exhibit necrotic neuron
death at all stages of postembryonic development, with the strongest effect seen in
developmental stage L3. PA had a dose-dependent neuroprotective effect at the L3 stage, with
complete rescue from death using 10 nM PA (Figure 6A). This concentration of PA had no
adverse effect on WT nematodes. We asked if the effect of PA is mediated by changing the
timing of neurodegeneration or by reducing it throughout development (Figure 6B). To examine
this, we studied the effect of PA on the ∆glt-3; nuIs5 double mutants as a function of larval stage
and we found neuronal death was reduced in all developmental stages, with the strongest effect
observed in the developmental stages most prone to excitotoxicity. Neuron death was reduced
in a statistically significant manner in larval stages L2 (3.4 ± 0.2 versus 2.5 ± 0.2 dying
neurons/animals, n = 44 versus n = 49, vehicle versus PA, p = 0.006) and L3 (4.2 ± 0.2 versus 2.2
± 0.1 dying neurons/animals, n = 63 versus n = 65, vehicle versus PA, p < 0.001) (Figure 6B).
In C. elegans, stress resistance and longevity is promoted by a reduction in the activity
of insulin growth factor receptor (IGFR) signaling pathway (i.e., hypomorphic alleles of IGFR, daf2, and PI3’K, age-1) and this requires daf-16, the nematode homolog of FOXO3a. This led us to
wonder if reducing activity in the IGFR signaling pathway would alleviate nematode
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excitotoxicity. To that end, we crossed the ∆glt-3; nuIs5 double mutants with an age-1 mutant
that carries the hx546 allele. This allele has a specific anti-aging effect but does not affect
development 211. We generated triple mutant nematodes (age-1; ∆glt-3; nuIs5) and found a
robust neuroprotective effect of age-1 at larval stages L1, L2 and L3 (all p values  0.001) (Figure
6C).
Finally, while we showed that PA leads to accumulation of FOXO3a in mammalian
neuronal nuclei, we wished to determine if the same was true in C. elegans. To this end, we
studied nematodes in which a DAF-16::GFP fusion protein was expressed in body wall muscles.
Addition of PA, but not vehicle, to the growth substrate led to nuclear localization of the fusion
protein and quantification of the nucleus/cytoplasm ratio of DAF-16::GFP revealed a statistically
significant effect of PA (1.46 ± 0.05 versus 3.44 ± 0.55, n = 36 versus n=27, vehicle versus PA, p <
0.0001) (Figure 6D). This result indicates that PA has an evolutionarily conserved capacity to
promote nuclear localization of the DAF16/FOXO3a transcription factor and this is associated
with resistance to necrotic neuron death. Another method for promoting nuclear localization of
DAF-16 (i.e., mutation of age-1) has a neuroprotective effect and further re-enforces the notion
that manipulation of the IGFR signaling pathway could have promise as a neuroprotective
strategy.
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Figure 6. PA treatment or reducing the activity of IGFR signaling pathway alleviate nematode excitotoxicity. Panel A. PA has a dosedependent neuroprotective effect on nematode excitotoxicity: ∆glt-3; nuIs5 double mutant nematodes were cultured in presence of
increasing concentrations of PA in the medium. The number of swollen, degenerating head neurons was scored under Nomarski DIC
optics in live animals at the L3 developmental stage. PA shows a statistically significant, dose-dependent neuroprotective effect.
Panel B. The neuroprotective effect of PA is mediated by reducing the extent of neurodegeneration throughout development. Panel
C. age-1(hx546), a mutation that reduces IGFR signaling pathway without altering developmental decisions, protects C. elegans from
excitotoxicity. Degenerating head neurons were scored in live animals as above. Panel D. PA causes preferential nuclear localization
of DAF-16, the nematode homolog of FOXO3a. Animals express a transgene (Pmyo-3:daf-16::gfp) that directs the expression of DAF16::GFP fusion protein in body-wall muscle cells. In control animals (i.) DAF-16::GFP is abundantly present in the cytoplasm. Animals
grown in the presence of 10nM PA (ii.) show preferential (though not uniform) accumulation of DAF-16::GFP in the nucleus.
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Discussion:

Biochemical pathways that regulate longevity in yeast, C. elegans, Drosophila
melanogaster and mice also play a fundamental role in resistance to stresses such as UV
radiation, oxidative conditions, heat shock and misfolded and aggregation-prone proteins 118.
Two transcription factors, Heat-shock factor 1 and DAF-16/FOXO3a, are essential mediators of
this longevity/stress resistance program in nematodes 4,119. Here we show that genetic and
pharmacological maneuvers that enhance nuclear localization of FOXO3a protect mammalian
motor neurons in vitro from 4 insults directly relevant to motor neuron diseases and abrogate
neurodegeneration in two in vivo invertebrate model systems. The broad neuroprotective
action of PA suggests it acts on a phylogenetically conserved, core stress resistance pathway.

Nuclear FOXO3a and PA can evoke a neuroprotective program
We have employed several complementary experimental platforms (each with its own
unique advantage) to investigate the biological actions of PA. In sum the experimental result
suggest that the neuroprotective actions of PA are mediated, at least in part, by FOXO3a/DAF16. First, in both rat neuron cultures and C. elegans, application of PA promotes nuclear
accumulation of FOXO3a or DAF-16. Second, PA evokes a dose-dependent increase in FOXOdependent transcription. Third, constitutive nuclear localization of FOXO3a mimics the
neuroprotective action of PA. Fourth, PA-mediated protection against mutant AR-evoked
degeneration is dFOXO-dependent. Even without knowledge of the direct molecular target of
PA, this evidence favors the view that PA acts, at least in part, in a FOXO3a transcriptiondependent manner.
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Upon nuclear localization, members of the FOXO family of transcription factors can
control the expression of messages that impact glucose metabolism, tumor suppression
(through effects on cell cycle progression and apoptotic responses), stress resistance and
longevity 99,176. The specific effects of FOXOs are both cell-type and context-dependent and
specific posttranslational modifications (i.e. phosphorylation, ubiquitination, acetylation) play a
key role in controlling the transcriptional read-out 97,167,181,212}. For example, work from the
Brunet lab has demonstrated that AMPK phosphorylates FOXO3a at 6 sites and the state of
phosphorylation at these sites does not affect nuclear localization 179. Instead these sites are
vital for expression of genes involved in oxidative stress management and energy metabolism.
Our finding that induction of MnSOD by PA in cultures expressing mutant SOD parallels the
observation of Greer et al. that AMPK induction of sod-3 expression in nematodes is FOXO/DAF16-dependent 213. Our preliminary studies suggest that expression of mutant SOD ± PA does not
influence the state of phosphorylation of FOXO3a at AMPK sites S413 or S588 (unpublished
observations). Further work is required to determine if FOXO3a undergoes posttranslational
modifications in cells expressing mutant SOD, if PA influences such a change, and whether this
has functional consequences.
It is noteworthy that expression of mutant SOD in neurons in vivo, prior to neuron loss,
is associated with an increase in FOXO3a phosphorylation at T32 (one of the three key sites
controlling nuclear/cytoplasmic partitioning) and a reduction in the abundance of MnSOD.
These observations may indicate that as a consequence of expressing mutant SOD, neurons
upregulate the activity of FOXO3a kinases (and/or decrease the activity of FOXO3a
phosphatases) and this results in a reduction in the expression of FOXO3a-regulated transcripts
that combat proteotoxicity. In fact, there is a 2.5 fold increase in PI3’K activity and protein in
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spinal cords of ALS patients (the activator of the FOXO3a kinases AKT and SGK 214) as well as a
3.6 fold increase in phosphoAKT itself in mutant SOD mice 215. These observations may indicate
that a putatively beneficial response to stress, such as increased expression and activity of an
anti-apoptotic pathway, may have an unintended adverse additional action on FOXO3a
transcription.
While we found that constitutive nuclear localization of FOXO3a is neuroprotective,
other groups obtained the opposite result. Heterologous expression of TM-FOXO3a led to death
of purified motor neurons and cerebellar granule neurons (97 as well as PTEN-deficient tumor
cells 216. One factor that may contribute to these disparate observations is experimental
platform. A second contributory factor may be the level of transgene expression. It has been
suggested that the level of nuclear FOXO3a dictates the cellular read-out 102 and the promoter in
the HSV-based system we employ generally evokes moderate level of transgene expression 122.

Invertebrate models support PA acts via a conserved mechanism
Given the potent neuroprotective activity of PA in vitro we sought to examine its effects
in vivo. The two model systems we chose have features that are reminiscent of human motor
neuron diseases. Neurons in the ∆glt-3: nuIs5 nematode die an excitotoxic cell death and there
is abundant evidence that implicating excitotoxic mechanisms in ALS 106. Spinobulbar muscular
atrophy is caused by expression of the proteotoxic polyQ expanded AR and transgenic
expression of this mutant in the fly eye similarly causes degeneration 111. The neuroprotective
activity of PA in these model systems complements the in vitro studies with mammalian motor
neurons. A simple explanation for these observations is that PA operates on a biochemical
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pathway common in all these experimental systems that can overcome a diversity of noxious
insults.
Extending these observations to the mutant SOD mouse model of ALS at the present
time is hindered by the lack of evidence that PA can cross the blood-brain barrier. In preliminary
studies we have not detected PA in brain homogenates after intraperitoneal administration.
Administration using an intrathecal catheter/osmotic minipump may be a viable option 217,
although the long-term stability of PA at body temperatures is not known. It may be possible to
synthesize derivatives of PA that retain the essential biological activity and cross the blood-brain
barrier 218.

Healthful aging and the FOXO3a signaling pathway
The onset of many neurodegenerative diseases in adulthood raises the possibility that
the causes of aging are specific contributors to disease pathogenesis. To the extent that this is
true, applying our understanding of the molecular biology of longevity may lead to new types of
therapy for neurodegenerative diseases. The present work on FOXO3a is an example of how
manipulation of a phylogenetically conserved, longevity-promoting signaling pathway can
effectively block neurodegeneration. This is particularly interesting in light of a recent
population-based study of human longevity showing a strong association of FOXO3a and healthy
aging 27. Agents that trigger neurodegeneration may act in part by subverting the normally
healthful actions of an aging pathway.
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